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Abstract 
Human norovirus (HuNV) is a leading cause of acute gastroenteritis worldwide. 
Despite advances in HuNV cell culture the virus remains difficult to study in the 
laboratory. Murine norovirus (MNV) is routinely utilised as a model virus for 
the study of HuNV replication and pathogenesis. MNV has been shown to 
manipulate the host cell to induce a G0/G1 cell cycle arrest and gain a beneficial 
replication environment. Expression of the viral protein genome-linked (VPg) 
protein of MNV is sufficient to induce cell cycle arrest. Manipulation of the cell 
cycle is independent of the known translation and replication functions of VPg 
and can be induced with the first 62 N-terminal amino acids. This research aimed 
to further characterise the interaction between norovirus VPg proteins and the 
cell cycle.  
 
All viruses in the Caliciviridae family encode a VPg protein however it is not 
known if the G0/G1 arrest induced by MNV VPg is conserved in other 
calicivirus VPg proteins. The cell cycle effect of representative VPg proteins from 
five norovirus genogroups and four other Caliciviridae genera were analysed. A 
G0/G1 cell cycle arrest was observed for all norovirus VPg proteins and 
representative VPg proteins from the Lagovirus and Sapovirus genera. These 
findings show that manipulation of the host cell cycle is a highly conserved 
function of the VPg proteins of caliciviruses and consequently is likely to be 
important for the viral lifecycle.  
 
Alignment of VPg protein sequences revealed a conserved KGKxKxGRG N-
terminal motif with high levels of positively charged amino acids. To test the 
importance of this region for inducing a G0/G1 arrest, truncated or mutated 
MNV VPg constructs were tested. Removal of the N-terminal motif prevented 
an accumulation of cells in the G0/G1 phase confirming the importance of this 
region. Single point or triple mutations of lysine and arginine significantly 
reduced the accumulation of cells in the G0/G1 phase but did not completely 
inhibit the arrest confirming the role of positively charged amino acids in this 
activity. However, expression of the N-terminal motif fused to EGFP was not 
able to manipulate the cell cycle, indicating that there are additional elements of 
MNV VPg that contribute to an arrest.  
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Bioinformatic and literature analysis of the N-terminal motif of MNV VPg 
indicated three activities that could have a role in inducing a G0/G1 phase arrest. 
The N-terminal region was predicted to have RNA binding activity, function as 
a nuclear localisation sequence and interact with eIF4E. Gel shift analysis 
showed that MNV VPg and HuNV VPg bind to RNA in a non-specific manner 
and the lysine and arginine residues within the N-terminal motif were shown to 
be important for this activity. No evidence was found for nuclear localisation of 
MNV VPg. Infection of cells with MNV resulted in a dysregulation of eIF4E 
leading to an increase in nuclear eIF4E levels. Changes in the 
nuclear/cytoplasmic ratios of eIF4E is a possible mechanism by which VPg 
could induce a G0/G1 phase arrest.  
 
This thesis provides evidence that manipulation of the host cell cycle by VPg 
proteins is a common feature of caliciviruses that involves a positively charged 
motif at the N-terminus of VPg. Both RNA binding and dysregulation of eIF4E 
were identified and remain as possible mechanisms by which MNV VPg may 
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The Caliciviridae family consists of small non-enveloped viruses with positive-
sense single-stranded ribonucleic acid (RNA) genomes. Recently, the family was 
expanded to include 11 genera; Nebovirus, Lagovirus, Vesivirus, Sapovirus, 
Norovirus, Bavovirus, Nacovirus, Recovirus, Valovirus, Minovirus and Salovirus (1). 
Caliciviruses infect a broad range of hosts resulting in a variety of diseases 
including gastroenteritis, respiratory illness and haemorrhagic disease (2-4).  
 
Neboviruses have been detected in calves where they cause an endemic 
diarrhoeal disease, similar experimentally to that of the bovine noroviruses (5,6). 
The genus consists of two species; Newbury 1 and Nebraska bovine enteric 
calicivirus. Currently, neboviruses cannot be grown in cell culture and relatively 
little is known about their biological properties and replication.  
 
Lagoviruses have two type species; rabbit haemorrhagic disease virus (RHDV) 
and European brown hare syndrome virus which infect rabbits and hares 
respectively. RHDV has been of particular interest as a pest control agent due to 
the rapid disease progression and high mortality (4).   
 
The vesivirus, feline calicivirus (FCV), primarily infects cats and causes an upper 
respiratory tract infection although more virulent strains associated with severe 
systemic infection have been noted (7, 8). Importantly, the virus is one of a 
limited number of caliciviruses to replicate in cell culture lines, including 
Crandell-Rees feline kidney cells (CRFKs), and has therefore been used as a 
model calicivirus.  
 
Viruses in the sapovirus genus have been isolated from both humans and pigs 
although only the latter is permissive for replication in cell culture. Human 
sapovirus (HuSV) infections induce an acute gastroenteritis which typically 
resolves within a week (9). Similar to human sapoviruses, human noroviruses 
also induce gastroenteritis although generally a more severe form (10). Viruses 
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in the norovirus genus are probably the most diverse and have been identified 
to infect humans and other mammals including mice, cows and pigs.  
 
The Bavovirus, Nacovirus, Recovirus, Valovirus, Minovirus and Salovirus genera 
infect birds, fish, pigs and monkeys (11-16). These viruses have only recently 
been assigned as members of the Caliciviridae family and as such relatively little 
is known about them.  
1.2 Norovirus 
1.2.1 Norovirus classification 
The first norovirus, Norwalk virus (NV), was identified in 1972 as the causative 
agent of an outbreak of gastroenteritis in Norwalk, Ohio (17). This virus was 
designated the prototype genogroup I (GI) virus in the Norovirus genus. Based 
on phylogenetic analysis of the VP1 capsid protein there are currently 10 
accepted norovirus genogroups (GI-GX) (18). GI, GII, GIV, GVIII and GIX 
viruses infect humans and GV consists of viruses that infect mice and rats. Each 
genogroup is further divided into genotypes, with GII noroviruses containing 
the highest diversity of 27 genotypes (18). Norovirus evolution is driven by 
either recombination events predominantly at the open reading frame 1 (ORF1) 
and ORF2 junction or point mutations within the viral genome (19).   
 
1.2.2 Norovirus epidemiology and disease 
Human norovirus (HuNV) infections are a leading cause of gastroenteritis and 
account for approximately one-fifth of acute gastroenteritis across all age groups 
(20). Each year norovirus infections are estimated to cause 699 million cases 
resulting in ~219, 000 deaths with direct health care and societal costs upwards 
of $60 billion USD (21). Worldwide GII human noroviruses are the predominant 
strain, with GII.4 viruses accounting for 50%-70% of yearly outbreaks (22-24). 
Recently, the GII.17 strain has emerged as a significant cause of norovirus 
gastroenteritis predominantly in east Asian countries including China and Japan 
(25, 26). In New Zealand and Australia, GII noroviruses have been identified as 
the causative agents for 81% of reported outbreaks with GII.4 Sydney 2012 or 
GII.4 Sydney 2012 recombinant viruses as the dominant strains (27, 28). 
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Infections are primarily spread person-to-person via the faecal-oral route but 
may also be transmitted by contaminated food and water. The virus is highly 
transmissible due to the low infectious dose, prolonged viral shedding and 
environmental stability (29-31). Outbreaks, predominantly caused by GII 
noroviruses, typically occur in semi-enclosed areas including rest homes, 
hospital wards, childcare centres and cruise ships (27, 28).  
 
Norovirus infections are short lived, the incubation period is estimated to be 24-
48 hours and symptoms will typically subside within one to three days. In 
healthy individuals, norovirus infections are self-limiting and clinical symptoms 
include diarrhea, vomiting, nausea and abdominal cramps. Asymptomatic 
infections are common, especially in children, with associated faecal excretion 
that may persist for several weeks aiding in spread of the virus (32, 33). Infection 
of immunocompromised, elderly and very young individuals is associated with 
more prolonged and severe disease (34, 35).  
 
Current treatment for norovirus gastroenteritis primarily involves rehydration 
and general rest but drugs to relieve vomiting and diarrhoea may be 
administered in some cases. There are no approved vaccines or antiviral 
treatments towards human norovirus infections although there are a number in 
development (reviewed in (36)). Development of vaccines and antivirals has 
traditionally been hampered by the lack of robust and reproducible models for 
direct study of human norovirus.  
 
1.2.3 Human norovirus model systems 
HuNV infections are common in both developed and developing countries 
however the viral lifecycle is not well understood. This is largely due to 
difficulties in replicating HuNV in either an animal model or cell culture system 
(37, 38). Initially human volunteers were used to gain an understanding of viral 
transmission and shedding but this model is not suitable for more invasive 
studies (30, 39). Despite robust replication and disease in humans, attempts to 
develop non-human primates for replication have proven challenging. Infection 
of chimpanzees, rhesus macaques, cynomolgus macaques, cotton-top tamarins 
and common marmosets with HuNV strains resulted in production of virus 
specific serum antibodies and induced viral shedding but did not induce 
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gastroenteritis symptoms (37, 40, 41). Inoculation of neonatal macaques 
supported replication of NV, as evidenced by development of antibodies and 
prolonged viral shedding and unlike other studies, there was evidence of 
diarrhoea (42). Serial passage of virus shed in the stool through adult macaques 
induced further shedding of the virus and clinical symptoms in one of two 
animals (42). Other animal models which have been tested include gnotobiotic 
pigs and calves which develop mild clinical symptoms with viral shedding and 
low to moderate serum titres (43-45).  
 
The use of large animal models for the study of human norovirus has significant 
ethical implications and associated costs, limiting the use of these models by 
researchers. In 2013 Taube et al. developed a mouse model for human norovirus 
using recombination activation gene (Rag -/-) and common gamma chain (gc -/-) 
deficient BALB/c mice (46). The virus was identified in multiple tissue types, 
including the intestine and was shed in the faeces, although the majority of mice 
did not show clinical symptoms (46). The mouse model has been used to validate 
the inhibitory effect of a nucleoside inhibitor, 2’-C-methylcytidine on GII.4 
human norovirus replication (47). In addition to mice, in 2019 zebrafish larvae 
were reported to support replication of GI and GII human noroviruses (48). The 
researchers showed that the virus was able to replicate to high titres and induced 
increased expression of innate immune response genes, including interferon. 
Treatment of infected larvae with a polymerase inhibitor significantly reduced 
viral RNA titres, indicating that zebrafish larvae may be a promising new model 
for antiviral studies (48).  
 
Several cell culture models for the study of human norovirus have recently been 
described. Jones et al. reported replication of HuNV in a continuous human B 
cell line (49) and in 2016 replication in human intestinal enteroids was described 
(50, 51). While both of these systems support HuNV infection major drawbacks 
include reproducibility by researchers in other laboratories and variable 
replication rates between different norovirus strains (50). Other norovirus cell 
culture methods have revolved around the use of reverse genetics to establish 
HuNV replicon systems. Experiments with Norwalk virus have shown that 
transfection of RNA into Huh7 or Caco-2 cells results in only a single round of 
replication likely due to a block at receptor binding or uncoating stages (52). In 
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2005 Asanaka et al. reported the first replicon system for expression of GI.1 
HuNV in human embryonic kidney 293T cells. This system uses a helper virus, 
modified vaccinia Ankara virus (MVA), to express T7 RNA polymerase and 
drive the T7 promoter controlling expression of the norovirus genome (53). The 
MVA-T7 system successfully produced both genomic and sub-genomic viral 
RNA and the expressed proteins assembled into virus particles. Since then a 
number of replicon systems have been established for different HuNV strains 
including NV (54) and GII.3 HuNV (55). In addition, an infectious clone of GII.4 
Sydney 2012 has been described (56). Experimentally, replicon systems have 
been used for screening and characterisation of compounds with anti-noroviral 
activity (57-60). 
 
Due to the difficulties in cultivating norovirus, a large portion of the current 
knowledge on HuNV has been inferred from studies using alternative 
caliciviruses of animal origins. Ideally surrogate viruses should be as similar to 
human norovirus as possible sharing, biological, biochemical and biophysical 
similarities. One of the first viruses to be adopted as a norovirus surrogate was 
FCV, belonging to the Vesivirus genus. FCV can be routinely passaged in culture 
and a suitable reverse genetics system is available (61, 62). As a HuNV surrogate, 
FCV has been utilised in environmental stability studies (63, 64) and as a model 
of calicivirus replication and translation (65, 66). However, FCV induces a 
respiratory disease, not gastroenteritis, and displays different environmental 
characteristics to HuNV limiting its usefulness (67). In 2008 Tulane virus (TV) 
the prototype virus of the Recovirus genus was identified in rhesus macaques 
and was shown to be closely related to noroviruses (13). TV grows in monkey 
kidney cells and uses histo-blood group antigens (HBGAs) for attachment to 
cells, making it a potentially useful surrogate for HuNV (68). Another potential 
norovirus surrogate is porcine sapovirus as it can be replicated in a porcine 
kidney continuous cell line in the presence of bile acids (69).  
 
Each of the above examples are members of the Caliciviridae family but they are 
genetically distinct from HuNV. Several HuNV surrogates exist within the 
Norovirus genus. Before 2003 suitable animal viruses within the Norovirus genus 
were limited to bovine norovirus (GIII) and porcine norovirus (GII). Both of 
 6 
these options could be viable surrogates for HuNV however they lack a cell 
culture line permissible to infection and the cost for animal studies is high.  
1.3 Murine norovirus 
In 2003 Karst et al. described the discovery of murine norovirus 1 (MNV-1) from 
the brain tissue of immunodeficient mice (70). Since the initial discovery MNV 
has been shown to replicate in signal transducers and activators of transcription 
knockout (STAT-/-) mice, RAG2-/- mice, STAT-/-RAG1-/- mice, interferon abgR-/- 
mice and wild type mice (70, 71).  
 
Interestingly MNV-1 infection has different symptoms and outcomes in mice 
lacking components of the innate or adaptive immune response. Mice which lack 
a functional innate immune response develop a systemic infection with viral 
RNA isolated from a wide variety of tissue types (70). Unlike the majority of 
human infections, STAT or interferon receptor deficient mice who contract MNV 
will eventually succumb to infection, although the exact cause of death is not 
known (70). This suggests that there is a reliance on the innate immune response 
to control MNV infection and prevent lethality (72). It was recently shown that 
treatment of uninfected mice with interferon lambda prevents transmission of 
the virus, further supporting the importance of the innate immune response for 
controlling norovirus (73). In contrast mice lacking a functional adaptive 
immune response, RAG1-/- and RAG2-/-, do not experience MNV-1 induced 
lethality (70). In these mice the viral infection is systemic and is not efficiently 
cleared from infected tissues leading to persistent infection and shed of MNV 
indicating that the adaptive response is required to clear infection. In wild type 
mice MNV induces an asymptomatic infection which is not systemic and is 
rapidly cleared by the immune system. In these mice MNV-1 replication has 
been detected in gut associated immune cells, including macrophages, dendritic 
cells, T cells and B cells (74). Similar to HuNV, MNV infected mice develop some 
enteric characteristics, such as faecal inconsistency and the virus can be spread 
by faecal oral transmission (70, 75, 76).  
 
Following characterisation in mice it was quickly shown that MNV is capable of 
replication in vitro in cells of the hematopoietic lineage, specifically macrophages 
and dendritic cells (71). B cell lines will support replication of MNV strains 
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although peak titres are reached later than in RAW 264.7 macrophages (49). 
Subsequent studies with MNV have revealed that the virus recognises the 
CD300lf receptor expressed on a subset of intestinal cells termed Tuft cells (77-
79).  
 
The discovery of MNV provided the first norovirus that can be replicated in cell 
culture and in a small animal model. However, as with all surrogates MNV does 
not mimic all aspects of HuNV infections. Mice do not often develop diarrhoea 
and do not have an emetic reflex and as a result cannot vomit. Multiple strains 
of MNV have been identified but it is not as genetically diverse as HuNV. 
Nevertheless, MNV has been extensively utilised as the model of choice by 
researchers to gain insights into the norovirus lifecycle.  
 
1.3.1 Morphology and genome layout 
Norovirus particles form icosahedral structures 27-40 nm in diameter composed 
of 180 copies of the major capsid protein, viral protein 1 (VP1), and one or two 
copies of the minor capsid protein (1). Viruses in the family have linear positive-
sense single-stranded RNA genomes, of ~7.3-7.5 kb in size. The viral RNA is 
covalently attached at the 5’ end to viral protein genome-linked (VPg) and is 
poly-A tailed at the 3’ end (Figure 1.1). Members of the Norovirus genus have 
three ORFs with the exception of MNV which has four (80) (Figure 1.1). ORF1 
encodes a large polyprotein which is co- and post-translationally cleaved by the 
viral protease (Pro) to release the six non-structural proteins (N-term, NTPase, 
3A-like, VPg, Pro and RdRp) (81). The major and minor structural proteins, VP1 
and VP2, are translated from a subgenomic RNA encoded by ORF2 and ORF3 
respectively. Within the norovirus genus murine noroviruses are unique in that 
they possess a fourth ORF (ORF4) that encodes for a protein termed virulence 
factor 1 (VF1) (80). Flanking the coding regions of the genome are short 
untranslated regions (UTRs), for MNV these are 5 nucleotides and 78 nucleotides 
at the 5’ and 3’ ends respectively. These regions contain conserved RNA 





Figure 1.1 Comparison of HuNV and MNV genomes 
Schematic representation of the genomes of human norovirus and murine norovirus. 
Red boxes indicate ORF1 non-structural (NS) proteins with the gene names indicated 
below. Green boxes indicate structural proteins expressed from ORF2 and ORF3 on the 
subgenomic RNA (sgRNA). The yellow box indicates virulence factor (VF1) encoded by 
ORF4 from the sgRNA. The blue circle represents covalent linkage of VPg to the 5’ 
genomic and subgenomic RNA.  
 
1.3.2 Non-structural proteins 
NS1-2 is an inherently disordered protein that is predicted to contribute to 
multiple roles in the viral lifecycle although the exact function remains unclear 
(84, 85). Within cells NS1-2 localises to the endoplasmic reticulum (ER) (86) and 
interacts with the host proteins VAPA and VAPB (87). In mouse models 
expression of NS1-2 has been linked to viral persistence. A single amino acid 
change within the NS1 region of NS1-2 is sufficient to promote persistence and 
increased replication (88). Recent studies have shown that the MNV and GI.1 
HuNV NS1-2 proteins are processed by cellular caspase-3 during infection and 
cleaved into NS1 and NS2 (89, 90). Whether caspase cleavage also occurs during 
GII HuNV infection and the function of NS2 still remains to be determined. 
Cleavage of MNV NS1-2 is thought to promote apoptotic cell death and enable 
spread and persistence of the virus (89). NS1 is secreted from infected cells and 
has been linked to suppression of the intestinal interferon-l response (89). In 
support of secretion of NS1, mice immunised with NS1 protein, to generate an 
antibody response, are resistant to MNV infection (89). These results suggest that 
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NS1-2 is crucial for viral persistence within the host and targets the interferon 
response to facilitate viral replication.  
 
The norovirus NS3 protein possesses three specific motifs (A, B and C) which 
classify it within the superfamily 3 group of RNA helicases. MNV NS3 is 
associated with NTPase and RNA chaperone activity but not RNA helicase 
activity which has only been demonstrated for GI HuNV NS3 (91, 92). The 
activities of norovirus NS3 are believed to contribute to viral replication by 
ensuring correct folding of RNA and unwinding of dsRNA complexes. HuNV 
NS3 can aid in RNA-dependent RNA polymerase (RdRp) mediated RNA 
synthesis to promote viral replication (91). Within infected cells NS3 localises to 
the replication complex bringing it in close proximity to the viral RNA and other 
non-structural proteins (93). NV and MNV NS3 proteins have been shown to 
induce vesicular structures which undergo microtubule dependent transport 
that may contribute to the formation of the membrane rich replication complex 
(86, 94). Finally, MNV NS3 can arrest host cell translation during replication 
while viral translation is not affected (95).  
 
The role of NS4 for the viral lifecycle is largely unknown. Similar to other non-
structural proteins NS4 co-localises with dsRNA in the viral replication complex 
(93). Transfection of NS4 shows co-localisation with multiple membrane 
markers and induces changes to membrane structures implying that the protein 
may be involved in membrane recruitment for the replication complex (86, 96). 
The amino acid sequence of NS4 shows a YXjESDG motif which mimics a di-
acidic ER export signal (97). This mimic inhibits normal vesicle trafficking 
resulting in Golgi disassembly and antagonism of protein secretion (97).   
 
The norovirus VPg protein is critical to the viral lifecycle. VPg acts as a genome 
cap and is covalently linked to both the noroviral genomic and subgenomic 
RNA. For translation of the viral proteins, VPg recruits eukaryotic initiation 
factor 4G (eIF4G) to stimulate formation of the host elongation initiation 
complex (66, 98). VPg also serves as a protein primer for replication of the 
genomic RNA by RdRp (99).  
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The cysteine protease (Pro) (NS6) of noroviruses is responsible for proteolytic 
cleavage of the ORF1 polyprotein and recognises five cleavage sites with 
differing efficiencies (81, 100). The crystal structure of norovirus protease reveals 
a catalytic triad containing a cysteine residue consistent with its function as a 3C-
like protease (101). The catalytic triad is essential for protease activity and 
replacement of these residues reduces activity (102). In addition to cleaving viral 
proteins norovirus proteases have been shown to cleave host proteins. HuNV 
protease cleaves poly-A binding protein (PABP) to supress host cell translation 
although there is evidence that NS3 also performs this function (103, 104). 
Cleavage of host proteins, particularly those involved in translation, may allow 
the virus to direct more effective viral translation.  
 
The norovirus RdRp (NS7) is the last protein in the ORF1 polyprotein and is 
required for replication of the genomic and subgenomic RNA. The RdRp is 
characteristic of positive-sense RNA virus polymerase proteins, with finger, 
thumb and palm domains evident in the crystal structure (105, 106). RdRp 
catalyses RNA synthesis of the viral genome in either a primer dependent or 
primer independent manner (107, 108). Primer dependent RNA replication is 
reliant on VPg. RdRp catalyses a reaction to covalently link VPg to a nucleotide 
which then serves as the primer for extension by RdRp (109). In contrast de novo 
RNA synthesis does not require VPg and is believed to be important for the 
initiation of subgenomic RNA. It has been proposed that a poly(C) stretch on the 
3’ end of anti-subgenomic RNA stimulates de novo synthesis (107). As with 
other positive-sense RNA viruses the norovirus RdRp replicates RNA with low 
fidelity as it does not have a proofreading mechanism contributing to the high 
genetic diversity of these viruses (110). Both polymerase and protease have been 
a major focus as potential antiviral targets, due to their highly conserved 
structures and functions across multiple norovirus strains (reviewed in (36)).  
 
In addition to individual expression of proteins a number of protein precursors, 
including large but less stable processing intermediates and stable precursor 
proteins such as NS4-VPg and Pro-RdRp are expressed (81, 111, 112). These 
precursors are believed to have alternate functions to mature proteins, 
contributing to the complex lifecycle of noroviruses. Of particular interest to 
researchers is the Pro-RdRp protein which possesses both protease and 
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polymerase activity and has been shown to be highly effective at catalysing the 
nucleotidylylation reaction required for VPg dependent genome replication (99, 
113, 114).  
 
VF1 the product of ORF4 is expressed in MNV, but has not been identified in 
other norovirus strains (80, 115). In vivo VF1 is required for pathogenesis as the 
replication of a VF1 mutant MNV is attenuated compared to a wild-type (WT) 
virus (80, 116). Expression of VF1 is not directly required for replication in cell 
culture although mutation does come at a fitness cost to the virus (80). VF1 
primarily localises to the mitochondria and affects mitochondrial innate immune 
signalling by delaying the upregulation of a number of genes, including 
interferon-b, that are activated by the innate pathway (80). 
 
1.3.3 Structural proteins 
The major structural protein of noroviruses, VP1, ranges in size from 58-60 kDa. 
When expressed individually VP1 self-assembles into virus-like particles (VLP) 
which structurally mimic intact virus (117-119). The self-assembly property of 
VP1 has made it an attractive vaccine candidate and there are currently a number 
of clinical trials of VLP based vaccines (120-122). X-ray crystallography of 
Norwalk virus shows that the capsid is composed of 180 copies of VP1 which 
form an icosahedral virion (123). In the capsid VP1 folds into two major domains, 
the shell domain and the protruding (P) domain (123). The P domain is further 
subdivided into the P1 and P2 domains and the hypervariable region of the latter 
is thought to be important for receptor binding (124).   
 
VP2 is expressed from ORF3 (125) and is the smaller of the two capsid proteins 
ranging in size from 22-29 kDa. The exact amount of VP2 in each norovirus 
particle is unknown but is estimated to be one to two copies per VLP (126). 
Conley et al. recently reported that twelve copies of FCV VP2 arrange themselves 
on the capsid surface to from a large portal-like structure. The formation of this 
structure opens a pore in the capsid, thought to facilitate delivery of RNA into 
cells (127). VP2 is not directly required for formation of VLP however in FCV, it 
is essential for production of infectious virus (128). A direct interaction between 
VP2 and the shell domain of VP1 has been demonstrated and shows that VP2 is 
located on the inside of the capsid (129). It is thought that the basic nature and 
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location of VP2 within the capsid allows it to interact with viral RNA to help 
with packaging of the virus particle which could explain why VP2 is essential 
(126, 129). Finally, VP2 may play a role in stability of virus particles and allow 
the virus to withstand environmental changes such as pH (130).  
 
1.3.4 Replication  
The replication cycle of noroviruses is not completely understood (Figure 1.2). 
First the virus must recognise and bind cellular receptors on the cell surface, for 
MNV this has been identified as CD300lf (78, 79). The exact receptor for HuNV 




Figure 1.2 Schematic of replication cycle of MNV 
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Figure adapted from de Graaf et al (132). Schematic of the replication of MNV in infected 
cells. 1; attachment to cells via the CD300lf receptor, 2; internalisation, 3; uncoating and 
disassembly of the virus, 4; pioneer round of translation directly off the positive-sense 
RNA genome, 5; post-translational cleavage of the ORF1 polyprotein to release the non-
structural proteins, 6; replication of the viral genome by RdRp using VPg dependent or 
de novo RNA synthesis, 7; encapsidation of the viral genome and 8; release of progeny 
virus.  
 
Internalisation of MNV has been shown to be dependent on host-derived 
dynamin and cholesterol (133). Following internalisation and uncoating, the 
positive-sense RNA genome acts as a template for the pioneer round of 
translation (Figure 1.2). Initially the non-structural proteins are translated 
directly from the incoming RNA while the structural proteins and VF1 are 
translated from the subgenomic RNA. Translation is initiated by the interaction 
of VPg with host translation initiation factors and the recruitment of the 
translation initiation complex (66, 134-136). The norovirus RNA sequence 
including the UTRs and coding regions contains conserved hairpin and stem-
loop structures (82, 137). These regions further contribute to translation through 
interactions with host proteins including La, PABP isoforms and DDX3 (83, 138). 
Translation of ORF1 and proteolytic cleavage by Pro releases the six non-
structural proteins following which a replication complex is formed (Figure 1.2). 
Noroviruses replicate in the cytoplasm and the replication complex is assembled 
adjacent to the nucleus in close association with host derived membranes (93, 
139). Replication of the viral genome occurs through the formation of a negative-
sense RNA intermediate which serves as a template for the positive-sense 
genomic and the subgenomic RNA. All viral RNA is synthesised by RdRp either 
de novo or in a VPg dependent manner (107) (Figure 1.2). The final stages of viral 
assembly, encapsidation and release have not been extensively studied. As non-
enveloped viruses, noroviruses have been presumed to require cell lysis for 
release, which can be observed during infection of cell culture lines. However, it 
was recently shown that HuNV can be transmitted as clusters of viruses inside 
exosomes (140), indicating that the mechanisms employed by noroviruses to exit 
and infect surrounding cells are more complex than was initially presumed.  
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1.4 Viral protein genome-linked 
In vertebrate viruses, VPg proteins have been identified in members of the 
Caliciviridae, Picornaviridae and Astroviridae families (reviewed in (141)) (142). The 
presence of VPg proteins have also been described for plant viruses (Comoviridae, 
Luteoviridae, Potyviridae families and Sobemovirus genus) and fungal viruses 
(Barnaviridae family) all of which are positive-sense single-stranded RNA viruses 
(143, 144). There are two characteristic conserved amino acids motifs among 
calicivirus VPg proteins. A KGK(N/T)K motif at the N-terminus of the protein 
and a (D/E)EY(D/E)E motif at the nucleotidylylation site (145). MNV VPg 
shares ~14-53% sequence identity with other VPg proteins from the calicivirus 
family and ~2-13% sequence identity with VPg proteins encoded by other virus 
families. Despite the apparent lack of sequence homology, the size of calicivirus 
VPg proteins (10-15 kDa) is more similar to potyvirus VPg proteins (~21 kDa) 
than those of the picornavirus family (2-4 kDa).  
 
1.4.1 Structure 
MNV VPg is 124 amino acids in length and by nuclear magnetic resonance 
spectroscopy (NMR), consists of a structured helical core flanked by regions of 
disorder at the N- and C-termini (146). Researchers have used NMR to solve the 
structure of amino acids 11-85 of MNV VPg, with the largely disordered N- and 
C-termini removed (146). Within the core, two alpha helices were identified, one 
at residues 23 to 35 and a second at residues 42 to 55. A third alpha helix present 
in FCV VPg and porcine sapovirus (PSV) VPg was absent from MNV VPg (146, 
147). Crystal structures of MNV VPg in complex with RdRp support the helical 
conformation (108). In contrast, attempts to solve the crystal structure of the NV 
VPg-Pro precursor showed that the protein lacked density leading the authors 
to the conclude that NV VPg is disordered in crystals (148). 
 
In MNV VPg the first helix contains the conserved tyrosine (Y26) which is 
nucleotidylylated by RdRp for viral RNA replication. Modelling of the 
structured core of both MNV and FCV VPg suggests the protein is too large to 
fit within the substrate-binding channel of the RdRp for nucleotidylylation of 
tyrosine  26 (Y26) (146). It is therefore likely that there is a significant 
conformational change to either VPg or RdRp to allow the formation of a 
nucleotidylylation competent complex. Alternatively, the Pro-RdRp precursor 
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protein can nucleotidylylate VPg with higher efficiency than RdRp alone (113). 
The crystal structure for Pro-RdRp has not been solved and it is possible that it 
may have a different structure to RdRp, that allows access to Y26.  
 
The picornavirus and potyvirus VPg proteins are considered intrinsically 
disordered (149-151). While norovirus VPg proteins may not be fully disordered, 
the N- and C- terminal regions are predicted to be disordered (108, 152). In 
support of the predictive modelling, norovirus VPg proteins are rich in basic and 
flexible amino acids which are often enriched in regions of disorder (153). 
Intrinsically disordered protein regions (IDPRs) are domains that lack a stable 
secondary and/or tertiary structure (154). Many IDPRs adopt a defined 
conformation upon interaction with a target molecule (155, 156). Disorder is 
thought to be a property that allows for multiple functions and could contribute 
to the multi-functional nature of VPg. In addition to disorder, post translational 
phosphorylation of FCV VPg, potato virus A (PVA) VPg and VPg proteins from 
members of the Sobemovirus genus have been detected (157-159). The biological 
relevance of these modifications is not known but could further contribute to the 
multi-functional nature of VPg proteins.  
 
1.4.2 VPg localisation 
MNV VPg and other non-structural proteins co-localise with dsRNA, a viral 
RNA replication intermediate, in the perinuclear region as part of the replication 
complex (86, 93, 139). Expression of just the ORF1 polyprotein again shows a 
perinuclear localisation for MNV VPg (160). Although a cell line that supports 
HuNV replication has not yet been identified, several localisation studies have 
been performed using RNA transfections or replicons. Transfection of NV RNA 
and a HuNV GII.3 replicon both exhibit a diffuse cytoplasmic staining of VPg in 
standard laboratory cell lines (52, 55). In 2018 Yen et al. showed that transfection 
of GII.4 VPg into human melanoma A7 cells displayed a nuclear and cytoplasmic 
distribution (161). This provides the first evidence of nuclear localisation for a 
norovirus VPg. Other calicivirus or potyvirus VPg proteins have shown to have 
both cytoplasmic and nuclear localisations (162-164). 
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1.4.3 Functional roles of VPg 
RNA replication 
Linkage of VPg to the genomic and subgenomic RNA occurs during RNA 
replication, where VPg acts as a protein primer, a function which is conserved 
across both vertebrate and plant viruses (107, 165). The first step of RNA 
replication involves nucleotidylylation of VPg by the RdRp or the Pro-RdRp 
precursor protein (99, 107, 113). The RdRp catalyses VPg nucleotidylylation to 
covalently link a nucleotide, generally guanine, to the free hydroxyl of a tyrosine 
residue in VPg (157). For MNV VPg this tyrosine residue has been identified at 
position 26 of the protein and mutation studies have shown that viral RNA 
replication cannot occur in the absence of Y26 (146, 157). Conserved tyrosine 
residues for nucleotidylylation have also been identified for HuNV VPg (99), 
FCV VPg (166) and RHDV VPg (167). 
 
In picornaviruses formation of a nucleotide linked VPg is reliant on a cis-active 
RNA element (CRE) within the viral genome (168, 169). 3DPol, VPg and uridine 
triphosphate (UTP) interact with the CRE thus bringing all three components 
into close association with one another for uridylylation of VPg into VPgpUpUOH 
(170, 171). Noroviruses have been shown to contain evolutionarily conserved 
RNA secondary structures which when disrupted reduces or completely 
destroys the replication ability of MNV (82, 172). A potential CRE-like structure 
that enhances nucleotidylylation has been identified near the 3’ end of HuNV 
strain MD145, although norovirus nucleotidylylation in the absence of RNA also 
occurs (99). Additional study is required to answer questions around the 
importance of norovirus RNA secondary structures for nucleotidylylation. 
Following nucleotidylylation of VPg the protein must be transferred to the 3’ 
end of either the positive- or negative-sense RNA where it provides a free 3’ 
hydroxyl for extension by RdRp.  
 
The exact mechanism by which norovirus negative-sense RNA replication is 
primed is currently unclear and there are a number of proposed mechanisms. In 
poliovirus infected cells, negative-sense RNA can be isolated with VPg 
covalently bound to the 5’ end, suggesting that replication occurs in a VPg 
dependent manner (173). In contrast norovirus negative-sense RNA replication 
has been proposed to occur in a de novo manner (174). To date there is no 
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conclusive evidence of whether or not the norovirus negative-sense RNA is VPg-
linked (157). 
 
VPg can be found linked to the positive-sense RNA suggesting that replication 
of the RNA is reliant on VPg (157, 175). The 5’ terminal nucleotide of the MNV 
genome and other noroviruses is guanine and therefore cytosine on the negative-
sense RNA. Following nucleotidylylation by RdRp, guanylylated VPg is 
transferred to the 3’ end of the negative-sense RNA, where the guanine forms 
the first base of the positive-sense genomic RNA. With VPg serving as a primer, 




Treatment of calicivirus RNA with proteinase K removes VPg from the 5’ 
genomic RNA and abolishes viral protein expression (52, 176). This led to the 
hypothesis that VPg acts to stimulate translation of the viral genome.  
 
In the host cell, translation initiation is a key regulatory step for the production 
of protein from mRNA transcripts (reviewed in (177)). The majority of 
eukaryotic mRNA transcripts contain a 5’ mRNA cap structure which is 
recognised by eIF4E, the cap binding protein. The complex is then bound by 
eIF4G, the scaffold protein, which contains binding sites the RNA helicase 
(eIF4A), PABP and eIF3. Together eIF4E, eIF4G and eIF4A constitute the 
translation initiation complex eIF4F. This then leads to recruitment of the 
ribosome and translation of mRNA transcripts.  
 
As obligate intracellular parasites viruses must either produce RNA with a 5’ 
cap or initiate translation through an alternative mechanism while also 
competing for translation of the viral RNA in the presence of high concentrations 
of cellular RNA. Norovirus RNA does not have a cap structure for the initiation 
of translation. The first evidence for MNV VPg functioning as a proteinaceous 
cap to stimulate translation was obtained from co-purification studies showing 
that VPg interacts with components of the host elongation initiation complex, 
including eIF4G and eIF4E (66, 134, 135). Unlike FCV, PSV and RHDV the 
interaction of MNV VPg with eIF4E is not essential and MNV VPg instead uses 
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the interaction with eIF4G to drive viral translation (66, 134, 136, 178). Further 
studies have shown that ~20 amino acids at the C-terminus of MNV VPg 
interacts with the HEAT-1 domain of eIF4G (98). Mutagenesis studies, 
investigating the role of the C-terminus of MNV VPg for translation show that 
several amino acids including a highly conserved phenylalanine 123 (F123) are 
critical for the interaction with eIF4G. The function of VPg as a proteinaceous 
cap for translation is conserved across caliciviruses and potyviruses but is not 
required for picornavirus translation (179, 180).  
 
Additional roles of VPg 
VPg is a multi-functional protein and is involved in many processes during the 
viral replication cycle in addition to RNA replication and translation.  
 
The interaction between MNV VPg and eIF4E is of particular interest as 
depletion of eIF4E has little to no effect on viral translation (66, 134). Despite 
evidence of direct binding between MNV VPg and eIF4E the significance of the 
interaction for the viral lifecycle is largely unknown (66, 134). In 2015 Royall et 
al. posited that MNV infection induces changes to the translational profile of the 
cell by stimulating the phosphorylation of eIF4E (181). During infection the 
MAPK pathway is activated resulting in a modest increase in phosphorylated 
eIF4E (181). Phosphorylated eIF4E relocates to the polysomes thus changing the 
translational profile of a subset of host mRNAs and potentially contributing to 
an environment beneficial to viral replication. Whether the phosphorylation of 
eIF4E is driven specifically by the VPg-eIF4E interaction has not yet been 
determined.  
 
The N-terminus of calicivirus VPg proteins typically contains a stretch of 
positively charged lysine and arginine amino acids which may be able to bind 
negatively charged RNA. MNV VPg can be purified using phosphocellulose or 
heparin-affinity chromatography, common features of RNA binding proteins 
(182). The positive N-terminus of HuNV VPg binds individual nucleotide 
triphosphates (NTPs) as has also been seen with potyvirus VPg proteins (113, 
150, 165). In addition, the N-terminal region of PVA VPg binds non-specifically 
to RNA (150). The functional importance for an interaction with RNA has not 
been determined.  
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Many positive-sense RNA viruses produce RNA with a 5’ triphosphate group 
which is detected by the cytoplasmic sensors, RIG-I and protein kinase R to 
activate the innate immune response. In norovirus VPg acts as a 5’ cap thus 
protecting the 5’ triphosphorylated RNA and possibly avoiding the immune 
response (141).   
  
A role for VPg in selective encapsidation of the viral RNA during packaging has 
been proposed. A yeast-two hybrid assay of FCV VPg showed a direct 
interaction between VPg and the major capsid protein VP1 (183). Similarly, for 
MNV VPg an interaction with VP1 has been detected, although the article was 
later retracted (184). An interaction between VPg and VP1 could provide a 
mechanism for encapsidation of the VPg capped RNA even in the presence of 
high concentrations of host mRNA.    
 
A further function of VPg is as a regulator of the host cell cycle. Specifically, 
MNV VPg induces an accumulation of cells in the gap 0/gap 1 (G0/G1) phase 
and a consequent decrease in synthesis (S) phase cells (185, 186).   
1.5 The mammalian cell cycle 
In eukaryotes the cell cycle is a highly regulated and complex process during 
which a cell undergoes division to produce two identical daughter cells. The cell 
cycle is generally characterised into four sequential phases: G1 phase, S phase, 
gap 2 phase (G2) and mitosis phase (M). Between the M phase and the G1 phase 
cells may enter a quiescent state known as the G0 phase during which they are 
non-replicative. Following the G0 phase, if cells receive the right mitogenic 
stimuli they will re-enter the cell division cycle at G1 phase. G1 is a growth phase 
and serves to prepare the cell for subsequent deoxyribonucleic acid (DNA) 
replication and division. During this phase the cell grows in size and synthesises 
mRNA and proteins required for DNA synthesis (187). In S phase the DNA is 
replicated, resulting in a cell with two identical DNA copies and the cell then 
enters the G2 phase. G2 is similar to G1, in that there are high levels of 
transcription and translation occurring in preparation for M phase. The 
relatively short M phase consists of separation of sister chromatids followed by 
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division of the nucleus and finally division of the cell itself and all cellular 
components.   
 
Progression and regulation of the cell cycle is tightly controlled by a network of 
cellular components including proteins and RNAs. Of these, cyclins, cyclin-
dependent kinases (CDKs) and cyclin-dependent kinase inhibitors (CKIs) have 
been identified as major controllers of cell cycle progression (188-190). Cyclins 
are a family of proteins that regulate cell cycle progression by binding and 
activating CDKs. In their active form, CDKs phosphorylate specific substrate 
proteins leading to regulation of gene expression. Expression of CKIs negatively 
regulates cell cycle progression by inhibiting CDKs. Throughout the cell cycle 
levels and/or activation states of these proteins rise and fall in a sequential 
manner to control progression and ensure proper cell division. 
 
1.5.1 The G1 phase 
The G1 phase is the first phase of the eukaryotic cell cycle and entry either from 
the M phase or the G0 phase is stimulated by mitogenic signals. Cells that receive 
environmental signals to enter G1 upregulate expression of D-type cyclins, the 
major drivers of G1 progression. Early in the cell cycle cells have not committed 
to a full round of division and mitogenic stimuli for expression of cyclin D must 
be sustained. During mid- to late-G1 phase the cell will pass through the R point, 
which is described as the stage of the cell cycle at which the cell becomes 
committed to division and no longer requires mitogenic signals to continue 
progression (191). Activation of CDK2 and hyperphosphorylation of 
retinoblastoma (Rb) protein have been interpreted to indicate passage through 
the restriction point. 
 
In mid- to late-G1 accumulated cyclin D complexed with either CDK4 or CDK6 
begins the process of phosphorylation of Rb (Figure 1.3). Rb is a key protein in 
regulating cell cycle progression and is an essential component of the G1 
restriction point (189). The progressive phosphorylation of Rb during the G1 
phase results in dissociation of the E2 factor (E2F) family of transcription factors 
(Figure 1.3). In turn, freed E2F activates transcription of certain promoters for 
genes involved in cell cycle progression and DNA synthesis, including cyclins E 
and A (192, 193).  
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1.5.2 The G1/S transition 
The G1/S transition of the cell cycle functions as a highly controlled checkpoint 
(Figure 1.3). Through E2F dependent transcription, cyclin E levels begin to rise 
in late-G1 and cyclin E then interacts with CDK2. Active cyclin E/CDK2 
complexes complete the hyperphosphorylation of Rb by phosphorylating 
additional sites separate from those recognised by cyclin D/CDK complexes 
(194). Through the increased phosphorylation of Rb, cyclin E/CDK2 forms a 
positive feedback loop to further amplify cyclin E transcription (192) (Figure 1.3). 
In addition, cyclin E/CDK2 complexes can phosphorylate E2F transcription 
factors to modulate activity and stimulate additional transcription (195). Other 
targets of the cyclin E/CDK2 complex include phosphorylation of the CKIs, p27 
and p21, targeting them for degradation (196). The expression of cyclin E initiates 
a cascade of events leading to expression of S phase specific genes to drive the 
G1/S transition.  
 
 
Figure 1.3 Schematic representation of the G1/S transition of the mammalian cell 
cycle. 
Progression through the G1/S transition is primarily controlled by the phosphorylation 

























complexes. Rb is phosphorylated by cyclin D/CDK4/6 and cyclin E/CDK2 complexes. 
Phosphorylation leads to the release of the transcription factor E2F (pink oval) resulting 
in transcription of S phase promoting genes. The green rectangles represent the cell 
cycle inhibitors, p21 and p27, which bind to and inhibit cyclin-CDK complexes. P in a 
circle indicates phosphorylation. 
 
The S phase of the cell cycle is characterised by replication of the genomic DNA 
and the majority of proteins for DNA synthesis are transcribed during the G1 
phase. The formation of stable replication complexes enables helicases to 
unwind the DNA and the loading of polymerases which then incorporate free 
nucleotides to synthesise DNA. Both cyclin E and cyclin A have been shown to 
contribute in different manners to DNA replication.  
 
Cyclin E/CDK2 complexes stimulate replication complex assembly via Cdc6 
(197) and Mcm proteins (198) as well as regulating transcriptional programmes 
through interactions with proteins such as Id2 and Id3 (199, 200).  
 
Cyclin A begins to be expressed at the G1/S transition and accumulates through 
the S phase to maintain progression. During the S phase, cyclin A binds to CDK2 
largely replacing cyclin E. As the cell progresses through S phase, cyclin 
A/CDK2 complexes negatively regulate specific members of the E2F family to 
prevent DNA binding (201, 202). This function is linked to the orderly regulation 
of gene expression and maintains proper progression through S phase, thus 
providing a mechanism by which the wave of gene expression associated with 
the G1/S transition can be turned off. Cyclin A/CDK2 complexes activate DNA 
synthesis on assembled replication complexes and also inhibit the assembly of 
new complexes (197). In late S phase, cyclin A associates with CDK1 and remains 
in this complex into the late G2 phase. The formation of cyclin A/CDK1 complex 
is thought to be involved in the activation of transcription factors which in turn 
regulate cyclin B transcription (203). At the end of the G2 phase cyclin A is 
degraded by the proteasome and is replaced by cyclin B.  
 
1.5.3 The G2/M transition 
The final stages of the cell cycle involve the transition out of the S phase through 
a second growth phase (G2) and into M phase where the cell divides into two 
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identical daughter cells. Progression from the G2 phase into M phase is primarily 
governed by the expression and activity of cyclin B in complex with CDK1 
(Figure 1.4). 
 
Figure 1.4 Schematic representation of the G2/M transition of the mammalian cell 
cycle. 
Progression through the G2/M transition is primarily controlled by the activity of cyclin 
(yellow ovals) and CDK (orange ovals) complexes. In late-S phase cyclin A complexes 
with CDK1 leading to the initiation of expression of cyclin B. During G2 phase active 
cyclin B/CDK1 complexes accumulate leading to increased transcription of genes for 
the G2/M transition. The green rectangles represent DNA damage response proteins; 
Myt1, Wee1 and p21 which negatively regulate the activity of cyclin B/CDK1 
complexes. The pink rectangle indicates Cdc25, a positive regulator of cyclin B/CDK1 
complexes. P in a circle indicates phosphorylation. 
 
During S phase cyclin A accumulates and is degraded as the cell enters mitosis, 
an event which is required for transition from G2 to M phase (204). The 
transcription of cyclin B is stimulated in S phase by transcription factors which 
are in turn activated by cyclin A/CDK1 complexes, ensuring sequential 
activation of the cyclins (205, 206) (Figure 1.4). Throughout S phase and for the 


























The G2/M boundary serves as a major DNA damage checkpoint in the cell cycle. 
If damage is detected cells must either transiently arrest mitotic entry via 
inactivation of cyclin B/CDK1 complexes or leave the cell cycle completely 
resulting in apoptosis. DNA damage is detected through sensor proteins which 
relay the signal through to the key signalling kinases, ataxia-telangiectasia 
mutated (ATM) and ATM- and Rad3-Related (ATR). While there are likely 
hundreds of proteins regulated by ATM/ATR some of the most well studied 
downstream proteins are Chk1, Chk2 and p53 (207-209). The checkpoint kinases, 
Chk1 and Chk2, act to inhibit progression into M phase through multiple 
pathways. Chk1 and Chk2 phosphorylate Cdc25C thus marking it for 
degradation and inhibiting the activation of cyclin B/CDK1 complexes (208, 
210). Additionally, Chk1 can activate Wee1, an inhibitor of CDK1 (211).  
 
ATM and ATR can also stimulate the DNA damage response through a p53 
dependent pathway. Sensing of damage stabilises p53 which in turn activates 
transcription of many genes including p21, 14-3-3s and GADD45 (212, 213). 
These negatively influence cyclin B/CDK1 complexes to either inhibit activity, 
dissociate the complex or inhibit nuclear import thus leading to a cell cycle 
arrest. As well as contributing to a G2/M arrest, p53 inhibits G1/S progression 
through increased expression of p21 leading to inhibition of CDK2, CDK4 and 
CDK6 (214).  
 
The activation status of cyclin B/CDK1 complexes are controlled in multiple 
ways, primarily by post translational modifications to CDK1. The 
phosphorylation state of CDK1 is controlled by the balance of Wee1/Myt1 
kinases and Cdc25 phosphatases, which are in turn regulated by cyclin B/CDK1 
complexes (Figure 1.4). Through this feedback loop the cyclin B/CDK1 complex 
can further stimulate its own activation and advance the G2/M transition.  
 
1.5.4 M phase 
The M phase is the final and shortest phase of the cell cycle and is characterised 
by a decrease in cyclin A and increasing cyclin B levels in a complex with CDK1. 
Mitosis is further divided into prophase, prometaphase, metaphase, anaphase, 
telophase and cytokinesis. Progression through M phase is primarily driven by 
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cyclin B/CDK1 complexes, which shifts from a cytoplasmic to nuclear 
localisation during prophase (215). Once active, cyclin B/CDK1 complexes 
contribute to mitosis by stimulating spindle assembly, breakdown of the nuclear 
envelope and disassembly of the Golgi apparatus and the ER (216-218). 
 
Arguably the most important regulators of mitosis are the Cdc25 phosphatases 
(Cdc25A, B and C) which regulate cyclin B/CDK1 activity. While Cdc25A 
functions at the G1/S transition, Cdc25B and Cdc25C are important for the 
G2/M transition (219, 220). Throughout interphase Cdc25C is phosphorylated 
on an inhibitory residue thereby inhibiting its activity. Immediately prior to 
mitotic entry Cdc25 becomes dephosphorylated allowing it to activate cyclin 
B/CBK1 which then forms a positive feedback loop (220) (Figure 1.4). Another 
regulator of cyclin B/CDK1 activity is Polo-like kinase 1 (Plk1), which positively 
regulates Cdc25C activation further stimulating M phase progression (221). In 
addition, Plk1 negatively regulates the DNA damage response to prevent cell 
cycle arrest during mitosis (222). Progression through the final M phase stage, 
cytokinesis, requires degradation of cyclin B and any remaining cyclin A by the 
anaphase-promoting complex/cyclosome.  
1.6 Viral manipulation of the cell cycle 
Viruses depend on the host cell to provide resources for replication however 
access to certain resources may be limited depending on the cell cycle phase. 
Manipulation of the host cell cycle is a common strategy employed by viruses to 
generate a beneficial environment for replication. This subversion of the cell 
cycle can be achieved by either arresting the cell cycle in a certain phase or by 
promoting faster progression through a phase or checkpoint.  
 
1.6.1 DNA viruses and retroviruses 
Alteration of the cell cycle by DNA and retroviruses has been studied 
extensively. DNA viruses primarily replicate in the nucleus and are therefore 
either reliant on the host cell to provide replication machinery or must provide 
the replication machinery themselves.  
 
The small DNA virus, human papillomavirus (HPV), infects nondividing (G0) 
epithelial cells with little to no replication machinery available. To overcome this 
 26 
HPV encodes gene products termed E6 and E7 which stimulate re-entry into the 
cell cycle and progression into S phase through interactions with p53 and Rb 
respectively (223-225). Expression of E4 can inhibit M phase progression which 
in combination with E6 and E7 can induce a replication competent pseudo-S 
phase beneficial for the virus (226). While many DNA viruses favour an S phase 
cell cycle arrest, large DNA viruses such as those in the Herpesviridae family 
encode their own replication machinery and do not require the S phase 
environment for replication. Due to the complex lifecycle of herpes simplex virus 
studies have shown that multiple viral proteins, including ICP0 and UL24 
contribute in different ways to a cell cycle arrest and there is evidence for both 
G2/M and G0/G1 arrests (227-229).  
 
Some retroviruses have also been documented to arrest the cell cycle. A well-
studied example is human immunodeficiency virus (HIV) which arrests infected 
cells in the G2 phase. It is possible that this arrest prevents a T-cell-mediated 
immune response by inhibiting clonal expansion thus allowing the virus to go 
undetected (230). Replication of retroviruses requires integration of the viral 
cDNA into the host genome. HIV-1 proteins contain a nuclear localisation 
sequence (NLS) to facilitate entry of the DNA into the nucleus and therefore do 
not require breakdown of the nuclear membrane (231). In contrast, murine 
leukemia virus has developed a mechanism to induce an accumulation of cells 
in M phase leading to nuclear membrane breakdown in order to get the viral 
DNA into the nucleus for integration (232). 
 
1.6.2 RNA viruses 
The genomes of RNA viruses are typically shorter than those of DNA viruses 
and have limited coding capacity. Despite the cytoplasmic replication of RNA 
viruses, a number of both negative- and positive-sense RNA viruses have been 
shown to induce changes in the cell cycle. For many viruses the mechanisms 
governing these arrests have not fully elucidated however certain themes can be 
seen with G0/G1 or G2/M arrests favoured, and the arrest is often mediated 
through a p53 dependent pathway.    
 
Influenza virus is a negative-sense RNA virus and has been shown to 
manipulate the cell cycle in multiple ways. Replication of influenza A virus in 
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cells induces a G0/G1 cell cycle which provides favourable conditions for viral 
replication (233). Currently, three proteins from influenza have been shown to 
contribute to an arrest. The non-structural protein NS1 induces G0/G1 arrest 
through manipulation of the RhoA protein, an upstream kinase for Rb (234). A 
second protein shown to manipulate cell cycle pathways is the nucleoprotein 
(NP) of influenza. Under normal conditions expression and stabilisation of p53 
is activated at DNA checkpoints at the G1/S and G2/M interfaces when DNA 
damage is detected. NP increases p53 activity by inhibiting the interaction with 
Mdm2 (235-237). Increased p53 activity further enhances p21 transcription and 
could contribute to a cell cycle arrest (238). Finally, the matrix 1 (M1) from 
several influenza virus strains interacts with the host protein SLD5 to induce a 
G0/G1 arrest (239). SLD5 is part of a complex of proteins which are required for 
the initiation of DNA synthesis. Expression of SLD5 was found to partially 
rescue an M1 induced cell cycle arrest (239). The ability to induce a G0/G1 arrest 
during influenza virus infection seems to be of importance. The virus has 
evolved multiple mechanisms to control the cell cycle, specifically the G0/G1 
phase with proteins likely working in concert to provide an environment 
beneficial to viral replication.   
 
Infection of cells with Newcastle disease virus (NDV) results in a G0/G1 cell 
cycle arrest by delaying entry into the S phase (240). The G1 arrest selectively 
favoured viral replication and was shown to be consistent across several NDV 
strains (240). Increased p53 expression along with decreased expression of 
phosphorylated Rb, cyclin D1, cyclin E, p21 and p27 were observed with NDV 
infection (240). The researchers then went on to show that the PERK/eIF42a 
protein cascade is active in infected cells (241). This pathway inhibits host 
protein translation and a downstream effector is growth arrest and DNA 
damage-inducible gene 153 (GADD153). Overexpression of GADD153 further 
enhanced the decrease in cyclin D1 levels during NDV infection suggesting a 
possible pathway by which an NDV cell cycle arrest could be mediated (240).  
 
Within the coronavirus family there is considerable variation in the mechanism 
and cell cycle phase where an arrest is induced. The N protein of infectious 
bronchitis virus, mouse hepatitis virus (MHV) and severe acute respiratory 
syndrome coronavirus have been shown to induce a G2/M cell cycle arrest. The 
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arrest is achieved by delaying the exit of cells from the G2/M phase possibly 
through aberrant cytokinesis (242-245). The N protein of another coronavirus, 
transmissible gastroenteritis virus, induces a G2/M arrest and the same protein 
also contributes to an S phase arrest (246, 247). In addition to G2/M arrests, 
G0/G1 cell cycle arrests have been reported for a number of coronaviruses. The 
non-structural protein, p28, of mouse hepatis virus (MHV) arrests cells in the 
G0/G1 phase (248). Expression of either p28 or infection with MHV results in an 
increase in un/hypophosphorylated Rb, stabilisation of p53 and decreased 
activity of cyclin/CDK complexes which in turn prevents the G1/S transition 
(248, 249). A G0/G1 arrest has also been reported for porcine epidemic diarrhoea 
virus although the protein responsible has not yet been identified (250). Overall 
these results suggest that cell cycle control by coronaviruses is conserved. 
Viruses in this family are able to manipulate the cell cycle using a number of 
different proteins to achieve generally either a G2/M or G0/G1 phase cell cycle 
arrest.  
 
Another positive-sense RNA virus which manipulates the cell cycle to induce a 
G1/S arrest is red spotted grouper nervous necrosis virus (RGNNV) (251). The 
arrest is induced by the B1 protein which localises to both the cytoplasm and 
nucleus. Two arginine rich domains of B1 mediate nuclear targeting which also 
correlates with the induction of cell cycle arrest. The arrest is characterised by an 
increase in p53 and p21 and a decrease in cyclin D1, CDK4 and Mdm2 (251, 252). 
Blocking of the p53 pathway reduces the ability of the virus to induce a cell cycle 
arrest suggesting that arrest occurs through a p53 dependent mechanism (252). 
The G0/G1 phase and the S phase were shown to support higher levels of viral 
replication than cells in G2/M (252). It is possible that the RGNNV B1 protein 
mediated G1/S arrest may inhibit early cell death allowing the virus to gain a 
replication advantage. In support of this idea B1 has been shown to have an anti-
necrotic function when expressed in fish cells (253). The underlying mechanism 
for the G1/S arrest has not been defined, although the dual localisation in the 
cytoplasm and nucleus may allow B1 to directly inhibit mRNA transcription, 
stability or translation (251).  
 
These are just some of the RNA viruses that manipulate the cell cycle and other 
examples include zika virus, Japanese encephalitis virus, avian reovirus, 
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enterovirus 71 and spring viremia of carp virus (254-258). Viruses have evolved 
to express one or more proteins which interfere with the cell cycle and do so 
through various pathways. Clearly manipulation of the host cell cycle by RNA 
viruses is a common method employed to modify the cellular environment.  
1.7 Manipulation of the cell cycle by MNV VPg 
In addition to the above examples, MNV is also able to manipulate the host cell 
cycle. Infection of RAW 264.7 murine macrophages with MNV induces changes 
to mRNA transcripts associated with the cell cycle including downregulation of 
cyclins E, A and B, CDK4, CDK2, Skp2 and upregulation of Mdm2 (185). MNV 
manipulates the cell cycle to induce an accumulation of cells in the G0/G1 phase, 
at ~75% compared with mock transfected cells at ~55% (Figure 1.5A) (185). There 
is a corresponding decrease in the proportion of cells in the S phase and no 
change to the G2/M phase over the course of a 12-hour infection (185). These 
changes are consistent with other viruses that arrest the cell cycle in the G0/G1 
phase (234, 249 252, 259).  
 
Synchronisation of cells into different phases of the cell cycle using inhibitors has  
shown that MNV induces an arrest by delaying the transition from the G1 phase 
into the S phase (185). In cells synchronised with sodium butyrate into the G1 
phase MNV infection is able to hold cells in G0/G1 while uninfected cells 
progress out of this phase and into S phase (Figure 1.5B). In contrast 
synchronisation of cells in the M phase followed by infection does not affect 
progression out of the M phase and into G0/G1 (185). In addition, MNV 
replication is highest in cells that are progressing through the G1 phase, as 
opposed to any other cell cycle phase (Figure 1.5 C and D) (185). It was therefore 
proposed that MNV prolongs the G1 phase by delaying the G1/S transition and 
gains a beneficial replication environment (185).  
 
Analysis of cyclin protein expression during infection revealed a decrease in 
cyclin A, likely due to the decreased percentage of cells in S phase. Unlike with 
many of the other RNA viruses which arrest in the G0/G1 phase, no change in 
protein levels of cyclins D or E were observed during infection (185). A cell cycle 
arrest in G0/G1 supported increased viral replication, as evidenced by increased 
viral titres and protein expression. 
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Figure 1.5 MNV arrests cells at the G1/S transition to obtain a beneficial replication 
environment. 
Figure adapted from Davies et al (185). (A) Unsynchronised RAW-Blue cells were either 
infected with MNV of mock infected. Cells were harvested at the indicated hours post 
infection and the percentage of cells in the G0/G1 phase determined. (B) Cells were 
synchronised into the G1 phase with sodium butyrate, released and either infected with 
MNV or mock infected. Cells were harvested at the indicated hours post infection. The 
percentage of cells in the G0/G1 phase is shown. (C) Expression of capsid protein at 9 
hpi in RAW-Blue cells held in different phases of the cell cycle. G1> represents cells 
synchronised into M phase and then released prior to infection to create a population of 
cells progressing through G1. (D) RAW-Blue cells were either left unsynchronised or 
synchronised and held in the indicated cell cycle phase for infection. MNV progeny 
virus release at 9 hpi was determined by plaque assay.  
 
Experiments to look at the protein responsible for arrest showed that expression 
of VPg alone was sufficient to induce an arrest indistinguishable to that of the 
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or translation (F123) activities of VPg had no effect on the cell cycle arrest 
indicating that the arrest is independent of these roles (186). Truncation of MNV 
VPg to express different structural regions of the protein showed that the first 62 
N-terminal amino acids were sufficient to induce arrest despite a decrease in 
total protein compared to full length VPg (Figure 1.5). The construct expressing 
the VPg 11-107 which lacks the disordered N-terminus and eIF binding site was 
not able to induce arrest. A third construct expressing the disordered C-terminal 
region and the eIF binding site (VPg 63-124) did not arrest cells but expression 
could not be confirmed (Figure 1.5) (260). Although these experiments have 
shown that MNV VPg induces a G0/G1 cell cycle arrest to favour viral 
replication, a mechanism for cell cycle control has not been identified.  
 
 
Figure 1.6 Schematic of truncated VPg proteins 
Diagram of full length (1-124 residues) MNV VPg and truncated MNV VPg constructs. 
Helices are shown in yellow and the eIF binding site is shown in orange. The numbers 
above each construct indicate the position of amino acids within VPg. A positive G0/G1 
cell cycle arrest is indicated by a tick (✓) and constructs which did not induce cell cycle 
arrest are indicated with a cross (✕). Expression of each construct was confirmed by 

































1.8 Focus of my research 
Norovirus remains a leading cause of gastroenteritis worldwide with a 
significant economic burden. Despite advances in norovirus cell culture there 
are currently no vaccines or antiviral treatments available. Development of 
effective treatments is reliant on a thorough understanding of the norovirus 
lifecycle and interaction with the host cell. Manipulation of the host cell cycle by 
MNV VPg has been demonstrated to induce a beneficial replication environment 
for the virus. The aim of my project was to further determine the role of VPg in 
induction of a cell cycle arrest. Specifically, the conservation of a G0/G1 cell cycle 
arrest by VPg proteins in the Norovirus genus and the Caliciviridae family was 
investigated using flow cytometry to monitor the effect of VPg proteins on cell 
cycle progression. To identify and examine the region of MNV VPg responsible 
for inducing a cell cycle arrest protein sequences were aligned and the ability of 
mutant VPg proteins to arrest the cell cycle was measured. Lastly the mechanism 
by which MNV VPg manipulates the cell cycle was explored using bioinformatic 
sequence analysis to predict potential mechanisms. Each of these were then 
experimentally investigated. Study of norovirus manipulation of the host cell 
cycle will provide insights into the viral lifecycle and may help in the 





2.1 Analysis of the role of VPg proteins on the cell cycle   
2.1.1 Ethical approvals 
In accordance with New Zealand regulatory standards, the use of a RAW-BlueTM 
cells (InvivoGen) was covered by the hazardous substances and new organisms 
(HSNO) approval number GMD101729 and transformation of Escherichia coli (E. 
coli) by GMD101715.  
 
2.1.2 Design of synthetic VPg constructs for RNA transfection 
Unless otherwise stated all transfections were performed using in vitro 
transcribed RNA. Viral ORF1 polyprotein sequences were obtained from 
GenBank and the VPg sequence identified using either experimentally defined 
or predicted protease cleavage sites. Following identification of the VPg 
sequence, synthetic VPg constructs were designed using SeqBuilder Pro from 
the Lasergene suite of sequence analysis software (DNASTAR). Each construct 
included a viral VPg gene flanked by 5’ and 3’ restriction enzyme sites, a T7 
promoter sequence for RNA transcription, a start codon and a stop codon 
(Figure 2.1) (Table 2.1). Where indicated a 3’ Strep-tag II sequence was 
incorporated between the VPg gene and the stop codon (Table 2.1). The full 
length MNV VPg and enhanced green fluorescent protein (EGFP) constructs 
used in these experiments were previously produced in the Ward Laboratory in 
a pUC8 vector (261).  
 
 
Figure 2.1 Design overview for synthetic VPg constructs 
Each VPg construct contained a T7 RNA polymerase promoter (blue triangle), a start 
(ATG) and a stop (TAA) codon. The synthetic construct was flanked by a 5’ and 3’ 
restriction enzyme (RE) site. Where indicated a Strep-tag II was incorporated at the C-





Synthetic VPg constructs to investigate the role of the N-terminal region for 
induction of a cell cycle arrest were designed as above (Figure 2.1). All constructs 
are full length MNV VPg unless otherwise stated and are derived from MNV-1 
CW1 (GenBank: DQ285629) (Table 2.2).  
 
All constructs were synthesised by GenScript and cloned into either a pUC57, 
pUC57-simple or pJET2.1 vector. All VPg constructs were sequenced to confirm 
identity prior to arrival. Lyophilised plasmid DNA was centrifuged at 6000 x g 
for one minute to avoid loss of material during opening and reconstituted in 20 
µl of MilliQ water.  
 

































AFJ21375 BamH I No 
HuSV Sapovirus X86379 Hind III No 
RHDV Lagovirus U54983 Hind III No 
FCV Vesivirus M86379 Hind III Strep-tag II 
Newbury 1 virus Nebovirus DQ013304 Hind III Strep-tag II 
a All constructs were designed without a C-terminal tag. Where indicated, a second 
construct was designed to incorporate a C-terminal Strep-tag II for detection. The Strep-




Table 2.2 Synthetic MNV VPg constructs to investigate the role of the N-terminal 




Description of modificationa 
11-124 VPg Hind III First 10 N-terminal amino acids removed 
K5A VPg Hind III Single point mutation lysine 5 to alanine 
K7A VPg Hind III Single point mutation lysine 7 to alanine 
G9A VPg Hind III Single point mutation glycine 9 to alanine 
R10A VPg Hind III Single point mutation arginine 10 to alanine 
MNV VPg 
triple mutant 
EcoR I Mutation to alanine at positions K5, K7 and 
R10 
M20/EGFP EcoR I First 20 N-terminal amino acids of MNV 
VPg fused to EGFP 
M20/FCV VPg EcoR I First 20 N-terminal amino acids of MNV 
VPg fused to amino acids 18-111 of FCV VPg 
F18/MNV VPg EcoR I First 18 N-terminal amino acids of FCV VPg 
fused to amino acids 21-124 of MNV VPg 
M20/NB1 VPg EcoR I First 20 N-terminal amino acids of MNV 




EcoR I First 9 N-terminal amino acids of Newbury 
1 VPg fused to amino acids 21-124 of MNV 
VPg 
a Each modified construct incorporated a methionine codon and stop codon for 
translation 
 
2.1.3 Preparation of rubidium chloride competent E. coli cells  
XL1-Blue MRF’ E. coli cells were streaked onto a LB agar plate containing 12.5 
µg/ml tetracycline and 10 mM magnesium chloride. The plate was incubated 
overnight and a single colony was inoculated into a 5 ml broth containing 50 
µg/ml ampicillin. The culture was grown overnight at 37 °C with oscitation at 
200 revolutions per minute (RPM). The following morning, 120 ml of pre-
warmed LB broth was inoculated with 1.2 ml of the overnight culture and grown 
until the OD600 reached 0.38 (2-3 hours). The culture was placed on ice for 15 
minutes, transferred to four JA20 centrifuge tubes and centrifuged at 3000 x g for 
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10 minutes at 4 °C. The supernatant was discarded and each E. coli pellet was 
resuspended in 10 ml of transformation buffer I (Appendix I) and combined into 
two JA20 tubes. The cells were centrifuged again at 3000 x g for 10 minutes at 4 
°C, the supernatant discarded and each pellet resuspended in 2 ml of 
transformation buffer II (Appendix I). Competent cells were divided into 100 µl 
aliquots and stored at -80 °C. 
 
2.1.4 Transformation 
To amplify the plasmid, rubidium chloride competent E. coli cells were 
transformed with plasmid DNA. An aliquot of E. coli cells was thawed on ice for 
30 minutes, following this 0.5 µl of reconstituted plasmid DNA was added and 
incubated on ice for a further 30 minutes. The mix was heat shocked at 37 °C for 
five minutes before addition of 900 µl of pre-warmed LB broth. The 
transformation mix was incubated at 37 °C for one hour and 200 µl was plated 
onto a LB agar plate with the appropriate antibiotic resistance. Plates were 
grown for 14-16 hours at 37 °C.  
 
2.1.5 Plasmid extraction (Midi and Miniprep) 
Transformed colonies were single colony purified and grown in LB broth with 
the appropriate antibiotic selection until the OD600 reached 0.8. Plasmids were 
extracted for linearisation and RNA transcription using the PureLinkTM HiPure 
Plasmid Midiprep kit (Thermo Fisher Scientific) according to manufacturer’s 
instructions. The DNA was aliquoted into microcentrifuge tubes and 
resuspended in 30 µl of MilliQ water. Plasmids were extracted for restriction 
enzyme digest and cloning using the QIAprep Spin Miniprep kit (Qiagen) 
according to manufacturer’s instructions and the DNA resuspended in 50 µl of 
MilliQ water.  
 
2.1.6 Plasmid linearisation and ethanol precipitation 
Plasmid DNA was linearised at the 3’ end of the viral VPg gene using the 
appropriate restriction enzyme (Tables 2.1 and 2.2). Each 50 µl digest contained 
16 µg of plasmid DNA, 2 µl (20 units) of restriction enzyme and 5 µl of the 
appropriate restriction enzyme buffer. The reaction was incubated at 37 °C for 
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three hours. The linearised DNA from each digest was purified by ethanol 
precipitation. To each digest the following was added: 1/10 volume of 3 M 
sodium acetate and 2 volumes of -20 °C 100% ethanol. This was incubated at -20 
°C overnight and the DNA was then pelleted at 13,000 x g for 15 minutes. The 
supernatant was removed and pellet air dried before being resuspended in 15 µl 
of MilliQ water and stored at -20 °C, following which 1 µg of linear DNA was 
run on an agarose gel to confirm linearisation. 
 
2.1.7 Agarose gel electrophoresis 
DNA was analysed by agarose gel electrophoresis on a 1% agarose gel with 1 x 
tris-acetate (TAE) buffer (Appendix I). Prior to loading 3 µl of loading dye (New 
England Biolabs) was added to each sample and the gel was electrophoresed in 
1 x TAE buffer at 100 V, 400 mA for one hour. The gel was then stained in 
ethidium bromide (1 µg/ml) for one hour and the DNA bands visualised using 
ultraviolet light on the UVIDOC HD6 gel documentation system (UVITEC 
Cambridge).  
 
2.1.8 Generation of RNA transcripts 
Messenger RNA (mRNA) transcripts were generated using the mMessage 
mMachine T7 ultra transcription kit (Ambion) and purified using the 
MEGAclearTM Transcription Clean-Up kit (Ambion) according to 
manufacturer’s instructions. Briefly, the transcription and capping reaction was 
assembled with 1 µg of linear DNA, 2 µl of 10 x reaction buffer, 10 µl 
NTP/ARCA, 2 µl T7 RNA polymerase and nuclease free water to a final reaction 
volume of 20 µl. The transcription reaction was incubated at 37 °C for two hours 
following which 1 µl of DNase was added and incubated for 15 minutes to 
degrade the DNA template. For poly A-tailing of the RNA transcript the 
following were added; 36 µl of nuclease free water, 20 µl of 5 x E-PAP buffer, 10 
µl 25 mM MnCl2, 10 µl 10 mM ATP solution and 4 µl E-PAP. The reaction was 
incubated at 37 °C for 45 minutes and then transferred onto ice. The RNA was 
purified using the MEGAclear TM Transcription Clean-Up kit (Ambion) 
following manufacturer’s instructions. Purified RNA was eluted in a total 
volume of 50 µl nuclease free water and a 1/10 dilution was analysed on the 
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NanoDrop One spectrophotometer (Thermo Fisher Scientific). RNA was stored 
at -80 °C in aliquots of 4-5 µg.  
 
2.1.9 Mammalian cell culture 
RAW-Blue cells 
RAW-BlueTM cells (InvivoGen) are a murine macrophage cell line derived from 
RAW 264.7 cells which express a secreted embryonic alkaline phosphatase under 
transcriptional control of NFκB/AP-1. These cells have been shown to support 
the replication of MNV-1(262). Cells were maintained in Dulbecco’s modified 
eagle medium (DMEM) (Gibco, Thermo Fisher Scientific) supplemented with 
10% foetal bovine serum (FBS) (referred to as RAW-Blue medium). All cell 
incubations were performed at 37 °C + 5% CO2 unless otherwise stated. Cells 
were passaged when they reached a confluency of approximately 70-80%. 
Briefly, medium was removed, cells were scraped into 10 ml of fresh medium 
and pelleted for five minutes at 300 x g. A 75 cm2 flask was seeded with 2.5x106 
cells in 20 ml of RAW-Blue medium and incubated at 37 °C + 5% CO2.   
 
Storage of RAW-Blue cells 
Cells were passaged as above, but were seeded into a 175 cm2 flask at 2x107 cells 
and grown overnight until they were ~70-80% confluent. The cells were scraped, 
washed and resuspended in freezing medium (90% FBS + 10% dimethyl 
sulfoxide) at ~3x106 cells/ml. The cells were aliquoted (1 ml) into cryotubes and 
cooled to -80 °C in a NalgeneTM Cryo Freezing container before being transferred 
to liquid nitrogen. RAW-Blue cells were recovered from liquid nitrogen by 
thawing an aliquot in a 37 °C water bath. The cells were then transferred to a 25 
cm2 cell culture flask containing 4 ml of RAW-Blue medium. The medium was 
replaced the following day and cells were grown until they were 70-80% 
confluent and were then transferred to a 75 cm2 flask and maintained as above.  
 
2.1.10 Transfection of RAW-Blue cells 
RNA transcripts were transfected into RAW-Blue cells using the Neon 
Transfection system (Thermo Fisher Scientific) according to manufacturer’s 
instructions. RAW-Blue cells were scraped, centrifuged at 300 x g for five 
minutes and resuspended in 5 ml of Dulbecco’s phosphate buffered saline 
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(dPBS). Cells were counted, centrifuged and resuspended in resuspension buffer 
(Appendix I) at 1x107 cells/ml. RNA transcripts (4 "g) were mixed with ~120 "l 
of cells, to allow for additional volume to avoid air bubbles and were drawn into 
a 100 "l Neon transfection tip. The RNA/cell mix was electroporated with 1 
pulse at 1730 V and 20 mA. Transfected cells were seeded in 6-well plates 
containing 2 ml pre-warmed RAW-Blue medium and incubated for 12 hours.  
 
2.1.11 Cell cycle analysis 
The percentage of cells in each phase of the cell cycle was determined using flow 
cytometry to analyse the DNA content of cells. Transfected cells were scraped 
into medium, pelleted at 300 x g for five minutes and resuspended in 3 ml of -20 
°C 70% ethanol to fix and permeabilise cells. The following day, cells were 
pelleted at 800 x g for three minutes and washed in 5 ml of dPBS. Fixed cells 
were centrifuged again and resuspended in 400 µl of dPBS with 50 µg/ml 
propidium iodide (PI) (Sigma-Aldrich) to stain DNA and 0.1 mg/ml RNase A 
(Sigma-Aldrich) (Appendix I) to degrade RNA. The cells were incubated at 37 
°C for 45 minutes, transferred to fluorescence cytometry tubes and analysed on 
the BD LSRFortessa flow cytometer (BD Biosciences). Three lasers were used; 
SSC, FSC and YG_610/20 on a linear scale and at least 30,000 cells were counted 
for each sample. FSC files exported from the BD LSRFortessa flow cytometer 
were opened in MODfit (Verity Software House), a programme designed for the 
purpose of analysing the DNA content of cells. Data was gated using the SSC-A 
vs FSC-A to remove debris and SSC-A vs SSC-H and FSC-A vs FSC-H to remove 




Figure 2.2 Example of the gating for flow cytometry analysis of the cell cycle 
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Gating was used to include single cells for cell cycle analysis with debris, clumps and 
doublets removed.  
2.2 Analysis of protein expression 
2.2.1 BCA protein estimation 
Protein concentrations in cell lysates was determined using the PierceTM BCA 
Protein Assay kit (Thermo Fisher Scientific) according to manufacturer’s 
instructions.  Briefly, 25 µl of cell lysate or BSA standard was loaded in triplicate 
in a 96-well plate and 200 µl of BCA working reagent (50:1 Reagent A: Reagent 
B) was added to each well. The plate was incubated at 37 °C for 30 minutes and 
the absorbance measured at 595 nm and analysed using Prism software.  
 
2.2.2 Purification of Strep-tag II constructs 
For detection of Strep-tag II labelled VPg proteins from RNA transfections, RAW 
Blue cells (~3x106) were scraped, centrifuged and washed in 1 ml of PBS. Cells 
were resuspended in 500 µl of lysis buffer (Appendix I) and lysed on ice for 10 
minutes. The soluble and insoluble fractions were separated by centrifugation at 
14,000 x g for 10 minutes and the supernatant transferred to a microfuge tube 
containing 10 µl of MagStrep “type 3” XT beads (IBA) to bind the Strep-tag II 
expressing protein. The beads and soluble supernatant were incubated for 2 
hous at 4 °C with rotation before separation of the beads using a magnetic 
separator. Beads were washed twice in wash buffer (Appendix I) and 
resuspended in 25 µl of wash buffer and 25 µl of 2 x sample buffer (Appendix I). 
Samples were stored at -20 °C until analysis by western blot. Transfected 
samples without a Strep-tag were directly resuspended in 25 µl of PBS and 25 µl 
of 2 x sample buffer.  
 
2.2.3 SDS-PAGE gels 
To visualise proteins of interest, lysates were separated on sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels followed by 
Coomassie blue G250 staining or western blotting. SDS-PAGE gels (Appendix I) 
were prepared and the gel system was assembled in 1 x SDS-PAGE running 
buffer (Appendix I). Protein samples in sample buffer were boiled for 10 minutes 
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to fully denature the proteins and loaded onto the gel. SDS-PAGE gels were 
electrophoresed at 170 V until the dye front reached the bottom of the gel. Gels 
were either processed for western blot analysis or directly stained in Coomassie 
blue stain (Appendix I) at RT overnight. Stained gels were then soaked overnight 
in destain solution (Appendix I) and imaged on the UVIDOC HD6 gel 
documentation system.  
 
2.2.4 Western blot 
Gels for western blot analysis were soaked for 15 minutes in cathode buffer 
(Appendix I). Six pieces of Whatmann 3 mm filter paper and a 0.2 "m 
nitrocellulose membrane (Amersham) were cut to the size of the gel. The 
nitrocellulose membrane and three pieces of filter paper were equilibrated in 
cathode buffer, two pieces of filter paper were equilibrated in anode buffer I 
(Appendix I) and one piece in anode buffer II (Appendix I) for five minutes. The 
transfer sandwich was assembled as follows (from the lower anode plate); two 
pieces of filter paper soaked in anode I, one piece of filter paper soaked in anode 
II, nitrocellulose membrane, SDS-PAGE gel and three pieces of filter paper 
soaked in cathode buffer. Proteins were transferred from the gel onto the 
membrane using the Bio-Rad Transblot TurboTM Transfer System (Bio-Rad) at 20 
V for 20 minutes and following transfer, the membrane was dried on the bench 
overnight. The membrane was probed for expression of specific proteins using 
antibodies towards the protein of interest (Table 2.3). Firstly, the membrane was 
blocked in blocking buffer (Appendix I) for one hour. The membrane was then 
probed with primary antibody diluted in antibody diluent (Appendix I) and 
incubated for one hour before being washed for five minutes in 10 ml of PBST 
(PBS + 0.1 % Tween-20), three times. After washing, the membrane was 
incubated with the corresponding secondary antibody (Table 2.3) for one hour 
in the dark and washed again. Protein expression was visualised on the LI-COR 
Biosciences Odyssey Fc Imager and analysed using ImageStudio Lite software 







Table 2.3 Antibodies for western blot analysis 
Antibody Dilution Source Catalogue number 
Rabbit a-VPga 1:1000 Ward Laboratoryc n/a 










1:500 Cell Signalling 
Technology 
9741 
Mouse a-Strepb 1:1000 Qiagen 34850 
Mouse a-Tetra Hisb 1:1000 Qiagen 34670 
Mouse a-GFPb 1:1000 Thermo Fisher Scientific A-11121 
Goat a-actin (I-19)a 1:2000 Santa Cruz sc-1616 
Rabbit a-Lamin B1a 1:1000 Abcam ab16048 
Rabbit a-Tubulina 1:1000 Abcam ab18251 
Donkey a-Rabbit IgG 
DyLight 800 
1:20000 Thermo Fisher Scientific SA5-10044 
Donkey a-Goat IgG 
DyLight 680 
1:20000 Thermo Fisher Scientific SA5-10090 
IRDye 680RD 
Donkey a-Mouse IgG 
1:20000 LI-COR Biosciences 926-68072 
a Polyclonal 
b Monoclonal 
c Antibody produced by Estelle Baker with specificity confirmed in (261) 
 
2.2.5 Mass spectrometry 
Expression of VPg proteins was confirmed by mass spectrometry. Briefly 
transfected RAW-Blue cells (~3x106 cells) were scraped directly into cell 
medium, centrifuged and washed in PBS. The cell pellet was resuspended in 50 
µl of RIPA buffer and 10 µl of 6 x sample buffer (Appendix I). Samples were run 
on an SDS-PAGE gel and stained in Coomassie blue G250 stain. Protein 
expression was insufficient to detect a specific protein band corresponding to 
VPg therefore the area corresponding to the predicted size was excised from the 
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gel with a scalpel blade. The gel slice was trypsin digested and analysed by LTQ-
Orbitrap XL mass spectrometry by the Centre for Protein Research (University 
of Otago, NZ). 
2.3 Construction of norovirus VPg vectors for protein 
expression in insect cells 
2.3.1 Design of synthetic genes 
Synthetic DNA constructs (Table 2.4) for expression of protein in insect cells 
were synthesised by GenScript. The constructs were synthesised in pUC57 and 
designed to incorporate an MNV VPg gene with a stop codon flanked by Bgl II 
and EcoR I at the 5’ and 3’ respectively. Synthetic genes were reconstituted, 
transformed into E. coli, single colony purified and the DNA extracted by 
miniprep as described previously. 
 





MNV VPg DQ285629 No 
MNV VPg triple 
mutant 
DQ285629 K5, K7 and R10 mutated to 
alanine 
MNV VPg K2-12 DQ285629 K2 – K8, R10 and R12 
mutated to alanine 
HuNV VPg GII JX459908 No 
CATb BBB3751.1 No 
FOX-1c Q9NWB1 RBDd (residues 109-208) 
a Where indicated constructs were modified from the original protein sequence 
b Chloramphenicol acetyltransferase 
c Feminizing locus on X 
d Only the RNA binding domain of FOX-1 was synthesised 
 
For expression and purification of norovirus genes in an insect cell system 
Vivienne Young (Ward laboratory) designed an N-terminal fusion which was 
cloned into a pAcpol- vector (termed pAc.NT*). The N-terminal fusion consists 
of two epitope tags (Strep-tag II and His6 tag) for protein purification and an NT* 
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tag to aid in protein solubility (Figure 2.3). The NT* tag is a solubility tag derived 
from spider silk protein that has been shown to reduce protein aggregation 
within the spider silk gland despite high protein concentrations (263). NT* has 
been used in the Ward laboratory to aid solubility of other norovirus proteins 
and VPg constructs were designed to clone into the Bgl II/EcoR I site of pAc.NT* 
(Figure 2.3).   
 
Figure 2.3 Schematic of pAc.NT* for expression of VPg genes 
The NT* fusion construct was cloned into a pAcpol- vector for expression in an insect 
cell line. The construct includes a p10 promoter (blue triangle), start codon (ATG), 
sequences to encode a His6 tag (His), Strep-tag II (Strep) and NT*tag. Genes for 
expression were ligated into the vector using Bgl II and EcoR I restriction enzymes. A 
stop codon was included as part of the gene ligated into the vector. As a protein, the 
entire NT* fusion can be removed by enterokinase cleavage and the His6 tag by tobacco 
etch virus (TEV) protease cleavage.  
 
2.3.2 Restriction enzyme digests and gel extraction 
For cloning of VPg genes into pAc.NT* restriction digests were performed using 
1-5 "g of pUC57.VPg DNA or pAc.NT* DNA. To each digest 2 "l of 10 x Buffer 
H (Roche), 5 U of Bgl II and 5 U of EcoR I was added. The reaction was bought 
to a final volume of 20 "l with MilliQ water and incubated at 37 °C for three 
hours. Following digestion, the DNA was analysed by agarose gel 
electrophoresis and bands corresponding to either VPg or pAc.NT* were excised 
with a scalpel and stored at -20 °C overnight.  To recover digested DNA 
fragments from agarose gel slices a gel extraction was performed using the 
QIAquick Gel Extraction kit (Qiagen) according to manufacturer’s instructions. 

























To ligate VPg inserts into a pAc.NT* vector backbone a 10 "l ligation consisting 
of; 7.5 "l of VPg, 1 "l of pAc.NT*, 1 unit of T4 DNA ligase and 1 "l of 10 x ligation 
buffer was assembled. The ligation was incubated overnight at 4 °C and was 
then transformed into rubidium chloride E. coli as described previously. Purified 
pAc.NT*/MNV VPg, pAc.NT*/MNV VPg triple mutant (TM), pAc.NT*/MNV 
VPg K2-12 and pAc.NT*/HuNV VPg expression vectors was obtained by 
miniprep.  For RNA binding assays, a gene encoding the negative control 
protein, CAT, was ligated into pAc.NT*. A gene encoding the positive control 
protein, FOX-1, was ligated into a pAcpol- vector with a His6 and Strep-tag II but 
without an NT* tag.  
2.4 Expression and purification of NT* tagged norovirus VPg 
proteins 
2.4.1 Ethical approvals 
The development and production of norovirus VPg proteins using recombinant 
baculovirus in Spodoptera frugiperda IPLB-Sf21 (Sf21) and Trichoplusia ni (T. ni) 
cells was undertaken under the HSNO approval numbers GMD101715 and 
GMD101729.   
 
2.4.2 Maintenance of insect cell culture lines 
Sf21 cells were maintained as suspension cultures in Sf-900TM III SFM medium 
(Thermo Fisher Scientific) and were split every 3-4 days. Maintenance cultures 
were seeded at 1x106 cells/ml in 20 ml and cultures for infection (either 10 ml or 
50 ml) were seeded at 8x105 cells/ml. T. ni cells were maintained as suspension 
cultures in ESF921 medium (Expression Systems) and were split every 2-3 days. 
Maintenance cultures (20 ml) and cultures for infection (50 ml) were seeded at 
8x105 cells/ml. All cells were grown at 27 °C with shaking at 125 RPM. 
 
2.4.3 Co-transfection of Sf21 cells 
Recombinant Autographa californica nucleopolyhedrovirus (referred to as 
recombinant baculovirus) was produced by co-transfection of each 
pAc.NT*/VPg transfer vector into Sf21 cells using the FlashBAC ULTRATM 
expression system (Oxford Expression Systems). Sf21 cells were seeded in a 6-
 46 
well plate at 5x105 cells/ml in 3 ml of Sf-900 III medium per well and incubated 
at 27 °C for one hour, to allow cells to settle. A mixture consisting of 6 µl FuGENE 
6 transfection reagent (Promega) in 100 µl of Sf-900 III medium was prepared. A 
second mixture containing 1 µg of vector DNA and 5 µl (80 ng) of FlashBAC 
ULTRATM in 100 µl of Sf-900 III medium was prepared and added to the 
FuGENE 6 mixture. The transfection mixture was incubated at room 
temperature for 30 minutes, following which the medium was removed from 
Sf21 cells and the transfection mixture added dropwise onto the cell monolayer. 
The cells and transfection mixture were incubated at room temperature for one 
hour with rocking every 20 minutes. After incubation, 3 ml of Sf-900 III medium 
containing 100 U/ml penicillin and 0.1 mg/ml streptomycin was added to each 
well. Cells were incubated for four days to allow homologous recombination of 
the pAc.NT*/VPg vector with FlashBAC ULTRATM and replication of the 
recombinant baculovirus. The supernatant containing budded virus was 
collected and stored at 4 °C. The viral inoculum was bulked up by serial passage 
through Sf21 cells, first in a 10 ml culture then a 50 ml culture. When cell death 
reached 30-80% (two to four days), as determined by trypan blue staining, 
infected cultures were harvested by centrifugation at 500 x g for five minutes to 
pellet cells and the viral inoculum (supernatant) stored at 4 °C.  
 
2.4.4 Neutral red plaque assay 
The titre of recombinant baculovirus inoculum was determined by neutral red 
plaque assay. Sf21 cells were seeded in a 6-well plate at 5x105 cells/ml in 3 ml of 
Sf-900 III medium and the cells allowed to settle for one hour at room 
temperature.  The medium was removed and 100 µl of a 10-fold dilution series 
of viral inoculum ranging from 10-3-10-8 was added dropwise to the cells. The 
plate was incubated at room temperature for one hour with rocking every 20 
minutes. Following adsorption, the virus dilution was removed and the cells 
were washed with 2 ml Sf-900 III medium. A 2 ml agarose overlay consisting of 
1.5% SeaPlaque agarose and 5% FBS in Sf-900 III medium was added to the cells. 
The plate was incubated at room temperature for 20-30 minutes to allow the 
agarose to set. Sf-900 III medium (1.5 ml) containing 10% FBS and 100 U/ml 
penicillin and 0.1 mg/ml streptomycin was added to each well and the plate was 
incubated at 27 °C for three to five days. To stain the plaques, 100 µl of neutral 
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red was added to each well and incubated at 27 °C for two hours. All liquid was 
removed from the wells and the plate stored overnight at room temperature in 
the dark to allow the stained plaques to develop. The plaques were counted and 
the viral titre of the inoculum calculated.  
 
2.4.5 Protein purification 
T. ni cells were seeded for infection and incubated overnight. The following 
morning cells (~2x106 cells/ml) were infected with recombinant baculovirus at 
a multiplicity of infection (MOI) of 1 and incubated for two to four days until 
~20-40% of cells were dead. The infected culture was centrifuged at 500 x g for 
five minutes and the pellet collected. For protein purification, the cell pellet was 
lysed on ice for 15 minutes with 20 ml (20 ml/50 ml of starting culture) of lysis 
buffer (Appendix I). The lysate was centrifuged at 16,000 x g for 20 minutes at 4 
°C to separate the soluble and insoluble fractions. The soluble fraction was 
filtered through a 0.8 µm filter and incubated with 500 µl of Strep-Tactin XT 
Superflow beads (IBA) on a roller for two hours at 4 °C, to allow binding with 
the Strep-tag II present in the N-terminal fusion. Following incubation, the beads 
with bound protein were loaded onto a PierceTM Centrifuge Column (Thermo 
Fisher Scientific). The beads were washed twice in 5 ml of wash buffer 
(Appendix I), to remove non-specific proteins. Purified protein was eluted using 
a biotin elution buffer (Appendix I). Protein concentration was measured on the 
nanodrop and confirmed by SDS-PAGE gel and western blot. Eluted protein was 
stored in 500 µl aliquots at -80 °C.  
 
2.4.6 Bovine enterokinase cleavage of recombinant proteins 
The N-terminal NT* fusion contains an enterokinase cleavage site immediately 
prior to the Bgl II/EcoR I cloning site (Figure 2.3). To remove the N-terminal NT* 
fusion, purified protein was cleaved with bovine enterokinase (EK) (New 
England Biolabs). Calcium chloride at a final concentration of 2 mM was added 
directly to recombinant protein in elution buffer and the protein was diluted to 
1 mg/ml. EK (0.016 U/µg) was added to the reaction and incubated at 4 °C with 
rotation for 15 hours. To remove the EK, trypsin inhibitor agarose (Sigma-
Aldrich) (75 µl agarose/5U EK) was added to the reaction and incubated at 4 °C 
with rotation for 15 minutes. The EK reaction was centrifuged to pellet the 
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agarose and the supernatant containing cleaved and uncleaved protein collected. 
For removal of the cleaved NT* fusion and residual uncleaved protein NiNTA 
beads (20 µl/1 mg of protein) (Qiagen) were added to the reaction and incubated 
for two hours at 4 °C. The beads were pelleted by centrifugation at 5000 x g for 
two minutes, and the supernatant containing purified cleaved protein collected. 
Protein purity was confirmed by SDS-PAGE gel and western blot.   
 
2.4.7 Buffer exchange 
Cleaved and purified proteins were buffer exchanged into RNA binding buffer 
(Appendix I) using Amicon Ultra Centrifugal Filters (Merck) with either a 3 kDa 
or 10 kDa cut-off. Protein was loaded onto an Amicon filter and centrifuged at 
14,000 x g for five minutes (or until only ~100 µl remained). The filter was 
washed three times with RNA binding buffer and the protein harvested in ~100 
µl of RNA binding buffer. Protein concentration was measured on the nanodrop 
and stored at -80 °C.  
2.5 RNA binding experiments: 
The RNA binding potential of VPg was screened using a series of plasmids 
encoding for Pentaprobes (264). The ssRNA probes were labelled with ATTO 
680 rUTP (Jena Biosciences) and the interaction with purified VPg proteins was 
analysed by electrophoretic mobility shift assay (EMSA).  
 
2.5.1 Pentaprobes  
RNA binding proteins often recognise short sequence motifs of 4-5 nucleotides. 
Researchers have designed a series of nucleotide probes, termed Pentaprobes, 
using an algorithm to predict every possible five nucleotide long RNA binding 
motif expressed as 12 probes each 100 nucleotides long (264) (Appendix II). For 
ssRNA production 12 plasmids capable of expressing the 12 Pentaprobe 
sequences under control of a T7 promoter were gifted by Professor Joel Mackay 
(Addgene plasmid # 83326 – 83337) (264). Pentaprobes arrived as bacterial agar 
stabs and were streaked onto agar plates, the plasmid DNA was amplified and 
purified by midi-prep.  
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Generation of Pentaprobe RNA 
Plasmid DNA was linearised with ApaI and concentrated by ethanol 
precipitation. A transcription reaction consisting of; 4 µL of 5 x Transcription 
Optimised buffer (Promega), 1 µg of DNA template, 0.5 mM rATP, 0.5 mM rCTP, 
0.5 mM rGTP, 12.5 µM rUTP (Promega), 20 µM rUTP ATTO 680 (Jena 
Biosciences) and 40 U T7 RNA polymerase (Promega), was assembled to a final 
reaction volume of 20 µl with nuclease free water. The transcription reaction was 
incubated in the dark at 37 °C for two hours. The DNA was degraded with 
DNase (1 U/µg template DNA) (Promega) in the dark for 15 minutes at 37 °C. 
RNA was purified using the MEGAclearTM Transcription Clean-Up kit 
(Ambion), eluted in 40 µl of nuclease free water and the concentration was 
measured on a nanodrop spectrophotometer. 
 
2.5.2 RNA binding assays 
For EMSAs, Pentaprobe RNA was heated to 95 °C for one minute and then 
immediately cooled on ice to partially denature the RNA. Binding reactions were 
assembled on ice and consisted of; ~100 nM Pentaprobe RNA and purified 
protein in RNA binding buffer at the indicated concentration. The reaction was 
bought to a final volume of 9 µl with RNA binding buffer. Assembled reactions 
were incubated at 4 °C for 30 minutes to allow binding of the RNA and protein. 
Prior to loading the native tris-borate-EDTA (TBE) gel, 1 µl of RNA loading 
buffer (Appendix I) was added to each reaction. Competition assays with 
unlabelled DNA were assembled as above, with 100-fold molar excess of DNA 
probe.  
 
2.5.3 Native TBE gel electrophoresis  
Native TBE gels (Appendix I) were pre-run in 0.5 x TBE buffer (Appendix I) at 
120 V for 30 minutes prior to loading. The entire RNA binding reaction was 
loaded onto the gel and electrophoresed at 120 V until the dye front reached the 
bottom the gel (approximately 40 minutes). The gel was immediately imaged on 
the Odyssey Fc imager in the 700 nm channel. 
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2.6 Immunofluorescence microscopy 
2.6.1 Ethical approvals 
Purification of MNV-1 was carried out under HSNO approval number 
GMD101715 
 
2.6.2 Preparation of MNV-1 stocks 
MNV-1 was previously generated in the Ward laboratory by reverse genetics 
from the parental virus MNV-1 CW1.P3 (265). RAW-Blue cells were seeded into 
175 cm2 flasks at 2x107 cells and incubated overnight until they reached a 
confluency of 70-80% at which point they were infected with MNV at a MOI of 
0.1. Infected cells were incubated for 48 hours and then freeze (-80 °C) thawed 
(37 °C) twice to lyse infected cells. Cellular debris was removed by centrifugation 
at 1000 x g for 20 minutes. The supernatant was transferred to SW32 polyallomer 
tubes and a 3 ml 30% (w/v) sucrose cushion underlay was added. Purified MNV 
stocks were generated by centrifugation at 112, 700 x g for four hours at room 
temperature in a SW32 rotor (Beckman Coulter). Following the spin, the 
supernatant was discarded and each pellet was resuspended overnight at 4 °C 
in 1 ml of RAW-Blue medium. The virus inoculum was filter sterilised through 
a 0.45 µm filter to remove any contaminants and stored at -80 °C.  
 
Crystal violet plaque assay 
RAW-Blue cells were seeded in a 6-well plate at 1.2x106 cells and incubated 
overnight. The following day, a 10-fold serial dilution of purified viral inoculum 
in RAW-Blue medium was prepared. The medium was removed from the cells 
and 200 µl of serial dilutions ranging from 1x10-3–1x10-8 was added. Plates were 
incubated for one hour with rocking every 15 minutes to allow virus to adhere 
to the cells. The supernatant was removed and cells washed with 1 ml of medium 
to remove unbound virus. The cells were overlaid with 2 ml of DMEM 
containing 2.5% FBS, 0.35% Sea Plaque agarose (Lonza, Maine, USA), 100 U/ml 
penicillin and 0.1 mg/ml streptomycin (Roche). The overlay was allowed to set 
at room temperature and the plate was then incubated at 37 °C for 48 hours. Cells 
were fixed and virus inactivated with 1 ml of 4% formaldehyde for 30 minutes 
at room temperature. The entire agarose-formalin mixture was removed and 
cells washed with 2 ml MilliQ water. To visualise plaques the cells were stained 
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with 1 ml of 0.2% crystal violet (Appendix I) for 20 minutes at room temperature. 
The stain was removed and the plaques counted to determine the viral titre. 
 
2.6.3 Preparation of coverslips 
Coverslips were treated with HistoGrip (Thermo Fisher Scientific) to promote 
adhesion of the cells. Concentrated (50 x) HistoGrip was diluted to 1 x in acetone 
and coverslips were incubated for two minutes. The coverslips were thoroughly 
washed in MilliQ water and left to dry in 6-well plates.  
 
2.6.4 Infection of RAW-Blue cells 
Cells were seeded in 6-well plates with coverslips at 8x105 cells and left to grow 
overnight. The medium was removed from cells and MNV added at the 
indicated MOI and cells were incubated for one hour with rocking every 15 
minutes. The unbound virus was removed, cells were washed and 2 ml of fresh 
RAW-Blue medium was added to each well. Infected and mock infected cells 
were incubated for the indicated time period. 
 
2.6.5 Leptomycin B treatment of cells 
Toxicity of leptomycin B (LMB) on RAW-Blue cells was measured using the 
CellToxTM Green Cytotoxicity assay (Promega) according to manufacturer’s 
instructions. RAW-Blue cells were seeded on coverslips in 6-well plates and 
infected with MNV. At 6 hours post infection (hpi), 20 nM of LMB was added 
directly to the medium and incubated with cells for the duration of the infection. 
 
2.6.6 Preparation of coverslips for immunofluorescence analysis 
At the time of harvest, cells were fixed in 4% paraformaldehyde for 15 minutes 
at room temperature, washed and stored overnight in PBS at 4 °C. The cells were 
then permeabilized in PBS containing 0.1% Triton X-100 for 15 minutes at room 
temperature. Fixed cells were stained with the relevant primary antibodies 
diluted in PBS containing 3% BSA for one hour at room temperature (Table 2.4). 
After incubation, the coverslips were washed three times in PBS to remove 
unbound primary antibody. Cells were incubated with secondary antibody 
diluted in PBS containing 3% BSA for one hour at room temperature (Table 2.4) 
and washed again. Coverslips were mounted with Prolong Gold Antifade 
Reagent with DAPI (Invitrogen) and cured overnight at room temperature in the 
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dark. The coverslips were sealed with nail polish and the slides were stored in 
the dark at 4 °C. 
 
Table 2.5 Antibodies used for immunofluorescence 
Antibody Dilution Source 
Catalogue 
number 
Mouse a-eIF4Ea 1:100 BD Biosciences 610270 
Rabbit a-MNV VPgb 1:50 Ward laboratory N/A 
Rabbit a-cyclin B1b 1:100 abcam ab2949 
Goat a-mouse IgGb 
488 
1:1000 Merck SAB4600043 
Goat a-rabbit IgGb 
633 
1:1000 Merck SAB4600140 
a Monoclonal  
b Polyclonal 
 
2.6.7 Imaging and analysis 
Images were acquired with an inverted Olympus FV1200 laser scanning confocal 
microscope, using the 100 X objective. Fields of view were randomly selected 
and imaged as Z stacks spaced 1.0 µm apart starting above the cell and ending 
below. Images were captured in the 633 nm, 488 nm and 405 nm channels and 
were analysed using Fiji ImageJ software version 1.52f (266).   
2.7 Nuclear cytoplasmic splits 
RAW-Blue cells were seeded in a 6-well plate and incubated overnight. Cells 
were either mock infected or infected with MNV at a MOI of 5 and the plate was 
incubated for the indicated time periods. For harvesting, ~3x106 cells were 
scraped directly into medium, centrifuged at 300 x g for five minutes and washed 
in dPBS. Total cell samples were resuspended in RIPA buffer (Appendix I) and 
stored at -80 °C. Nuclear and cytoplasmic fractions were processed using the NE-
PER Nuclear and Cytoplasmic Extraction kit (Thermo Fisher Scientific) 
according to manufacturer’s instructions. Briefly, cells were resuspended in CER 
I and incubated on ice for 10 minutes before the addition of CER II. The reaction 
was incubated on ice for one minute and centrifuged to pellet the insoluble 
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fraction. The supernatant (cytoplasmic extract) was collected and stored at -80 
°C. The insoluble pellet was washed in dPBS, resuspended in NER and 
incubated on ice for 40 minutes with vortexing every 10 minutes. The sample 
was centrifuged and the supernatant (nuclear extract) was collected and stored 
at -80 °C. Protein concentration was determined by BCA assay and samples were 
analysed by western blot.  
2.8 Alignments 
VPg amino acid sequences were acquired from GenBank and alignments of 
sequences was performed using Clustal Omega Software (267) on the default 
settings. Sequences were manually adjusted.  
2.9 Statistical analysis 
Statistical analysis was performed using Prism (Version 8.3.0, GraphPad 
Software, Inc). Statistics were analysed using a one-way ANOVA to compare 




3.1 Conservation of a G0/G1 cell cycle arrest among diverse 
VPg proteins 
3.1.1 Introduction 
Manipulation of the host cell cycle is a common method employed by viruses to 
generate a beneficial replication environment. MNV infection of RAW-Blue 
murine macrophages consistently induces a G1/S arrest, characterised by an 
increase in the percentage of cells in the G0/G1 phase and a corresponding 
decrease in the S phase (185, 260). Expression of the VPg protein of MNV is 
sufficient to induce a cell cycle arrest similar to infection conditions (186). 
Although all viruses within the Caliciviridae family encode a VPg protein it is 
unknown if the G1/S arrest induced by MNV VPg is conserved in other 
members of the family. As there is not a readily available cell line permissible to 
these viruses, RAW-Blue cells were selected for analysis of the cell cycle in 
response to VPg proteins. This cell line has previously shown reproducible 
transfection and cell cycle profiles in response to MNV VPg (186). The aim of this 
research was to express VPg proteins representing each of the norovirus 
genogroups and calicivirus genera, and screen for the ability to manipulate the 
cell cycle. 
 
3.1.2 Transfection efficiency of RAW-Blue cells 
RAW 264.7 macrophages become activated upon transfection of DNA plasmids 
into the cell (261). However, using RNA transcripts a transfection efficiency 
upwards of 90% can be achieved at 12 hours post-transfection (hpt) (261). To 
measure the transfection efficiency of RAW-Blue cells, cells were transfected 
with RNA encoding for EGFP. The cells were harvested at 12 hpt and analysed 
on the flow cytometer. Cells were gated to remove debris and percentage of 
EGFP positive cells was measured. A transfection efficiency of ~85% was 
measured (Figure 3.1), suggesting that transfection of RAW-Blue cells with RNA 
results in high transfection efficiency and that this is a reliable method to test the 
cell cycle response of various VPg proteins.  
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Figure 3.1 Transfection efficiency of RAW-Blue cells  
RAW-Blue cells were transfected with RNA encoding for EGFP or mock transfected 
(MT) without RNA. Cells were harvested for flow cytometry analysis at 12 hpt. (A) 
Representative histograms from one of three experiments. (B) The percentage of EGFP 
positive cells were gated and graphed. The results present the mean and SD from three 
independent experiments.  
 
3.1.3 Conservation of a G0/G1 cell cycle arrest in norovirus genogroup 
VPg proteins 
At the time of testing, the norovirus genus within the Caliciviridae family was 
classified into five genogroups which were further separated into genotypes, 
based on the amino acid sequence similarity of the capsid protein. A 
representative norovirus VPg was selected from each genogroup within the 
norovirus genus and the VPg protein levels and effect on the cell cycle measured. 
For the analysis of protein levels and cell cycle manipulation a timepoint of 12 
hpt was selected. This timepoint has previously been shown to support maximal 
MNV VPg protein levels and accumulation of cells in the G0/G1 phase (260).  
 
Detection of Norovirus VPg proteins 
A broadly cross-reactive antibody towards VPg proteins was not available 
therefore the protein was detected by mass spectrometry. RAW-Blue cells were 
transfected with RNA encoding for VPg, separated by SDS-PAGE gel 
electrophoresis and the region corresponding to the predicted size of VPg 
excised for analysis. Unique peptides were detected for MNV VPg, GIII VPg and 
GIV VPg, confirming their expression (Table 3.1). The presence of GI VPg and 
GII VPg at 12 hpt could not be confirmed by mass spectrometry suggesting either 
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Table 3.1 Detection of norovirus genogroup VPg proteins by mass spectrometry 
a Full VPg sequence for each protein with peptides detected by mass spectrometry 
shown in red 
b ND; not detected, expression of constructs could not be confirmed by mass 
spectrometry 
 
GI VPg and GII VPg constructs were subsequently labelled with a C-terminal 
Strep-tag II. These proteins could not be directly detected from a cell lysate, 
instead the lysate was incubated with StrepTactin XT resin to concentrate the 
VPg protein before western blotting against the Strep-tag II (Figure 3.2). GI VPg 
was detected at ~17 kDa as a doublet band possibly indicating a post-
translational modification or translational truncation. GII VPg was detected at 
~16 kDa as only a single band. That concentration of the cellular lysate was 
required prior to detection indicates that the levels of these proteins are low.  
 






GI VPg NDb 









Figure 3.2 Detection of GI VPg and GII VPg proteins 
RAW-Blue cells were transfected with VPg constructs corresponding to GI VPg and GII 
VPg labelled with a C-terminal Strep-tag II. Cells (~3x106 cells) were harvested at 12 hpt, 
lysed and the protein concentrated on MagStrep “type 3” XT resin. The purified lysates 
were probed for the presence of a Strep-tag II by western blot. (A) GI VPg western blot 
and (B) GII VPg western blot.   
 
Analysis of the cell cycle response of Norovirus VPg proteins 
Following confirmation of expression, the cell cycle effect of each of the four 
norovirus VPg proteins was measured. Asynchronous RAW-Blue cells were 
transfected with RNA encoding for GI VPg, GII VPg, GIII VPg and GIV VPg and 
harvested at 12 hpt for flow cytometry analysis of the cell cycle. Mock transfected 
cells and EGFP were included as negative controls and MNV (GV) VPg was 
included as a positive control. Mass spectrometry or purification of epitope 
tagged VPg are not quantitative analysis methods and therefore quantitative 
comparison of total VPg protein levels and the corresponding accumulation of 
cells in the G0/G1 phase cannot be performed. Using three replicates, a 
statistically significant change in the cell cycle relative to mock transfected cells 
has been interpreted as positive for an arrest. Expression of GI, GII and GIV VPg 
induced a significant increase in the G0/G1 population and a corresponding 
decrease in the S phase population compared to mock transfected cells (Figure 
3.3). In particular VPg from GI and GII human noroviruses strongly increased 
the percentage of cells in the G0/G1 phase to ~85% and ~81% respectively, 
compared to mock transfected cells at ~60% (Figure 3.3). GIII VPg from Jena 
virus induced a modest though significant G0/G1 population increase and a 











significant (Figure 3.3). There was no significant change in the G2/M population 
for all VPg proteins tested over this timeframe. The increase in the G0/G1 phase 
and decrease in S phase is consistent with the arrest induced by MNV VPg and 
shows that manipulation of the cell cycle is a conserved function of viral VPg 
proteins from five of the norovirus genogroups.  
 
 
Figure 3.3 Conservation of a G0/G1 cell cycle arrest by norovirus genogroup VPg 
proteins 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to EGFP, 
MNV VPg, GI VPg, GII VPg, GIII VPg or GIV VPg. Mock transfected (MT) cells were 
seeded at the time of transfection as a negative control. At 12 hpt cells were harvested 
G0/G1 S G2/M
t=0 MT EGFP MNV VPg (GV)

































































































for flow cytometry analysis of the cell cycle. (A) Representative histograms from one of 
three experiments. (B) The histograms were analysed using MODfit LT 3.0 and the 
percentage of cells in each phase of the cell cycle are shown. The results present the 
mean and SD from three independent experiments. Statistical significance was 
determined for comparisons between transfected cells and mock transfected cells using 
a one-way ANOVA with Dunnett’s post-test. * P ≤ 0.05, ** P ≤ 0.01 and **** P ≤ 0.0001, 
ns not significant. 
 
3.1.4 Conservation of a G0/G1 cell cycle arrest in Caliciviridae VPg 
proteins 
The previous experiment showed that the ability of VPg to induce a G0/G1 cell 
cycle arrest is conserved within five of the norovirus genogroups. At the time of 
testing, the Caliciviridae family consisted of five accepted genera.  A 
representative viral VPg from each of the other calicivirus genera was selected; 
FCV VPg from the Vesivirus genus, Newbury 1 VPg from the Nebovirus genus, 
HuSV VPg from the Sapovirus genus and RHDV VPg from the Lagovirus genus. 
For each of these proteins the VPg protein level and cell cycle affect were 
analysed. 
 
Detection of calicivirus VPg proteins 
To confirm expression of calicivirus VPg proteins, transfected RAW-Blue cells 
were lysed and subjected to SDS-PAGE gel electrophoresis. The area of the gel 
corresponding to the predicted size of each VPg was excised and analysed by 
mass spectrometry. Unique peptides corresponding to RHDV VPg and HuSV 
VPg were detected confirming the presence of these proteins following 









Table 3.2 Detection of calicivirus VPg proteins by mass spectrometry 
a Full VPg sequence for each protein with peptides detected by mass spectrometry 
shown in red 
b ND; not detected, expression of construct could not be confirmed by mass 
spectrometry 
 
As FCV VPg and Newbury 1 VPg were not detected by mass spectrometry both 
constructs were subsequently labelled with a C-terminal Strep-tag II. Cells were 
transfected, harvested and Strep-tag II expressing proteins purified on resin and 
analysed by western blot. A labelled construct of MNV VPg was clearly detected 
by western blot at ~16 kDa (Figure 3.4). The predicted kilodalton sizes of FCV 
VPg and Newbury 1 VPg are 14 kDa and 9 kDa respectively, however no protein 
was detected at these sizes by western blot (Figure 3.4). Attempts to detect FCV 
VPg protein in CRFK cells, a cell line permissible to infection with FCV, was also 
unsuccessful (Appendix III).  







Newbury 1 VPg NDb 
FCV VPg NDb 
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Figure 3.4 FCV VPg and Newbury 1 VPg proteins cannot be detected 
RAW-Blue cells were transfected with VPg constructs corresponding to MNV VPg, FCV 
VPg and Newbury 1 VPg each labelled with a C-terminal Strep-tag II. Cells (~3x106 cells) 
were harvested at 12 hpt, lysed and the protein concentrated on MagStrep “type 3” XT 
beads. The purified lysates were probed for the presence of a Strep-tag II by western 
blot.  
 
Cell cycle analysis of calicivirus VPg proteins 
Asynchronous RAW-Blue cells were transfected with RNA encoding for HuSV 
VPg, RHDV VPg, FCV VPg and Newbury 1 VPg and harvested at 12 hours post-
transfection for flow cytometry analysis of the cell cycle. Cells transfected with 
FCV VPg and Newbury 1 VPg showed no change in the accumulation of cells in 
the G0/G1 phase indicating that a cell cycle arrest did not occur. HuSV VPg and 
RHDV VPg induced a significant increase in the G0/G1 phase population, to 
~80%, compared to mock transfected cells at ~60% (Figure 3.5). There was a 
corresponding significant decrease in the S phase population and no change in 
the G2/M phase. These results show that the cell cycle arrest is not only a 
function of norovirus VPg proteins but is also a conserved function found in 





















Figure 3.5 Conservation of a G0/G1 cell cycle arrest among Caliciviridae genera VPg 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to EGFP, 
MNV VPg, HuSV VPg, RHDV VPg, FCV VPg and Newbury 1 VPg. Mock transfected 
(MT) cells were seeded at the time of transfection as a negative control. At 12 hpt cells 
were harvested for flow cytometry analysis of the cell cycle. (A) Representative 
histograms from one of three experiments. (B) The histograms were analysed using 
MODfit LT 3.0 and the percentage of cells in each phase of the cell cycle are shown. The 
results present the mean and SD from three independent experiments. Statistical 
significance was determined for comparisons between transfected cells and mock 
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3.2 Identification of a conserved N-terminal region important 
for cell cycle arrest 
3.2.1 Introduction 
The previous section showed that the G0/G1 cell cycle arrest induced by MNV 
VPg was conserved within VPg proteins from the norovirus genus, lagovirus 
genus and sapovirus genus, leading us to hypothesise that a conserved region of 
the protein was responsible. It has been shown that the first 62 amino acids of 
MNV VPg are essential for arrest while regions corresponding to amino acids 
63-124 and 11-107 are unable to induce a cell cycle arrest (260). This suggests that 
there is a region within the first 62 amino acids of VPg responsible for inducing 
the arrest. In these experiments VPg amino acid sequences were aligned to 
identify a conserved motif and the importance of this region for a cell cycle arrest 
was analysed by truncation, point mutations and motif swapping.  
 
3.2.2 Sequence comparison of VPg proteins that arrest the cell cycle 
To identify conserved motifs the N-terminal amino acids of VPg proteins which 
arrest the cell cycle were aligned against the first 62 amino acids of MNV VPg 
using Clustal Omega (Figure 3.6). Alignment of the proteins showed a conserved 
N-terminal motif, KGKxKxGRG. The motif is present in all VPg proteins 
confirmed to arrest the cell cycle, except for GIII (Jena virus) VPg, which is 
missing the GRG component and has an extra amino acid in the KGKxK region. 
Interestingly, the cell cycle arrest induced by GIII VPg was not as marked as that 
of other VPg proteins which contain the full N-terminal motif (Figure 3.3). All 
sequences also showed similarities around the nucleotidylylation site and 
residues important for formation of the VPg helices. Nucleotidylylation of VPg 
is an essential role for replication of the viral genome however mutation of 
tyrosine 26 (Y26) of MNV VPg has no effect on cell cycle arrest indicating that 
this function does not contribute to arrest (186). Both leucine 21 (L21) and leucine 





Figure 3.6 Alignment of the first 62 amino acids of VPg from different norovirus 
genogroups and representative members of the Caliciviridae family shown to cause 
a cell cycle arrest 
An asterisk (*) indicates identical residues and a colon (:) indicates residues that are 
identical in >50% of sequences. Conserved amino acids of the N-terminal region are 
shown in red. The tyrosine residue (Y) corresponding to Y26 of MNV VPg is shown in 
bold. The represented genogroups are GI Norwalk virus VPg, GII Sydney 2012 VPg, 
GIII Jena virus VPg and GIV Lake Macquarie VPg. The position of lysine 5, lysine 7 and 
arginine 10 of MNV VPg is indicated on the consensus sequence.  
 
As expected, analysis of the percentage identities of the N-terminal sequences of 
VPg proteins which arrest the cell cycle showed higher similarities between 
genogroup VPg proteins than HuSV VPg and RHDV VPg (Table 3.4). Although 
MNV VPg shares only 30% and 41% amino acid identity with RHDV VPg and 
HuSV VPg respectively, all proteins are able to arrest the cell cycle in RAW-Blue 
cells.  
 
Table 3.3 Identity matrix for the first 62 amino acids of calicivirus VPg proteins 
 GI GII GIII GIV HuSV RHDV 
MNV (GV) 53.8 60.3 58.3 61.2 41.7 30.6 
GI  56.9 55.4 69.2 35.4 26.2 
GII   60.3 76.1 36.8 27.9 
GIII    59.7 34.2 23.3 
GIV     35.8 23.9 
HuSV      40.5 











***  * :::       :   :*:::**:* :  ::     : ::: ::* :: :  :: :    :
5 7 10
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3.2.3 Removal of the first 11 amino acids of MNV VPg 
The role of the N-terminal, KGKxKxGRG, motif for induction of a cell cycle 
arrest was investigated with a truncated MNV VPg construct. The construct was 
designed to express MNV VPg with the first 10 amino acids removed (11-124 
VPg) this corresponds to removal of the entire N-terminal motif. Cells were 
transfected with 11-124 VPg RNA and harvested at 12 hours post-transfection 
for western blot and cell cycle analysis. Expression of 11-124 VPg was confirmed 
by western blot using a polyclonal MNV VPg antibody to identify the 11-124 
VPg protein at ~15 kDa (Figure 3.7A). Compared to full length MNV VPg, the 
protein level of 11-124 VPg was decreased (Figure 3.7). At 12 hours post-
transfection, full length MNV VPg increased the percentage of cells in G0/G1 to 
~78% compared to mock transfected cells at ~59%. Despite a readily detectable 
protein level, the 11-124 VPg had no effect on either the G0/G1 phase population 
or the S phase population compared to mock transfected cells, indicating that the 




Figure 3.7 Contribution of the first 11 amino acids to a cell cycle arrest 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to EGFP, 
MNV VPg or MNV VPg 11-124. Mock transfected (MT) cells were seeded at the time of 
transfection as a negative control. At 12 hpt cells were harvested for western blot and 
flow cytometry analysis of the cell cycle. (A) Analysis of MNV VPg protein levels by 
western blot. (B) Representative histograms from one of three experiments. (C) The 
histograms were analysed using MODfit LT 3.0 and the percentage of cells in each phase 
of the cell cycle are shown. The results present the mean and SD from three independent 
experiments. Statistical significance was determined for comparisons between 
transfected cells and mock transfected cells using a one-way ANOVA with Dunnett’s 







































































3.2.4 Point mutation to the N-terminal region of MNV VPg 
To investigate the contribution of individual amino acids within the 
KGKxKxGRG motif (representing amino acids 3-11 of MNV VPg) constructs 
with single point mutations were designed. In each full length MNV VPg 
construct a single point mutation to alanine at position K5, K7, G9 or R10 was 
incorporated. RAW-Blue cells were transfected with either MNV VPg, K5A VPg, 
K7A VPg, G9A VPg or R10A VPg and harvested at 12 hours post-transfection 
for western blot and cell cycle analysis (Figure 3.8). All constructs were detected 
by western blot at ~16 kDa and expressed to a similar level as WT MNV VPg 
(Figure 3.8). Analysis of the cell cycle showed a significant decrease in the G0/G1 
population for the K5A, K7A and R10A point mutants when compared to WT 
MNV VPg (Figure 3.8). When compared to mock transfected cells, each of these 
constructs induced a significant increase in the G0/G1 population indicative of 
an arrest. This indicates that these mutant proteins are able to manipulate the 
cell cycle albeit not as effectively as WT MNV VPg. Mutation to G9 did not 
significantly decrease the percentage of cells in the G0/G1 phase compared to 
MNV VPg indicating that mutation of G9 does not alter the cell cycle 
functionality of MNV VPg. These results show that lysine and arginine residues 
within the N-terminal region of MNV VPg contribute to the G0/G1 arrest but 
mutation of single amino acids is not sufficient to completely ablate the VPg 




Figure 3.8 Single point mutations contribute to a cell cycle arrest 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to MNV 
VPg or single point mutant MNV VPg; K5A, K7A, G9A or R10A. Mock transfected (MT) 
cells were seeded at the time of transfection as a negative control. At 12 hpt cells were 
harvested for western blot and flow cytometry analysis of the cell cycle. (A) Analysis of 
MNV VPg and single point mutant protein levels by western blot with actin as a loading 
control. (B) Representative histograms from one of three experiments. (C) The 
histograms were analysed using MODfit LT 3.0 and the percentage of cells in each phase 
of the cell cycle are shown. The results present the mean and SD from three independent 
experiments. Statistical significance was determined for comparisons between 
transfected cells and mock transfected cells using a one-way ANOVA with Dunnett’s 
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3.2.5 Mutation of K5, K7 and R10 N-terminal residues decreases but does 
not completely inhibit cell cycle manipulation by MNV VPg 
A full length MNV VPg construct was designed with point mutations to alanine 
at positions K5, K7 and R10 to test if this would reduce the cell cycle arrest back 
to the levels of mock transfected cells. This MNV VPg triple mutant (MNV VPg 
TM) construct was transfected into cells and the cells were harvested for western 
blot and flow cytometry analysis of the cell cycle (Figure 3.9). Both WT MNV 
VPg and MNV VPg TM showed comparable protein levels post-transfection, 
with protein detected at ~16 kDa (Figure 3.9A). MNV VPg induced an increase 
in the G0/G1 population to ~70% compared to mock transfected cells at ~55%. 
Similar to the individual point mutation constructs, MNV VPg TM displayed an 
intermediate cell cycle arrest with ~63% of cells in G0/G1. The accumulation of 
cells in G0/G1 induced by MNV VPg TM was significantly different from both 
MT cells and MNV VPg transfected cells indicating that while there was still a 
change in the G0/G1 population it was decreased. Although not significant, 
there was a trend for a decreased percentage of cells in the S phase. These results 
indicate that within the conserved N-terminal region of MNV VPg lysine and 
arginine residues are important for a cell cycle arrest. 
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Figure 3.9 Manipulation of the cell cycle by MNV VPg TM 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to MNV 
VPg or MNV VPg TM. Mock transfected (MT) cells were seeded at the time of 
transfection as a negative control. At 12 hpt cells were harvested for western blot and 
flow cytometry analysis of the cell cycle. (A) Analysis of MNV VPg and MNV VPg TM 
protein levels by western blot with actin as a loading control. (B) Representative 
histograms from one of three experiments. (C) The histograms were analysed using 
MODfit LT 3.0 and the percentage of cells in each phase of the cell cycle are shown. The 
results present the mean and SD from three independent experiments. Statistical 
significance was determined using a one-way ANOVA with Dunnett’s post-test. ns; not 

















































































3.2.6 The N-terminal region alone is not sufficient to drive a cell cycle 
arrest 
An intact N-terminal region is required for the cell cycle arrest induced by MNV 
VPg, in particular, positively charged amino acids contribute to the arrest. To 
test if the N-terminal region of MNV VPg alone is sufficient to drive a cell cycle 
arrest a construct was designed to express the first 20 amino acids of MNV VPg 
as an N-terminal fusion with EGFP, the construct was termed M20EGFP. As a 
fusion partner EGFP consists of a flexible N-terminus to facilitate correct 
presentation of the first 20 amino acids of VPg, in addition, EGFP has access to 
both the cytoplasm and the nucleus (269, 270). RNA coding for M20EGFP was 
transfected into RAW-Blue cells and the cells were harvested at 12 hours post-
transfection for analysis by western blot and flow cytometry. Expression of 
M20EGFP and MNV VPg was confirmed using either an a-EGFP antibody or an 
a-MNV VPg antibody to detect proteins at ~30 kDa and ~16 kDa respectively 
(Figure 3.10). MNV VPg induced an increase in the G0/G1 phase to ~70% 
compared to mock transfected cells at ~50%, characteristic of a cell cycle arrest 
(Figure 3.10). Transfection of M20EGFP did not induce any significant changes in 
either the G0/G1 phase population or the S phase population compared to mock 
transfected cells. These results indicate that fusion of the first 20 amino acids of 
MNV VPg to EGFP is not sufficient to induce a cell cycle arrest. There are a 
number of possible reasons for this including improper folding of the protein or 
formation of multimers that inhibit the presentation of the N-terminus of VPg. 
Alternatively this result could indicate that the first 20 amino acids alone are not 
functionally active in a cell cycle arrest and that the there is a requirement for 




Figure 3.10 The first 20 N-terminal amino acids of MNV VPg do not induce a cell 
cycle arrest 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to MNV 
VPg or M20EGFP. Mock transfected (MT) cells were seeded at the time of transfection as 
a negative control. At 12 hpt cells were harvested for western blot and flow cytometry 
analysis of the cell cycle. (A) Analysis of M20EGFP and MNV VPg protein levels by 
western blot with actin as a loading control. (B) Representative histograms from one of 
three experiments. (C) The histograms were analysed using MODfit LT 3.0 and the 
percentage of cells in each phase of the cell cycle are shown. The results present the 
mean and SD from three independent experiments. Statistical significance was 
determined for comparisons between transfected cells and mock transfected cells using 
a one-way ANOVA with Dunnett’s post-test. ** P ≤ 0.01 























































































3.2.7 Chimeric VPg 
Analysis of the N-terminal region of Newbury 1 VPg and FCV VPg  
The N-terminal region of MNV VPg, containing a conserved KGKxKxGRG 
motif, contributes to a G0/G1 cell cycle arrest. An alignment of Newbury 1 VPg 
and FCV VPg was performed to determine if these proteins, both of which 
previously failed to express, contained an N-terminal motif similar to MNV VPg 
(Figure 3.11). Within the first 62 amino acids, there was considerable sequence 
divergence between MNV VPg and Newbury 1 VPg or FCV VPg with 20.8 – 24% 
sequence identity. The N-terminal motif present in MNV VPg is absent in 
Newbury 1 VPg with the exception of two glycine residues that appear to be 
independent of any matching motif (Figure 3.11). In FCV VPg the N-terminal 
motif is interrupted by a stretch of six amino acids, however there is still 
similarity between the proteins in terms of lysine and arginine residues (Figure 
3.11). Chimeric VPg constructs were designed to test the cell cycle functionality 
of the N-terminal regions of Newbury 1 VPg and FCV VPg in the context of 
MNV VPg. The reverse chimeras were designed to address if the N-terminal 
region of MNV VPg is sufficient to drive a cell cycle arrest when combined with 
either Newbury 1 VPg or FCV VPg. 
 
 
Figure 3.11 Alignment of the first 62 amino acids of Newbury 1 VPg and FCV VPg 
An asterisk (*) indicates identical residues and a colon (:) indicates residues that are 
identical in 50% of sequences. Conserved amino acids of the N-terminal motif are shown 
in red. The tyrosine (Y) residue corresponding to Y26 of MNV VPg is shown in bold. 
The conserved leucine (L) residue used as the junction point for construction of chimeric 
VPg constructs is shown in blue.  
 
MNV GKKGKNK------KGRGRPGVFRTRG--LTDEEYDEF----KK 31
NB 1 GWLS----------GSG---------VALSDEEYDEWMKYSKK 24
FCV -AKGKTKLKIGTYRGRG---------VALTDDEYDEWREHNAS 33
::: :   :   *:*       ::*:*:****: :    ::
MNV RRESRGGKYSIDDYLADRER-----EEELLERDEEE------ 62
NB 1 KGKKINA----DEFLQLRHRAAMGNDDDDARDYRSFYTAYQL 62
FCV RKLDLSV----EDFLMLRHRAALGADDNDAVKF--------- 62
:          :::* :*:*:: : :: :: 
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Chimeric Newbury 1 VPg and MNV VPg proteins do not induce a cell cycle arrest 
Newbury 1 virus is predicted to express a VPg product of ~65 amino acids, 
compared to the 124 amino acid MNV VPg. Newbury 1 VPg and MNV VPg 
share limited similarity within the first 10 N-terminal amino acids. There is a 
conserved leucine residue located five amino acids immediately prior to the 
conserved tyrosine for nucleotidylylation of VPg (Figure 3.11). This leucine is at 
position 10 and 21 of Newbury 1 VPg and MNV VPg respectively. Synthetic 
chimeric VPg constructs were designed by exchanging the N-terminal regions 
immediately prior to the conserved leucine residue (Figure 3.12). The resulting 
constructs were termed Nb19/MNV VPg (consisting of the first 9 amino acids of 
Newbury 1 VPg fused to MNV VPg from leucine 21) and M20/Nb1 VPg 
(consisting of the first 20 amino acids of MNV VPg fused to Newbury 1 VPg 
from leucine 10). For detection, a Strep-tag II was incorporated at the C-terminus 
of each construct.  
 
RAW-Blue cells were transfected with RNA corresponding to chimeric VPg 
constructs and cells were harvested at 12 hours post-transfection for western blot 
and cell cycle analysis. Chimeric constructs could not be directly detected from 
whole cell lysates, indicating that the protein levels are significantly decreased 
for the chimeras compared to MNV VPg. To confirm expression, Strep-tag II 
proteins were purified on resin followed by western blot and proteins of ~10 kDa 
and 14 kDa representing M20/Nb1 VPg and Nb19/MNV VPg respectively were 
detected (Figure 3.12).  
 
As a positive control MNV VPg induced a significant increase in the G0/G1 
phase population and a corresponding though not significant decrease in the S 
phase population, indicative of a G0/G1 cell cycle arrest. Nb19/MNV VPg 
showed no change in the cell cycle when compared to mock transfected cells, 
suggesting that when expressed the N-terminal region of Newbury 1 VPg does 
not induce a cell cycle arrest. Similar to the M20EGFP construct, transfection of 
M20/Nb1 VPg had no effect on the cell cycle and indicates that first 20 amino 
acids of MNV VPg do not induce arrest in the context of Newbury 1 VPg. 
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Figure 3.12 Chimeric MNV VPg and Newbury 1 VPg proteins do not induce a cell 
cycle arrest 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to MNV 
VPg, Nb19/MNV VPg and M20/Nb1 VPg. Mock transfected (MT) cells were seeded 
at the time of transfection as a negative control. At 12 hpt cells were harvested for 
western blot and flow cytometry analysis of the cell cycle. (A) Schematic for the design 
of chimeric constructs. Chimeric VPg constructs were designed around a conserved 
leucine residue of Newbury 1 VPg and MNV VPg to exchange the N-terminal region. 
(B) Expression of MNV VPg and chimeric VPg proteins was confirmed by purification 
of Strep-tag II protein on beads followed by western blot. (C) Representative histograms 







































































































and the percentage of cells in each phase of the cell cycle are shown. The results present 
the mean and SD from three independent experiments. Statistical significance was 
determined for comparisons between transfected cells and mock transfected cells using 
a one-way ANOVA with Dunnett’s post-test. * P ≤ 0.05. 
 
Chimeric FCV VPg and MNV VPg proteins  
A second set of chimeric VPg constructs was designed using FCV VPg and MNV 
VPg. The conserved leucine 19 of FCV VPg and leucine 21 of MNV VPg was used 
as the fusion point and the resulting chimeric constructs were termed F18/MNV 
VPg and M20/FCV VPg (Figure 3.13). RAW-Blue cells were transfected with 
RNA corresponding to chimeric constructs and cells were harvested at 12 hours 
post-transfection for western blot and flow cytometry analysis of the cell cycle. 
Protein levels of MNV VPg, F18/MNV VPg and M20/FCV VPg were confirmed 
by purification of Strep-tag II proteins on resin followed by western blot with 
proteins detected at ~16 kDa and 15 kDa. A quantitative analysis of the relative 
amounts of each protein following purification on a resin was not possible, 
however qualitatively the protein levels of chimeric VPg proteins are decreased 
compared to MNV VPg. Transfection of F18/MNV VPg induced a modest 
decrease in the S phase population but this was not supported by a significant 
increase in the G0/G1 phase. This indicates that the N-terminal region of FCV 
VPg is not functional for a G0/G1 cell cycle arrest in the system tested here. A 
significant increase in the G0/G1 population was observed for MNV VPg and 
M20/FCV VPg to ~80% compared to mock transfected cells at ~60%. A significant 
corresponding decrease in the S phase population was observed. That both 
chimeric VPg proteins expressed at comparable levels following purification but 
only M20/FCV VPg induced a cell cycle arrest indicates that the low protein level 
of F18/MNV VPg does not account for the lack of arrest. Overall these results 
show that despite lower protein levels M20/FCV VPg induces arrest at a 
comparable level to that of MNV VPg alone. Although the N-terminal 20 amino 
acids of MNV VPg are not able to induce an arrest in the context of M20/EGFP 
or M20/Nb1 VPg, when they are combined with FCV VPg an arrest occurs. This 
supports the prediction that there is a region(s) beyond the first 20 amino acids 
which contributes to arrest that is present within FCV VPg.  
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Figure 3.13 A chimeric protein M20/FCV VPg induces a cell cycle arrest 
RAW-Blue cells were transfected with 4-5 µg of transcript RNA corresponding to MNV 
VPg, F18/MNV VPg and M20/FCV VPg. Mock transfected (MT) cells were seeded at 
the time of transfection as a negative control. At 12 hpt cells were harvested for western 
blot and flow cytometry analysis of the cell cycle. (A) Schematic for the design of 
chimeric constructs. Chimeric VPg constructs were designed around a conserved 
leucine residue of Newbury 1 VPg and MNV VPg to exchange the N-terminal region. 
(B) Expression of MNV VPg and chimeric VPg proteins was confirmed by purification 
of Strep-tag II protein on beads followed by western blot. (C) Representative histograms 
from one of three experiments. (D) The histograms were analysed using MODfit LT 3.0 
and the percentage of cells in each phase of the cell cycle are shown. The results present 
the mean and SD from three independent experiments. Statistical significance was 
determined for comparisons between transfected cells and mock transfected cells using 

































































































3.2.8 Summary of N-terminal constructs 
Throughout the first two sections of this thesis several different VPg constructs 
were screened for protein expression and their ability to induce a G0/G1 cell 
cycle arrest in RAW-Blue cells. There was considerable variation in the total 
protein levels of different constructs as summarised in Table 3.4. These results 
indicate that, where VPg protein can be detected a cell cycle arrest can also be 
detected, if one is going to occur. This shows that barely detectable amounts of 
protein are required to induce the arrest and is particularly apparent with GI 
VPg that requires concentration on StrepTactin XT resin before protein can be 
detected despite a robust increase in cells in the G0/G1 phase. The data is also 
in agreement with previous research showing that the 1-62 fragment of MNV 
VPg can induce a cell cycle arrest despite a decrease in total protein levels 
compared to full length VPg (260).  
 
Table 3.4 Summary table of VPg protein levels and cell cycle arrest 
VPg Construct Protein Levela Cell Cycle Arrestb 
MNV VPg (GV) +++ ++ 
GI VPg + ++ 
GII VPg + ++ 
GIII VPg + + 
GIV VPg + + 
RHDV VPg + ++ 
HuSV VPg + ++ 
FCV VPg - - 
Newbury 1 VPg - - 
11-124 VPg ++ - 
K5A VPg +++ + 
K7A VPg +++ + 
G9A VPg +++ ++ 
R10A VPg +++ + 
MNV VPg TM +++ +c 
M20EGFP ++ - 
Nb19/MNV + - 
M20/Nb1 + - 
M20/FCV + ++ 
F18/MNV + - 
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a +++, up to WT MNV VPg expression levels detected; ++, Expression detected without 
concentration but at levels less than WT MNV VPg; +; Expression detected either by 
concentration on epitope resin or by mass spectrometry. 
b ++, > 75% of cells in G0/G1; +, ≥ 70% and ≤ 75% of cells in G0/G1; -, no accumulation 
of cells in G0/G1 compared to mock transfected cells.  
c MNV VPg TM only had 65% of cells in the G0/G1 phase but this was a statistically 
significant accumulation compared to mock transfected cells and was therefore still 
considered an arrest. 
 
3.2.9 Bioinformatic analysis of the N-terminal region of MNV VPg 
Nucleic acid binding predictions for MNV VPg 
The N-terminal region of MNV VPg is rich in positively charged lysine and 
arginine amino acids and it is possible that these possess nucleic acid binding 
activity, as has been demonstrated for a potyvirus VPg protein (150). The 
sequence of MNV VPg was analysed for predicted interaction with RNA and 
DNA using DRNAPred (268). Results predict interactions with RNA across 
multiple regions of VPg. In particular, the first 12 amino acids have probabilities 
between 0.91-0.83 for an interaction with RNA (Figure 3.14). Regions of VPg 
between amino acids 30-40, 70-80 and 95-100 have RNA binding probabilities 
between 0.5 and 0.7. Conversely there were no significant regions of MNV VPg 
predicted to interact with DNA (Figure 3.14).  
 
 
Figure 3.14 RNA and DNA binding predictions of MNV VPg 
A
B MNV VPg    ----GKKGKNK-K--GRGRPGVFRTRG
PVA VPg    GSAYTKKGKTKGKTHGMGKK-------
**** * * * *:






























DRNAPred graph showing predicted RNA and DNA binding probabilities of MNV 
VPg. Regions with probabilities above 0.5 are indicated by the dotted line through the 
x-axis.  
 
Prediction of a nuclear localisation sequence in MNV VPg  
Functional analysis of MNV VPg using the ELM server predicts a classical 
monopartite NLS within the first 11 amino acids (260). Additionally, there are 
several VPg proteins encoded by viruses in the potyvirus family that contain a 
bipartite NLS (271). To investigate the conservation of an NLS, MNV VPg was 
aligned with PVA VPg (Figure 3.15). The sequences share ~21% amino acid 
identity including 8 residues within the N-terminal region of MNV VPg. This 
region corresponds to the second half of the bipartite NLS of PVA VPg (271) 
providing further evidence of a putative NLS in MNV VPg and potentially 
giving VPg access to the nucleus.  
 
 
Figure 3.15 Sequence comparison between MNV VPg and PVA VPg 
Amino acid sequences from MNV VPg and PVA VPg were compared using Clustal 
Omega analysis. Amino acids of MNV that are conserved in viruses which arrest the 
cell cycle are shown in red. In blue, amino acids of PVA VPg that from the NLS domains. 
An asterisk (*) indicates fully conserved amino acids and a colon indicates (:) amino 
acids of a similar nature.  
 
Predictions of interactions with host eIF4E 
The cap protein, eIF4E is the limiting factor for translation of cap-dependent 
mRNAs. MNV VPg is known to directly interact with eIF4E however the 
interaction is not directly required for translation, raising the possibility that a 
VPg-eIF4E interaction functions separately to viral translation (66). Binding of 
MNV VPg ---------------------------------------GKKGKNK-K--GRGR--PGVF 16
PVA VPg GYNKRQRQKLKFARARDEKMGHYVEAPDSTLEHYFGSAYTKKGKTKGKTHGMGKKNHRFV 60
**** * *  * *:
MNV VPg RTRGLTDEEYDEFKKRRESRGGKYSIDD--YLA--------DREREEELLERDEEEAIFG 66
PVA VPg NMYGFDPSDYTFIRYVDPLTG--YTLDESPYTDIRLIQSQFSDIREQQLLNDELERNMVH 118
*    :*   :      *  *  *:  *             **  **  : *   
MNV VPg DGFGLKATRR-SRKAERAKLGLVSGGDIRARKPIDW-----NVV-GPSWADDDRQVDYGE 119
PVA VPg YKPGVQGYLVKDKTSQILKID------LTPHIPLKVCDATNNIAGHPDREGELRQTGKGQ 172
*::      :     *             *        *    *    : **   *
MNV VPg KINFE----------- 124
PVA VPg LLDYAELPQKKESVEF 188
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potato virus Y (PVY) VPg to eIF4E induces a change in the subcellular 
localisation of eIF4E, out of the nucleus and into the cytoplasm (272). The N-
terminal amino acids of MNV VPg were aligned with an eIF4E binding peptide 
of PVY VPg (Figure 3.16). Several amino acids including lysine, glycine and 
arginine residues were found to be conserved in both sequences. This could 
suggest that MNV VPg is able to induce a change in the subcellular localisation 
of eIF4E that is dependent on the N-terminal region.  
 
 
Figure 3.16 Prediction of eIF4E interaction with VPg 
Amino acid sequence alignment of the first 26 amino acids of MNV VPg and PVY VPg 
peptide shown to bind to eIF4E. Amino acids important for a cell cycle arrest are shown 
in red. An asterisk (*) indicates fully conserved amino acids and a colon (:) indicates 
conservation of charge. 
   
 
 
MNV VPg   1- GKKGKNKK---GRGRPGVFRTRGLTDEEY -26 
PVY VPg  41- RKKGKGKGTTVGMGKSS--R-RFINMYGF -56 
              **** *    * *:    * *       
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3.3 RNA binding potential of MNV VPg 
3.3.1 Introduction 
Nucleic acid binding predictions of MNV VPg suggest an interaction with RNA, 
in particular, the first 12 N-terminal amino acids (Figure 3.14). This work aims 
to establish the RNA binding capabilities of MNV VPg by expressing and 
purifying recombinant MNV VPg and assessing its ability to associate with 
fluorescent Pentaprobe RNA by EMSA.  
 
3.3.2 Production and purification of MNV VPg protein 
For VPg protein production, a synthetic MNV VPg gene was designed and 
synthesised by Genscript in the pJET2.1 plasmid. The plasmid was digested with 
Bgl II and EcoR I restriction enzymes to release a 381 bp DNA fragment, 
corresponding to the MNV VPg gene (Figure 3.17). The MNV VPg band was gel 
purified and ligated into a pAcpol- plasmid previously engineered by Vivienne 
Young to express protein with an N-terminal fusion of an NT* tag for solubility 
and a Strep-tag II and His6 tag for purification (Figure 2.1). An EK cleavage site 
was included at the N-terminus of VPg to allow cleavage and removal of NT*, 
Strep-tag II and His6 tags from VPg. Insertion of MNV VPg into pAcpol- was 
confirmed by a Bgl II and EcoR I digest (Figure 3.17) and the plasmid was termed 
pAc.NT*/VPg. The pAc.NT*/VPg plasmid was then co-transfected into Sf21 
cells using the FlashBAC ULTRA system to generate a recombinant baculovirus. 
The viral inoculum was amplified by repeated passage through Sf21 cells and 
the final titre determined by neutral red plaque assay. 
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Figure 3.17 Construction of pAcpol-.NT*/MNV VPg 
1% agarose gels stained with ethidium bromide. (A) Digest of pJET2.1.MNV VPg 
plasmid for cloning into the pAcpol- vector. 1; 1 kb Plus DNA ladder, 2; pJET2.1. MNV 
VPg digested with Bgl II and EcoR I. (B) Digest to confirm MNV VPg insertion. 1; 1 kb 
Plus DNA ladder, 2; pAc-.NT*/MNV VPg digested with Bgl II and EcoR I. DNA ladder 
sizes are indicated in bp.  
 
For expression, T. ni insect cells were infected with recombinant baculovirus at 
a MOI of 1 and incubated for four days. Infected cells were harvested by 
centrifugation and lysed to release the soluble intracellular NT*MNV VPg 
protein. The soluble fraction was incubated with Strep-Tactin resin (IBA) which 
bound to the Strep-tag II expressing protein. NT*MNV VPg was eluted from the 
column using 50 mM D-biotin (IBA) in elution buffer. Expression and 
purification of NT*MNV VPg was analysed by SDS-PAGE gel to confirm protein 
production (Figure 3.18). Protein was observed at ~33kDa corresponding to the 
predicted size of NT*MNV VPg. There was no degradation or truncation 
products of NT*MNV VPg visible on the gel, suggesting that the protein is 
relatively stable using this expression system. Two additional protein bands 
were observed, one at ~44 kDa and another at ~200 kDa (Figure 3.18). The bands 
were excised from the gel and analysed by mass spectrometry, which identified 
them as actin and myosin respectively. The identity of NT*MNV VPg was 
confirmed by western blot against the Strep-tag II present in the protein (Figure 




























Figure 3.18 Purification of NT*MNV VPg 
(A) Diagram of NT*MNV VPg protein. The expressed protein contains a methionine 
(M), His6 tag, Strep-tag II, NT* tag, VPg and a stop codon(S). The location of the TEV 
cleavage site and enterokinase cleavage sites are indicated by an arrow. (B) SDS-PAGE 
gel and (C) western blot of the NT*MNV VPg purification process. Equivalent volumes 
of total culture, soluble supernatent, flow through and wash fractions were analysed 
along with ~5 µg of eluted protein. Flow through; soluble protein after passing through 
the column, E1; elution 1 of NT*MNV VPg eluted during the purification. A PageRuler 
Unstained Broad Range protein ladder and a PageRuler Plus Prestained protein ladder 
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Bovine enterokinase cleavage of NT*MNV VPg 
The N-terminal fusion consisting of a His6 tag, Strep-tag II and NT* tag can be 
removed from MNV VPg by cleavage with bovine enterokinase leaving a mostly 
native VPg protein (Figure 3.19). Purified NT* MNV VPg was incubated with 
0.016 U/µg of bovine enterokinase for 15 hours at 4°C, enterokinase was 
removed following the incubation. The cleaved NT* fusion and uncleaved 
NT*MNV VPg were removed by incubation with NiNTA resin which bound the 
His6 tag present in both proteins. The enterokinase cleavage and purification of 
MNV VPg were analysed by SDS-PAGE and western blot (Figure 3.19). 
Incubation with enterokinase efficiently cleaved the NT* fusion away from MNV 
VPg. However, multiple bands of MNV VPg were seen on the gel, suggesting 
that VPg has an additional cleavage site recognised by enterokinase, generating 
VPg proteins termed MNV VPg 1 and MNV VPg 2. Each of these bands appeared 
as a doublet which could represent a post translational modification or slight 
variation in the cleavage site but this is not clear. There were also bands present 
at a lower molecular weight that are positive by western blot for MNV VPg and 
again it is unclear what these are (Figure 3.19B). Analysis of the MNV VPg 
sequence suggests that the most likely site for EK cleavage is at a DDDR motif at 
amino acid positions 110-113, resulting in removal of 11 amino acids at the C-
terminus of MNV VPg. The removal of these amino acids is predicted to cause a 
~1.5 kDa decrease in protein size. The truncation of MNV VPg by enterokinase 
removes the highly conserved eIF4G interaction motif but importantly maintains 
an intact N-terminal region. Following incubation with NiNTA resin MNV VPg 
was successfully purified and there was no detectable uncleaved NT*MNV VPg 
or NT* tag present in the purified sample as shown by the a-Strep tag western 




Figure 3.19 Bovine enterokinase cleavage of NT*MNV VPg 
NT*MNV VPg was digested with bovine enterokinase to remove the N-terminal fusion 
tags. (A) SDS-PAGE gel, (B) anti-MNV VPg western blot and (C) anti-Strep tag western 
blot of enterokinase cleavage of NT*MNV VPg. 1; no enterokinase added to the protein 
reaction, 2; enterokinase cleavage reaction, 3; purified MNV VPg sample. The total 
protein loaded in each lane was 5 µg. Molecular weights of proteins are indicated by 
PageRuler Unstained protein ladder (A) and PageRuler Prestained protein ladder (B 
and C). (D) Schematic showing the canonical enterokinase cleavage motif and the 
putative cleavage motif in MNV VPg.  
 
3.3.3 Optimization of Pentaprobe detection assay 
Plasmids containing the RNA Pentaprobe sequences were obtained from 
Addgene and expressed as single-stranded RNA probes. In order to determine 
the RNA binding abilities of MNV VPg, assay conditions for detection of the 
RNA Pentaprobes were first optimised.  
 
Staining of RNA Pentaprobes in ethidium bromide is not sensitive 
For an effective gel shift the RNA Pentaprobes need to be detected at a useable 
concentration. Unlabelled Pentaprobe 1 (PP1) RNA was produced, resolved on 
a native TBE gel and the RNA stained in ethidium bromide (Figure 3.20). PP1 
RNA was detected in the gel down to a concentration of 250 nM. At 1 µM and 
500 nM a high proportion of the PP1 RNA remained in the well, likely through 
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It was therefore determined that staining in ethidium bromide would not 
provide a sensitive gel shift assay for determining MNV VPg RNA binding.   
 
 
Figure 3.20 Detection of PP1 with ethidium bromide 
Unlabelled PP1 RNA was resolved at the indicated concentrations on a 5% TBE gel. The 
gel was directly stained in ethidium bromide for 1 hour and imaged.  
 
Fluorescent labelling of RNA Pentaprobes 
An ATTO 680 dye covalently bound to UTP by a flexible aminoallyl linker was 
selected to label Pentaprobe RNA as it has been shown that this dye does not 
interfere with RNA-protein binding interactions and has a high sensitivity (273). 
ATTO 680 labelled PP1 RNA was produced and analysed at the indicated 
concentrations on a 5% TBE gel (Figure 3.21). Unincorporated rNTPs were 
efficiently removed using the MegaClear transcription clean up kit. A 
fluorescent PP1 RNA band was detected down to 12.5 nM upon extended 
exposure (Figure 3.21B), although at this concentration the signal was weak. At 
100 nM an RNA band was clearly visible therefore all future EMSA experiments 





















Figure 3.21 Detection of ATTO 680 labelled Pentaprobe RNA 
ATTO680 labelled PP1 RNA was separated on a 5% TBE gel at the indicated 
concentrations and directly imaged in the 700 nm channel. Total RNA represents a 2 µl 
sample prior to processing through the MegaClear clean-up kit. (A) Image of the entire 
gel. (B) Gel image was cropped to exclude total RNA, 250 nM and 100nM and the 
exposure was increased to allow detection of PP1 RNA bands at the lower 
concentrations.  
 
3.3.4 MNV VPg binds Pentaprobe RNA 
To confirm the prediction of RNA binding by MNV VPg the interaction of 
protein with labelled Pentaprobe RNA was analysed. NT*MNV VPg was 
cleaved with enterokinase to remove the NT* fusion and MNV VPg protein was 
purified and buffer exchanged into RNA binding buffer. The purity of MNV VPg 
was confirmed by SDS-PAGE and western blot against VPg or the Strep-tag II to 
confirm removal of the NT* fusion (Figure 3.22). Increasing concentrations of 
MNV VPg were incubated with 100 nM of PP1 RNA and the interaction analysed 
by EMSA. An interaction is indicated by an upward shift of the labelled nucleic 
acid probe on a native polyacrylamide gel. Relative to an RNA only control, 5 
µM of MNV VPg produced a shifted RNA band, indicative of protein binding. 
As MNV VPg concentrations were increased the unbound RNA band 
disappeared and fluorescent bands which were just able to enter the gel were 
observed (Figure 3.22), mostly likely due to formation of protein-RNA 



































Figure 3.22 MNV VPg binds ATTO-680 labelled PP1 RNA 
(A) MNV VPg was incubated with 100 nM of ATTO 680 labelled PP1 RNA for 30 
minutes, separated on a 5% TBE gel and directly imaged in the 700 nm channel. MNV 
VPg was added to reactions at increasing concentrations; 2 µM, 5 µM, 10 µM and 20 µM. 
(B) Purity of MNV VPg protein (5 µg) was analysed by SDS-PAGE gel (1) and western 
blot against MNV VPg (2) and the Strep-tag II (3).  
 
3.3.5 The NT* tag does not affect the RNA binding abilities of MNV VPg 
The previous experiment showed that MNV VPg bound to PP1 RNA, however 
as the protein concentration increased, aggregates appeared to form. A native 
gel separates protein and nucleic acid on the basis of mass and charge. The 
predicted isoelectric point (pI) of enterokinase cleaved MNV VPg is 9.5 and in 
the pH 8 RNA binding buffer the protein will have a net positive charge 
hindering entrance into the native gel, even when bound to negatively charged 
RNA. In comparison the pI of NT*MNV VPg is predicted to be 5.8, suggesting a 
net negative charge in RNA binding buffer. An interaction of the NT* fusion with 
RNA has not previously been reported, therefore the RNA binding interaction 
of MNV VPg with and without the NT* tag was analysed by EMSA. The bacterial 
protein chloramphenicol acetyltransferase (CAT) with and without the NT* 
fusion was included as a negative control. Proteins were either cleaved with 
bovine enterokinase, purified and buffer exchanged into RNA binding buffer or 
directly buffer exchanged without cleavage. Protein purity and integrity was 














RNA for 30 minutes at 4°C and run on a 5% native TBE gel to observe the protein-
RNA interaction. At 10 µM, CAT and NT*CAT showed no shift on the EMSA 
gels compared to RNA alone, indicating that CAT and the NT* fusion do not 
bind RNA (Figure 3.23). An RNA shift was observed for MNV VPg at 5 µM and 
10 µM, however the majority of the fluorescent RNA remained in the well. At 5 
µM and 10 µM concentrations of NT*MNV VPg a shifted fluorescent PP1 RNA 
band was visible in the gel, confirming that NT*MNV VPg binds RNA. The 
addition of the NT* tag was successful in retaining the association of Pentaprobe 
RNA with MNV VPg and facilitating entry of protein-RNA complexes into the 
electrophoretic gel. In addition, NT*MNV VPg expresses as a single protein and 
resolves the issue of multiple VPg species when the protein is cleaved with EK 
(Figure 3.23C). All future experiments were performed with NT*MNV VPg.  
 
 
Figure 3.23 The presence of an NT* fusion does not affect RNA binding by MNV VPg 
Proteins at the indicated concentrations were incubated with 100 nM of ATTO 680 
labelled PP1 RNA for 30 minutes, separated on a 5% TBE gel and directly imaged in the 
700 nm channel. (A) EMSA gel image of MNV VPg binding to PP1 RNA. (B) EMSA gel 
image of NT*MNV VPg binding to PP1 RNA. (C) SDS-PAGE gel of purified proteins (3 









































































3.3.6 NT*MNV VPg interacts non-specifically with RNA 
The interaction of NT*MNV VPg with all 12 Pentaprobes was analysed by 
EMSA, to determine the specificity of MNV VPg RNA binding. NT*CAT at 8 µM 
showed no RNA binding activity across all 12 Pentaprobes when compared to 
the RNA only control. FOX-1, a known RNA binding protein, was included as a 
positive control (264, 274, 275). With the exception of PP10, addition of 8 µM of 
FOX-1 resulted in the complete disappearance of unbound probe as the protein-
RNA complexes did not enter the gel. Incubation of NT*MNV VPg with RNA 
resulted in a gel shift for each Pentaprobe (Figure 3.24). A full shift, characterised 
by the complete disappearance of unbound probe, was observed with 2-4 µM of 
NT*MNV VPg for Pentaprobes 1, 3, 4, 5, 9, 10 and 12. For Pentaprobes 2, 6, 7, 8 
and 11 a complete shift was not observed until 8 µM of NT*MNV VPg was 
incubated with RNA. In some instances, a second shift band was apparent which 
could indicate higher order structures or binding of multiple VPg proteins to a 
single piece of RNA. Overall the RNA EMSA assays indicate that MNV VPg 




Figure 3.24 Binding of NT*MNV VPg to RNA Pentaprobes 
Proteins were incubated with 100 nM UTP ATTO 680 labelled Pentaprobe RNA for 30 
minutes, separated on a 5% TBE gel and directly imaged in the 700 nm channel. The 























































































































































































NT*CAT (8 µM) was included as a negative control and FOX-1 (8 µM) as a positive 
control.  
 
3.3.7 NT*MNV VPg does not bind to either ssDNA or dsDNA 
Bioinformatic analysis predicted a weak probability of an interaction with DNA 
(Figure 3.14). Having established that NT*MNV VPg binds to RNA a 
competition assay was designed to determine if VPg also binds to either single-
stranded or double-stranded DNA. A 100-fold molar excess of unlabelled DNA 
probe was added to a standard ATTO 680 labelled RNA Pentaprobe reaction and 
the interaction with the RNA investigated by EMSA. Using PP9, an RNA shift 
was visible with 4 µM and 8 µM of NT*MNV VPg, when either a ssDNA probe 
or dsDNA probe was included in the reaction (Figure 3.25). These results show 
that even in the presence of a molar excess of unlabelled DNA MNV VPg 
preferentially binds to RNA and the gel shift is as strong as an NT*MNV VPg-
PP9 only assay.  
 
 
Figure 3.25 DNA does not interfere with RNA binding by NT*MNV VPg 
Proteins were incubated with 100 nM UTP ATTO 680 labelled Pentaprobe RNA and a 
100-fold molar excess of either single stranded (ss) or double-stranded (ds) unlabelled 
DNA probe for 30 minutes, separated on a 5% TBE gel and directly imaged in the 700 
nm channel. The concentration of NT*MNV VPg was increased from 0.5 µM to 8 µM in 
2-fold increments. NT*CAT (8 µM) was included as a negative control and FOX-1 (8 µM) 






























































3.3.8 Mutation of the N-terminal region of MNV VPg decreases RNA 
binding activity 
The N-terminal region of MNV VPg is important for cell cycle arrest and is 
predicted to be important for RNA binding. These experiments investigated the 
effect of N-terminal mutations on RNA binding by MNV VPg.  
 
Interaction of NT*MNV VPg triple mutant with Pentaprobe RNA 
Transfection of the MNV VPg TM construct into RAW-Blue cells significantly 
reduced the accumulation of cells in the G0/G1 phase of the cell cycle (Figure 
3.9). To test the importance of these residues for RNA binding an MNV VPg 
construct with lysines 5 and 7 and arginine 10 mutated to alanine was designed, 
expressed and purified with an N-terminal NT* tag. NT*MNV VPg TM protein 
purity was confirmed by SDS-PAGE gel (Figure 3.26) (Appendix IV) and the 
interaction with Pentaprobe RNA corresponding to PP4, PP7, and PP9 was 
analysed by EMSA (Figure 3.26). Free probe was observed as a single band for 
PP4 and PP9 and a double band for PP7. NT*CAT had no RNA binding activity 
while the positive control, FOX-1, showed a complete shift of the unbound 
probe. Incubation of NT*MNV VPg TM with RNA resulted in a gel shift for each 
Pentaprobe, characterised by a reduction in unbound probe and the appearance 
of a protein bound band. This indicates that MNV VPg TM is capable of binding 
to RNA. That MNV VPg TM binds RNA and induces a partial cell cycle arrest 
suggests that there may be a correlation between these functions but does not 
confirm a causal relationship.  
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Figure 3.26 MNV VPg triple mutant binds RNA 
(A) Schematic of the first 20 amino acids of MNV VPg, lysine and arginine residues 
shown in red were mutated to alanine in the NT*MNV VPg triple mutant (TM) 
construct. (B) SDS-PAGE gel of purified protein (3 µg) used for RNA binding 
experiments. 1; NT*MNV VPg TM, 2; NT*CAT, 3; FOX-1. (C) RNA EMSA of NT*MNV 
VPg TM with Pentaprobe RNA. Proteins were incubated with 100 nM UTP ATTO 680 
labelled Pentaprobe RNA for 30 minutes, separated on a 5% TBE gel and directly 
imaged in the 700 nm channel. The concentration of NT*MNV VPg TM was increased 
from 0.5 µM to 8 µM in 2-fold increments. NT*CAT (8 µM) was included as a negative 
control and FOX-1 (8 µM) as a positive control.  
 
Interaction of NT*MNV VPg K2-K12A with Pentaprobe RNA 
The N-terminal region of HuNV VPg directly binds to NTPs through an 
interaction reliant on lysine and arginine residues within the first 13 amino acids 
(113). Mutation of these residues reduces the interaction with NTPs. There are 
seven lysine and arginine residues within the first 12 amino acids of MNV VPg, 
each of these were mutated to alanine and the resulting protein was termed 
NT*MNV VPg K2-12 (Figure 3.27). The protein was expressed and purified from 
a recombinant baculovirus and the protein purity confirmed by SDS-PAGE gel 
(Figure 3.27) (Appendix IV). The interaction of NT*MNV VPg K2-12 with PP4, 
GKKGKNKKGRGRPGVFRTRG 
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PP7 and PP9 RNA was investigated by EMSA (Figure 3.27). While the positive 
control FOX-1 bound to all Pentaprobe RNAs, addition of NT*MNV VPg K2-12 
had no effect on the unbound Pentaprobe RNA at each of the protein 
concentrations tested. This suggests that the seven lysine and arginine residues 




Figure 3.27 NT*MNV VPg K2-12A does not bind to RNA 
(A) Schematic of the first 20 amino acids of MNV VPg, lysine and arginine residues 
shown in red were mutated to alanine in the NT*MNV VPg K2-12A construct. (B) SDS-
PAGE gel of purified protein (3 µg) used for RNA binding experiments. 1; NT*MNV 
VPg K2-12A, 2; NT*CAT, 3; FOX-1. (C) RNA EMSA of NT*MNV VPg K2-12A with 
Pentaprobe RNA. Proteins were incubated with 100 nM UTP ATTO 680 labelled 
Pentaprobe RNA for 30 minutes, separated on a 5% TBE gel and directly imaged in the 
700 nm channel. The concentration of NT*MNV VPg K2-12A was increased from 0.5 µM 
to 8 µM in 2-fold increments. NT*CAT (8 µM) was included as a negative control and 
FOX-1 (8 µM) as a positive control. 
 
3.3.9 Interaction of NT*HuNV VPg with Pentaprobe RNA 
The N-terminal region is highly conserved within the norovirus genogroups and 
it is therefore likely that an interaction with RNA is conserved. A recombinant 
GKKGKNKKGRGRPGVFRTRG 
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baculovirus was generated to express a GII.4 Sydney 2012 strain HuNV VPg 
with an N-terminal NT* tag. Purity of NT*HuNV VPg was confirmed by SDS-
PAGE gel (Figure 3.28) (Appendix IV) and the interaction with PP4, PP7 and PP9 
RNA was investigated by EMSA. As with previous experiments, there was no 
shift in the unbound RNA band upon incubation with NT*CAT and a complete 
disappearance with FOX-1. Addition of NT*HuNV VPg showed a gel shift with 
PP4, PP7 and PP9 RNA. The shift was identified by a decrease in the unbound 
RNA band and, for PP4 and PP7, the appearance of a shifted band visible when 
RNA was incubated with 2-8 µM of protein. Similar to MNV VPg, the binding of 




Figure 3.28 NT*HuNV VPg binds RNA 
(A) SDS-PAGE gel of purified protein (3 µg) used for RNA binding experiments. 1; 
NT*HuNV VPg, 2; NT*CAT, 3; FOX-1. (B) RNA EMSA of NT*HuNV VPg with 
Pentaprobe RNA. Proteins were incubated with 100 nM UTP ATTO 680 labelled 
Pentaprobe RNA for 30 minutes, separated on a 5% TBE gel and directly imaged in the 
700 nm channel. The concentration of NT*HuNV VPg was increased from 0.5 µM to 8 
µM in 2-fold increments. NT*CAT (8 µM) was included as a negative control and FOX-


























































3.4 Nuclear localisation sequence of MNV VPg 
3.4.1 Introduction 
The N-terminal region of MNV VPg is predicted to contain an NLS, which would 
give VPg access to the nuclear compartment. Many cell cycle proteins are 
localised within the nucleus, including cyclin/CDK complexes and E2F 
transcription factors. VPg within the nucleus could interact with these factors to 
regulate the G1/S transition. In this section the presence of an NLS within VPg 
was investigated by immunofluorescence microscopy.  
 
3.4.2 MNV VPg is localised in the cytoplasm during infection 
To determine if the N-terminal sequence of MNV VPg functions as an NLS, 
RAW-Blue cells were infected with MNV and harvested at 9 hpi and 12 hpi. Cells 
were probed with an MNV VPg specific antibody and the localisation 
determined by immunofluorescence (Figure 3.29). VPg was apparent in the 
cytoplasm of the cells but did not overlap with the nucleus as indicated by the 
DAPI staining. These results agree with published research showing the 
localisation of MNV VPg in replication complexes adjacent to the nucleus (93, 
139).  
 
To further confirm this result, cells were treated with LMB, an inhibitor of the 
nuclear export protein, CRM-1. RAW-Blue cells were infected with MNV and 
incubated until 6 hpi to allow the infection to establish and for progeny virus to 
be produced. The cells were then treated with 20 nM of LMB and were harvested 
at the indicated timepoints post-infection. Treatment of cells with LMB resulted 
in ~75% cell viability compared to untreated controls. Cyclin B1 was included as 
a positive control and showed a partial accumulation of nuclear protein when 
treated with LMB (Figure 3.30B). Quantification of the mean nuclear cyclin B1 
fluorescence with and without LMB showed an ~2-fold increase confirming that 
the inhibitor was functional (Figure 3.30D). In LMB treated cells, MNV VPg 
remained localised in the cytoplasm and did not accumulate in the nucleus 
(Figure 3.30A). This indicates that VPg does not accumulate in the nucleus when 
CRM-1 mediated export is inhibited although, there are other nuclear export 
pathways that LMB does not inhibit. Overall these results suggest that the N-
terminal region of MNV VPg does not function as an NLS and that the cell cycle 
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arrest induced by VPg is through interactions that occur in the cytoplasm and 
not the nucleus.  
 
 
Figure 3.29 MNV VPg does not localise to the nucleus during infection 
RAW-Blue cells were either infected with MNV at a MOI of 5 or mock infected. Cells 
were fixed at 9 hpi or 12 hpi, labelled with anti MNV VPg antibody and the nucleus 
stained with DAPI for confocal microscopy analysis. Images are representative of three 
independent experiments.  


















































































Figure 3.30 Treatment of RAW-Blue cells with LMB does not alter the localisation of 
MNV VPg 
RAW-Blue cells were either infected with MNV at a MOI of 5, at 6 hpi cells were treated 
with 20 nM LMB. (A) Cells were fixed at 9 hpi and 12 hpi and stained with DAPI and 
anti-MNV VPg. Stained samples were analysed by confocal immunofluorescence. (B) 
Mock cells were treated with 20 nM LMB for 6 hours or left untreated. Cells were fixed 
and stained with DAPI, anti-MNV VPg and anti-cyclin B1. (C) Viability of RAW-Blue 
cells following treatment with 20 nM LMB was measured using the CellTox Green 
Cytotoxicity assay. (D) Quantification of the nuclear cyclin B1 signal in LMB treated 
(n=118) and untreated (n=152) mock cells. Statistical significance was determined for 
comparisons between untreated and LMB treated cells using a two-tailed Student’s t 
test. **** P<0.0001. Images are representative of three independent experiments.  
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3.5 Interaction of MNV VPg with host factor eIF4E 
3.5.1 Introduction 
The expression and localisation of eIF4E is intimately associated with cell cycle 
progression. Analysis of the N-terminal region of MNV VPg indicates that it is 
similar to the eIF4E binding region of PVY VPg. Binding of eIF4E by PVY VPg 
was shown to inhibit the nuclear localisation of eIF4E in an insect cell line (272). 
In the nucleus eIF4E enhances the export of specific mRNA transcripts, including 
cyclins D1, E1, A and B, all of which are dysregulated during MNV infection 
(185). The aim of this research was to analyse eIF4E in infected cells to determine 
the cellular distribution as this could be a possible mechanism for induction of a 
G0/G1 cell cycle arrest.  
 
3.5.2 The effect of MNV infection on total eIF4E expression 
It has previously been shown that infection of MNV in RAW264.7 cells does not 
result in any changes to total eIF4E levels (181). To investigate the interaction of 
eIF4E with MNV VPg the expression of total eIF4E in RAW-Blue murine 
macrophages was first analysed to confirm that they behave in the same manner 
as RAW264.7 cells. RAW-Blue cells were infected with MNV and the total cell 
lysates harvested at 9 and 12 hours post infection for western blot analysis. The 
25 kDa protein band corresponding to total eIF4E levels showed no change over 
the course of infection (Figure 3.31), indicating that MNV infection does not 
degrade or stimulate expression of eIF4E to manipulate the cell cycle. MNV 
infection has been reported to stimulate an increase in phosphorylated eIF4E 
(181). Although the western blot was only performed once due to difficulties 
with the antibody, the results indicate that there is an increase in phosphorylated 
eIF4E at 9 hpi (Figure 3.31). At 12 hpi there was no difference in phosphorylated 
eIF4E between mock and infected cells. These results are consistent with the 
literature confirming that infected RAW-Blue behave in a similar manner to 




Figure 3.31 Total eIF4E expression levels do not change during MNV infection 
Asynchronous RAW-Blue cells were seeded at 1x106 cells in 6-well plates and mock-
infected or infected with MNV at a MOI of 5. At the indicated times post infection cells 
were harvested and the whole cell lysates collected. Lysates were probed by western 
blot for the presence of total eIF4E, phosphorylated eIF4E and MNV VPg. Actin was 
used as a loading control. Blots are representative of three independent experiments 
with the exception of phosphorylated eIF4E.  
 
3.5.3 Nuclear cytoplasmic splits of MNV infected cells 
Subcellular fractionation and immunofluorescence experiments were performed 
to investigate the nuclear-cytoplasmic localisation of eIF4E in infected cells. 
RAW-Blue cells were infected with MNV and the cells harvested at 9- and 12-
hours post-infection. Total cell samples were lysed in RIPA buffer and the 
nuclear and cytoplasmic fractions were produced following instructions in the 
NE-PER kit. The cellular localisation of eIF4E and MNV VPg was analysed by 
western blot (Figure 3.32). Lamin B1, a nuclear membrane protein, was included 
as a nuclear control protein and was present in the nuclear fraction but absent 
from the cytoplasmic fraction. Tubulin was used as a cytoplasmic control, that 
was present in the cytoplasmic fraction but mostly absent from the nucleus. 
Infection of RAW-Blue cells with MNV was confirmed by western blot against 
VPg. At 9 hpi MNV VPg was detected only in the cytoplasmic fraction but at 12 
hpi VPg was present in both the cytoplasmic and nuclear fractions. Replication 
of MNV is known to occur in conjunction with cellular membranes in close 
proximity to the nucleus (93). Detection of VPg in the nuclear fraction is probably 





9 hr 12 hr
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fraction involves partial breakdown of an insoluble pellet containing MNV. In 
support of this, at the same infection timepoints MNV VPg was not detected in 
the nucleus by immunofluorescence (Figures 3.29 and 3.30). At 9 hpi and 12 hpi 
there is an indication that the levels of eIF4E in the cytoplasmic samples are 
increased (Figure 3.32A) however, this was not consistent across three 
independent experiments (Figure 3.32B). Overall this indicates that MNV 
infection does not alter the nuclear-cytoplasmic distribution of eIF4E, at least in 
a manner detectable using the NE-PER kit.  
 
 
Figure 3.32 Nuclear/cytoplasmic analysis of eIF4E localisation during MNV infection 
RAW-Blue cells were either mock infected or infected with MNV at a MOI of 5. At 9 hpi 
and 12 hpi cells were processed using the NE-PER Nuclear and Cytoplasmic Extraction 
Kit. Samples were analysed by western blot to probe against eIF4E and MNV VPg with 
lamin B1 and tubulin as cytoplasmic and nuclear markers respectively. T (total), C 
(cytoplasmic) and N (nuclear) fractions. The blots are representative of two (A and B) of 
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It is possible that only a small fraction of eIF4E is shifting during infection, which 
could be masked using subcellular fractionation. To enable further analysis of 
the distribution of eIF4E immunofluorescence imaging of infected cells was 
performed (Figure 3.33A). Although not visually apparent, quantification of the 
nuclear eIF4E signal showed an ~1.6-fold increase in mean nuclear eIF4E 
florescence at 9 hpi (Figure 3.33B). Overall quantification of nuclear eIF4E signal 
showed a wider distribution of nuclear eIF4E fluorescence compared to mock 
infected cells. An increase in nuclear eIF4E was not expected however, it still 
provides a potential mechanism for a G0/G1 cell cycle arrest. These results 
indicate that MNV infection induces alterations to the nuclear distribution of 
eIF4E which could act to dysregulate the translational activity of eIF4E delaying 
cell cycle progression. 
 
In addition to a quantifiable change in nuclear eIF4E, several other alterations in 
eIF4E were observed in individual cells (Figure 3.33C, D and E). There was some 
overlap in the eIF4E and MNV VPg signals suggestive of co-localisation (Figure 
3.33C and D). This is consistent with an interaction between the two proteins as 
has previously been detected by capture ELISA (66). It was also observed that 
some cells showed eIF4E in punctate structures (Figure 3.33D) while others had 
a decrease in eIF4E both in the nucleus and the cytoplasm (Figure 3.33E). The 
changes in these individual cells were not consistent across the entire population 




Figure 3.33 MNV infection induces an increase in nuclear eIF4E 
RAW-Blue cells were either infected with MNV at a MOI of 5 or left uninfected. (A) 
Cells were fixed at 9 hpi and 12 hpi and stained with DAPI, anti-MNV VPg and anti-
eIF4E. Stained samples were analysed by confocal immunofluorescence. (B) 
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Quantification of the nuclear eIF4E signal in infected (9 hpi n=100 and 12 hpi n=126) 
and uninfected (n=183) samples. Statistical significance was determined for 
comparisons between mock and MNV infected cells using a two-tailed Student’s t test. 
**** P<0.0001. (C, D and E) Zoomed sections of infected cells to show observational 
changes in individual cells. (C) co-localisation of VPg and eIF4E, (D) punctate eIF4E and 





4.1 Induction of a G0/G1 cell cycle arrest by VPg proteins is 
conserved across a diverse range of noroviruses  
MNV VPg induces a G0/G1 cell cycle arrest during infection of a murine 
macrophage cell line (186). Although all viruses in the Caliciviridae family 
produce a VPg protein the sequence conservation is limited and the ability of 
these proteins to arrest the cell cycle is unknown. This study has investigated the 
ability of representative VPg proteins from five norovirus genogroups and four 
additional genera of the Caliciviridae family to induce a cell cycle arrest. A G0/G1 
arrest was induced by a range of norovirus VPg proteins, including human 
noroviruses, as well as VPg proteins from the Sapovirus and Lagovirus genera. 
The proportion of cells in the G0/G1 phase varied for each of the VPg proteins 
tested. For GIII VPg from Jena virus the arrest was not as marked as that of the 
other norovirus proteins. However, as expression could only be confirmed by 
qualitative methods it could be that the protein does not express as effectively. 
That the cell cycle arrest is conserved across a wide range of distantly related 
caliciviruses and not merely a function of MNV VPg points to this being an 
important function for the replication of caliciviruses.  
 
The VPg proteins tested originated from a diverse range of hosts, including 
humans, cows and rabbits but were all able to induce a G0/G1 cell cycle arrest 
in a murine macrophage cell line. This indicates that VPg interacts with a 
component within cells which is evolutionarily conserved rather than being a 
species-specific factor. Regulation and progression of the eukaryotic cell cycle is 
tightly controlled and highly conserved among eukaryotes (276-278). It seems 
likely that the diverse VPg proteins are manipulating a conserved component of 
the cell cycle to induce a favourable environment and thus gain a replication 
advantage.  
 
There are multiple reasons why noroviruses might manipulate cell cycle 
progression, specifically the G1 phase. As obligate intracellular parasites, 
noroviruses are reliant on the host cell to provide the necessary components for 
replication. Ribonucleotides are the precursors to deoxyribonucleotides, the 
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levels of which fluctuate throughout the cell cycle. As cells enter the S phase the 
levels of ribonucleotides drop due to an increase in the synthesis of 
deoxyribonucleotides for DNA replication (279, 280). Induction of a cell cycle 
arrest at the G1/S boundary, as has been characterised for MNV (185), would 
prevent the accumulation of deoxyribonucleotides and instead favour 
replication of the RNA genome of MNV. In addition, the G1 phase is 
characterised by high rates of cap-dependent translation (281). The induction of 
a G0/G1 cell cycle arrest may allow caliciviruses to exploit the high translation 
rates to favour translation of viral proteins leading to more efficient replication.  
4.2 A conserved N-terminal motif is required for a G0/G1 cell 
cycle arrest 
Given the conserved G0/G1 cell cycle arrest induced by VPg proteins found in 
different caliciviruses it was hypothesised that there would be a conserved motif 
present within these sequences that contributed to the cell cycle function. 
Alignment of VPg sequences spanning the first 62 amino acids identified a 
conserved N-terminal motif; KGKxKxGRG. The N-terminal motif is conserved 
in all norovirus genogroups, HuSV VPg and RHDV VPg implying that it is 
functionally important to the virus. 
 
To confirm the association between the N-terminal motif and induction of a cell 
cycle arrest a truncated 11-124 MNV VPg construct was expressed. This 
construct was not able to induce a cell cycle arrest however there was also a 
decrease in total protein expression by western blot. It is possible that the MNV 
VPg antibody recognises a motif towards the N-terminus of the protein or that 
removal of the N-terminal motif induces incorrect folding of the RNA to inhibit 
translation. Nevertheless, with other VPg proteins, such as the Norwalk GI VPg, 
where only low levels of protein are detected an arrest is still induced. This 
implies that a low level of protein expression is sufficient for manipulation of the 
cell cycle and if the 11-124 construct was going to induce arrest the protein levels 
detected should be sufficient. That the 11-124 construct does not induce cell cycle 
arrest indicates that the N-terminal motif is required for the G0/G1 phase arrest.  
 
Both the Newbury 1 VPg and FCV VPg constructs failed to express at detectable 
levels and therefore the contribution of the N-terminal motif for arrest could not 
 110 
be confirmed in the full-length protein. The Newbury 1 VPg construct was 
designed from predicted cleavage sites within the ORF1 polyprotein and has not 
been experimentally studied (282). The predicted Newbury 1 VPg protein is only 
65 amino acids while other VPg proteins in this study, range from 111-138 amino 
acids. In contrast, FCV VPg has previously been detected during infection (283) 
and expressed in E. coli (157) however, it could not be detected as an expressed 
protein in these cell cycle experiments. In order to study the cell cycle arrest 
induced by these proteins chimeric VPg were produced.  
 
A cell cycle arrest was not observed for Nb19/MNV VPg or F18/MNV VPg, 
indicating that the N-terminal regions of FCV VPg and Newbury 1 VPg are not 
functional for an arrest as chimeric proteins, although the native protein may 
function differently. Both Newbury 1 VPg and FCV VPg share less similarity 
with the consensus KGKxKxGRG N-terminal motif present in other VPg 
proteins which arrest the cell cycle. The sequence motif is completely absent in 
Newbury 1 VPg and in FCV VPg the GRG component is separated from the rest 
of the motif by seven amino acids. That the N-terminal regions of these proteins 
are not able to arrest the cell cycle in the context of MNV VPg further highlights 
the importance of the N-terminal motif for this function.  
 
Chimeric proteins were designed to investigate if the N-terminal region of MNV 
VPg could induce cell cycle arrest in the context of Newbury 1 VPg or FCV VPg. 
The construct M20/FCV VPg induced a G0/G1 arrest as strong as MNV VPg 
alone however M20/Nb1 VPg was not able to arrest cells. This suggests that there 
is an unidentified element C-terminal to the first 20 amino acids that is present 
in FCV VPg but absent in Newbury 1 VPg required for cell cycle arrest. MNV 
VPg is more similar to FCV VPg than Newbury 1 VPg in structure, function and 
protein size (66, 141, 146). It is possible that these similarities allow FCV VPg to 
complement MNV VPg in the M20/FCV VPg chimera to induce an arrest. 
Furthermore, the construct M20/EGFP which fuses the first 20 amino acids of 
MNV VPg with EGFP, was not able to induce arrest. This is consistent with the 
concept that an element downstream from the first 20 amino acids of MNV VPg 
is required for arrest and the N-terminal region alone, while essential, is not 
sufficient.  
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Recently, six new genera were added to the Caliciviridae family; Bavovirus, 
Minovirus, Nacovirus, Recovirus, Salovirus and Valovirus (1). Whether the VPg 
proteins from viruses in these new genera can manipulate the cell cycle is 
unknown. Given the conservation of the N-terminal motif in viruses that 
manipulate the cell cycle it is hypothesised that this region would be conserved 
to contribute to a cell cycle arrest by these viruses (Figure 4.1).  
 
The ORF1 polyprotein cleavage sites and expression of VPg proteins in each of 
these viruses has not been experimentally confirmed. For each new genus the 
ORF1 polyprotein sequence was obtained from GenBank and a putative 
E/DEYDE nucleotidylylation motif was identified (Figure 4.1). In 
experimentally confirmed VPg sequences the NS4/VPg protease cleavage site 
lies 15-30 amino acids upstream of the conserved tyrosine in the 
nucleotidylylation motif. For the new calicivirus genera the 30 amino acids 
immediately upstream to the conserved tyrosine were aligned and where 
possible a protease cleavage site and KGKxKxGRG motif identified (Figure 4.1). 
The N-terminal motif, KGKxKxGRG, was conserved in the Recovirus, Valovirus 
and Bavovirus genera suggesting that the VPg proteins may be able to induce a 
G0/G1 cell cycle arrest (Figure 4.1). The Nacovirus, Salovirus and Minovirus VPg 
sequences did not contain an identifiable KGKxKxGRG N-terminal motif 
upstream from the nucleotidylylation tyrosine or elsewhere in the ORF1 
polyprotein sequence. It is possible that these proteins do not manipulate the cell 
cycle, or another protein may perform the function without a KGKxKxGRG 
motif. As the VPg sequences of these genera are only putative, further work 
needs to be done to identify the VPg sequence before accurate cell cycle 




Figure 4.1 Alignment of putative N-terminal regions from the new genera in the 
Caliciviridae family 
An asterisk (*) indicates identical residues and a colon (:) indicates residues that are 
identical in ³ 50% of sequences. Protease cleavage sites are shown in green. Conserved 
amino acids of the N-terminal motif are shown in red. The tyrosine (Y) residue 
corresponding to Y26 of MNV VPg is shown in bold. The GenBank accession numbers 
for each sequence are: norovirus (GV) DQ285629, Recovirus EU391643, Valovirus 
FJ355928, Bavovirus HQ010042, Nacovirus JQ347522, Salovirus KJ577139 and 
Minovirus KX371097.  
 
Functionally, the cell cycle associated N-terminal motif of MNV VPg has 
previously been investigated in relation to nucleotidylylation (113, 146). In 
regard to the cell cycle it seems unlikely that nucleotidylylation of VPg is directly 
responsible for the cell cycle arrest. Previous work has shown that the mutation 
of Y26 essentially ablates nucleotidylylation but has no effect on the induction of 
a cell cycle arrest (186). Progressive truncation of HuNV VPg to delete the first 
three, eight or 20 N-terminal amino acids correlates with a progressive decrease 
in nucleotidylylation activity (99). However, for nucleotidylylation to occur the 
RdRp is required and this was not present during transfections of N-terminal 
modified constructs where a cell cycle arrest occurs. In addition, individual 
mutation of lysine and arginine residues, including K5, K7 and R10, has no effect 
on nucleotidylylation (113, 146). Mutation of two or more lysine and arginine 
residues has been shown to progressively decrease nucleotidylylation to 
undetectable levels (113). This indicates that although the N-terminal region is 
important for nucleotidylylation, single point mutations do not affect this 
function. The decreased cell cycle response of truncated or mutated VPg proteins 
is more likely to be caused by additional roles of the N-terminal motif rather than 
nucleotidylylation.  
Norovirus    YHSEGKKGKNKKGRGRPGVFRTRGL----TDEEY 30
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The N-terminal region of VPg binds directly to NTPs (113, 165) but it seems 
improbable that this is a mechanism for the G0/G1 cell cycle arrest. VPg binding 
to GTP is noticeably reduced when all lysines and arginines in the first 13 
residues (K2-13 VPg) are mutated (113). Other combinations including single 
point mutations to K7 and R10 and consecutive mutation of charged residues 
out to position 12 have no effect on NTP binding (113). This implies that the 
MNV VPg single point mutants and the triple mutant which have a reduced 
ability to induce a cell cycle arrest will still bind to nucleotides as well as WT 
VPg. An ~50% reduction in GTP concentrations has been shown to induce a G1 
arrest (284). Given the low VPg protein expression it does not seem likely that 
VPg binding to NTPs will sufficiently decrease NTP concentration to arrest cells.  
 
Overall these experiments have shown that VPg proteins that manipulate the 
cell cycle have a conserved motif, KGKxKxGRG. The importance of the N-
terminal motif to cell cycle arrest was shown through the use of truncation, point 
mutations and chimeric MNV VPg constructs. The results show that the N-
terminal region, in particular the first 10 amino acids, of MNV VPg are required 
for a G0/G1 cell cycle arrest in conjunction with a downstream element that is 
not the conserved nucleotidylylation tyrosine. 
4.3 Functions of the N-terminal region of MNV VPg 
Having established that the N-terminal region of MNV VPg is required for a 
G0/G1 cell cycle arrest, bioinformatic analyses were performed to try and 
identify a potential mechanism for the arrest.  
 
4.3.1 MNV VPg has RNA binding activity 
The N-terminal region of HuNV VPg binds NTPs (113) and the same region of 
MNV VPg is strongly predicted to interact with RNA. Previous reports have also 
suggested norovirus VPg proteins possess characteristics of RNA binding 
proteins (141). RNA binding experiments showed that purified MNV VPg was 
able to non-specifically bind to RNA. The interaction of MNV VPg was specific 
to RNA as no interference of the gel shifts were observed with either a ssDNA 
probe or a dsDNA probe. HuNV VPg showed similar RNA binding activity to 
MNV VPg, confirming that RNA binding activity is not unique to MNV VPg and 
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may be a conserved function of norovirus VPg proteins. These results provide 
evidence that MNV VPg is an RNA binding protein. 
 
Traditional RNA binding motifs include, the RNA recognition motif, DEAD box 
helicase domain and zinc finger domains.  All of these motifs are absent from 
MNV VPg, suggesting that the protein binds RNA in a non-canonical manner. 
Recently it has become apparent that the traditional view of RNA-binding is 
limited and that many RNA binding domains contain a region of disorder with 
RNA binding potential (285). One of these non-canonical RNA binding domains 
has been termed the K/R basic patch. Basic patches are normally composed of 
4-8 lysines and occasionally arginines which form a highly positive and exposed 
surface for binding to RNA (286, 287).  
 
Given the resemblance to a K/R basic patch, it seemed likely that the N-terminal 
region of MNV VPg which is enriched in lysine and arginine amino acids would 
be required for RNA binding activity. In support of this, PVA VPg has been 
shown to bind RNA in a sequence independent manner which is dependent on 
a stretch of amino acids with a high local positive charge (150, 180). Alanine 
substitutions to MNV VPg at positions K5, K7 and R10 did not inhibit RNA 
binding while mutation of all lysine and arginine residues within the first 12 
amino acids inhibited binding consistent with non-canonical RNA binding. In 
Jembrana disease virus, RNA binding is mediated by arginine residues which 
form electrostatic interactions with RNA that is stabilised by the surrounding 
amino acids (288, 289). Similarly, with PVA VPg it has been proposed that the 
protein has a loosely folded and positively charged contact surface at the edge 
of the protein. Mutation to lysine residues in this area is predicted to drop the 
surface charge of PVA VPg resulting in decreased attraction between the VPg 
and either RNA or individual NTPs (150). Given the decreased binding when 
charged amino acids are replaced with alanine, it seems likely that the N-
terminal residues of MNV VPg allow binding to RNA in a similar manner via 
electrostatic interactions.  
 
RNA binding proteins (RBPs) play a crucial role in the regulation of cell cycle 
progression (290). These proteins participate in a variety of post-transcriptional 
RNA processing steps including translation, RNA stability, localisation and 
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splicing for both mRNA and non-coding RNAs. This study has shown that the 
N-terminal region, and in particular charged amino acids of MNV VPg are 
important for induction of a cell cycle arrest and binding to RNA. At present a 
direct causal link between these two functions is not known. It is possible that a 
cell cycle arrest by MNV VPg could be induced by binding to cellular RNAs 
which regulate the G1/S transition, although further experiments would be 
required to confirm this. The RBP human antigen R (HuR) accumulates in the 
cytoplasm when damage is sensed and regulates the cell cycle. HuR binds many 
target RNAs, one of which is the mRNA encoding p21. Binding by HuR stabilises 
p21 mRNA resulting in increased expression of p21 that contributes to a G1/S 
cell cycle arrest (291). Transcriptomic analysis of MNV infected cells using 
microarray and RNA sequencing technologies shows a slight increase and no 
change in mRNA encoding for p21 and p27 respectively (185) (Unpublished data 
from Dr Zabeen Lateef). This could be indicative of increased transcription or 
stabilisation of p21 RNA. Another example of RBP regulation of the cell cycle 
occurs with cyclin A2. In addition to CDK1/2 binding, cyclin A2 has been shown 
to bind mRNA and promote translation of Mre11, a protein that contributes to 
DNA repair (292).  
 
That RNA binding appears to be a conserved function of norovirus, potyvirus 
and picornavirus VPg proteins indicates that this is role within the viral lifecycle 
(150, 180, 293). Aside from a possible link with induction of a G0/G1 phase cell 
cycle arrest the biological significance of RNA binding by norovirus and 
potyvirus VPg proteins is not clear. The gel shift assays with Pentaprobes 
indicated a non-specific RNA binding interaction however there are multiple 
ways in which specificity can be induced aside from just RNA sequence. While 
the Pentaprobes do have secondary structure, they were not designed for the 
purpose of systematic screening of RNA binding proteins with RNA secondary 
structure. In addition, the sequences do not accurately represent the norovirus 
genome, for which MNV VPg may have specific RNA binding activity.  
 
The RNA binding function of MNV VPg could aid in binding of RNA secondary 
structures to facilitate efficient nucleotidylylation of VPg by RdRp. In 
picornaviruses, VPg and 3D polymerase recognise a CRE in the centre of the 
genome that enhances nucleotidylylation of VPg (169-171). In vitro MNV RdRp 
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can stimulate the nucleotidylylation of VPg in the absence of RNA, although 
there is evidence that an element near the 3’ end of the genome enhances the 
efficiency of nucleotidylylation (99). 
 
Following nucleotidylylation of VPg the protein is translocated to the 3’ end of 
the negative- or positive-sense RNA for replication. The process by which this 
occurs has not been determined. One possibility is that the RNA binding activity 
of VPg allows recognition of an RNA secondary structure in proximity to the 3’ 
end of the RNA bringing VPg into close contact to the terminal nucleotides.  
Similar to MNV VPg, poliovirus RNA binding by 3AB, a VPg precursor, is non-
specific (293). In the presence of 3CD, the poliovirus Pro-RdRp, a 
ribonucleoprotein complex is formed that strongly associates with a 5’ cloverleaf 
RNA structure and can also bind to the 3’ UTR (294-296). The presence of these 
RNA structures in poliovirus are required for RNA replication (297, 298). It could 
be that in the presence of the polymerase or Pro-RdRp RNA binding by MNV 
VPg is specific for the viral genome and aids in RNA replication.  
 
4.3.2 MNV VPg does not contain an NLS 
Throughout the cell cycle there is a constant flux of regulatory proteins into and 
out of the nucleus. A nuclear accumulation of regulatory complexes is essential 
for activation of the transcriptional waves that progress the cell cycle. 
Bioinformatic analysis of MNV VPg suggested the presence of an NLS within 
the N-terminal motif. MNV VPg was found to localise in the cytoplasm adjacent 
to the nucleus but does not appear to enter the nuclear compartment even in the 
presence of LMB to concentrate nuclear proteins.  
 
These results indicate that the N-terminal motif of VPg does not function as an 
NLS. The cytoplasmic localisation of MNV VPg is consistent with previous 
research showing that VPg co-localises with dsRNA within the viral replication 
complex (93, 139). GII.4 HuNV VPg and RHDV VPg proteins both arrest the cell 
cycle and have been shown to display a nuclear and cytoplasmic distribution 
(161, 162). That cytoplasmic MNV VPg can also arrest cells indicates that the cell 
cycle arrest is not reliant on a VPg NLS and is instead induced by cytoplasmic 
rather than nuclear interactions. Many proteins involved in cell cycle 
progression are imported in and out of the nucleus. This includes cyclins, CDKs 
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and CKIs, the relative concentration and localisation of these proteins then 
influences cell cycle fate. In the case of VPg any direct interactions with these 
proteins must be occurring in the cytoplasm possibly inhibiting nuclear entry or 
leading to early protein degradation to influence cell cycle progression.  
 
4.3.3 Interaction of MNV with eIF4E  
MNV VPg interacts with the host eukaryotic translation initiation factor, eIF4E. 
Interestingly, depletion of eIF4E has no effect on viral translation implying that 
the interaction with eIF4E is for an alternate function (66, 134). The expression 
and activity of eIF4E are known to influence the cell cycle either by aiding 
nuclear export of mRNA or by stimulating translation. As the rate limiting step 
for translation, eIF4E is commonly targeted by viruses to regulate host cell cap-
dependent translation (299). 
 
It was therefore proposed that through an interaction with eIF4E MNV VPg 
could manipulate G1/S progression of the host cell cycle to induce a beneficial 
replication environment. In agreement with previous research, it was found that 
infection of murine macrophages with MNV does not induce changes to total 
expression of eIF4E (66, 181). This indicates that MNV VPg does not alter total 
eIF4E protein abundance to induce a cell cycle arrest.  
 
Downregulation or inhibition of eIF4E activity has been shown to promote a 
G0/G1 cell cycle arrest, increase apoptosis and limit protein synthesis in various 
cell lines and yeast models (300-303). Initially it was hypothesised that MNV VPg 
would induce a decrease in the nuclear localisation of eIF4E to limit eIF4E 
activity. However, immunofluorescence experiments showed that infection of 
RAW-Blue cells with MNV leads to an increase in nuclear eIF4E. In the nucleus 
eIF4E binds to specific mRNAs to facilitate nuclear export, including mRNAs 
encoding the cell cycle regulators cyclin D1, cyclin E1, cyclin A2, ODC and c-
Myc (304). Of these, the cyclins have all been shown to be decreased at the 
mRNA level during an MNV infection (185). It could be that there is a block in 
the nuclear export of eIF4E and associated mRNAs. VPg would need to interact 
with cytoplasmic components of nuclear import or export machinery to increase 
nuclear eIF4E.  
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A global shut-off of host protein synthesis can be induced by an accumulation of 
eIF4E in the nucleus, as has been observed for poliovirus (305). Inhibition of host 
mRNA translation occurs during MNV infection, although this has been 
attributed as a function of the NS3 protein (95). Expression of VPg alone does 
not inhibit translation, as measured by puromycin uptake of translationally 
active mRNAs (95). That VPg alone can induce a cell cycle arrest but cannot 
induce a translational shut-off suggests that global inhibition of protein 
synthesis through nuclear sequestration of eIF4E is not the mechanism for the 
cell cycle arrest.  
 
There was some co-localisation of eIF4E and MNV VPg observed by 
immunofluorescence experiments, this is consistent with reports of direct 
binding between the proteins (66, 134). The binding of VPg to eIF4E led to the 
hypothesis that VPg may act in a similar manner to a 4E-binding protein (4E-
BP). This, in combination with an increase in nuclear eIF4E levels could result in 
a partial inhibition of eIF4E activity. The intimate association of eIF4E with cell 
cycle progression suggests that this is still an attractive target for the VPg 
induced cell cycle arrest.   
 
There are reports where overexpression of 4E-BP1 induces changes in cell cycle 
proteins leading to a G0/G1 arrest but without a general shutdown of protein 
synthesis (300, 306). Specifically, protein levels of cyclin E and CDK2 were 
unaffected, p27 was increased and cyclin D1 was decreased (306). The MNV 
induced G0/G1 arrest does not result in changes to the protein expression of 
cyclin E or cyclin D1 (185). However, there is evidence that cyclin D contains an 
internal ribosome entry site and could therefore be translated in an eIF4E-
independent manner (307). MNV infection also increases the levels of 
phosphorylated eIF4E (181) which has been shown to favour translation of cyclin 
D1 transcripts (308). This could explain why cyclin D protein levels does not 
change with MNV infection. The expression levels of CDK2 and p27 proteins 
during MNV infection have not been established. Unlike MNV, other 
caliciviruses including RHDV, which induces a cell cycle arrest, require eIF4E 
for translation (178). The combination of increased nuclear eIF4E levels and 
direct binding by VPg could function to partially inhibit or redirect the 
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translational activity of eIF4E in infected cells resulting in a G0/G1 cell cycle 
arrest.  
 
Whether binding to eIF4E is mediated by the N-terminal motif of MNV VPg 
remains to be determined. PVY virus, a member of the potyvirus family, binds 
eIF4E through a region beginning 41RKK (309) which is immediately upstream 
of the NTP binding site. This region shares a conservation of amino acid 
sequence with the N-terminal cell cycle motif of MNV VPg. Interaction of PVY 
VPg and eIF4E has been proposed to decrease cap dependent translation via 
sequestration of eIF4E (309). Similarly, in an in vitro system PVA VPg limits 
translation of RNA transcripts and this function is inhibited when mutations are 
introduced to the NTP binding site (180).  
  
In addition to an increase in nuclear eIF4E, a subset of infected cells showed 
eIF4E in punctate structures within the cytoplasm. Aside from being present in 
the nucleus and cytoplasm, eIF4E is located in stress granules (SGs), polysomes 
and processing bodies (PBs). The punctate structures are not likely to be SGs as 
it has been shown that MNV impairs the integrated stress response significantly 
decreasing the formation of SGs (95, 310). Phosphorylated eIF4E relocates to 
polysomes, which are areas of active translation. MNV infection induces a 
modest increase in phosphorylated eIF4E and subsequent localisation to 
polysomes suggesting that the observed punctate structures could be polysomes 
(181). Another possibility for the punctate appearance of eIF4E is localisation in 
PBs, these granules are upregulated in times of stress and are sites of active 
mRNA decay (311). The effect of MNV infection on PBs is unknown. Further 
characterisation of eIF4E with either polysomes or PBs will require analysis with 
additional antibodies to define the components of the punctate structures.  
4.4 Conclusions 
This research has shown that induction of a G0/G1 cell cycle arrest is a 
conserved function of norovirus VPg proteins. The ability to manipulate the cell 
cycle extends to other members of the Caliciviridae family, including HuSV VPg 
and RHDV VPg. Alignment of the VPg protein sequences led to identification of 
a conserved N-terminal motif, KGKxKxGRG. The importance of the N-terminal 
motif to cell cycle arrest was shown through the use of truncation, point 
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mutations and chimeric MNV VPg constructs. These constructs show that 
positively charged amino acids are important for the arrest and indicate that 
there is a requirement for more than just the N-terminal motif. Functional 
predictions for the N-terminal motif suggested that it binds RNA, functions as 
an NLS and interacts with eIF4E. MNV VPg was found to bind RNA in a non-
specific manner that is dependent on charged amino acids in the N-terminal 
region. The N-terminal region does not function as an NLS, with no VPg 
detected in the nucleus even when LMB was added as a nuclear export inhibitor. 
Finally, infection of RAW-Blue cells with MNV induces a dysregulation in eIF4E, 
resulting in an accumulation of eIF4E in the nucleus. Overall two potential 
mechanisms, RNA binding and dysregulation of nuclear eIF4E, have been 
identified and could be responsible for the induction of a G0/G1 cell cycle arrest 
by MNV VPg.  
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5 Future Directions 
The cell cycle experiments carried out in this thesis were performed in RAW-
Blue cells and the arrest has also been confirmed in RAW246.7 cells (185). 
Analysis of the cell cycle response in additional cell lines, such as tuft cells and 
primary macrophages or dendritic cells which support MNV replication in vivo 
should be investigated. Experiments can investigate firstly if a cell cycle arrest is 
induced in these cell lines and secondly look at the transcriptomic changes 
induced during arrest. This will identify changes in cell cycle pathways and may 
suggest a mechanism for the G0/G1 cell cycle arrest. The transcriptomic 
response to MNV infection of primary bone marrow-derived macrophages 
(BMDMs) has previously been investigated (312). In these cells MNV infection 
does not induce the same changes in cell cycle specific mRNAs as is seen in RAW 
264.7 cells, although, there was only a low level of infection (185, 312). Conserved 
transcriptional alterations to pathways include interphase, cell cycle progression 
and cell cycle regulation by BTG proteins (312). At the individual gene level, in 
both cell types, increases in cdkn1a, which encodes the cell cycle inhibitor p21, 
were observed along with decreases in E2F7 and E2F8 (185, 312). To confirm 
these changes, select proteins from each pathway, p21 and proteins from the E2F 
family could be analysed by western blot. This will allow identification of 
conserved changes to cell cycle pathways across multiple MNV susceptible cell 
lines.  
 
MNV induces a G0/G1 arrest by delaying progression out of the G1 phase and 
into the S phase (185). Additional experiments could be performed to show that 
the arrest induced by norovirus genogroup and calicivirus VPg proteins is 
through a delay in the G1/S transition. This would help to characterise the cell 
cycle arrest and provide further evidence for a conserved mechanism. RAW-
Blue cells can be stimulated to synchronise into the G1 phase by treatment with 
N-butyrate and will re-enter the cell cycle upon removal of the inhibitor. The 
effect of different VPg proteins on progression of cells out of the G1 phase and 
into S phase can then be measured in order to determine if these proteins delay 
the G1/S transition.  
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The N-terminal region of MNV VPg is known to be disordered and likely 
participates in multiple functions throughout the viral replication cycle (146, 
152). The work presented in this thesis has shown that the N-terminal region of 
MNV VPg is required for a G0/G1 cell cycle arrest. K5, K7 and R10 of MNV VPg 
contribute to the G0/G1 arrest however, it is important to know the contribution 
of each amino acid within the KGKxKxGRG motif. This could be accomplished 
using an alanine scanning approach on the N-terminal region of MNV VPg. 
Generation of constructs containing multiple mutations could address which 
combinations of amino acids are required to induce arrest and whether 
disruption of the disordered nature of the N-terminal motif effects the arrest. 
These mutations could also be used to test the abilities of mutant VPg proteins 
to bind RNA and dysregulate eIF4E to link either activity to the cell cycle 
manipulation.  
 
While the N-terminal region is clearly important, it is not sufficient by itself to 
induce a G0/G1 cell cycle arrest. Given that the first 62 amino acids of MNV VPg 
induce arrest it appears that there is something else within those 62 amino acids 
that contributes to a G0/G1 arrest. The disordered N-terminal region may 
function in combination with a specific motif or structural element within the 
first 62 amino acids that induces a disorder-to-order transition required for a cell 
cycle arrest. Within the first 62 amino acids, only the nucleotidylylation motif 
(EYxE) and a leucine residue corresponding to position 46 on MNV VPg are 
conserved across all proteins shown to induce an arrest. The effect of mutation 
of these amino acids on the cell cycle, both individually and in combination with 
N-terminal amino acids should be analysed. Structurally, both of the alpha 
helices of MNV VPg are within the first 62 amino acids and it possible that these 
are required for a cell cycle arrest (108, 146). In support of this, the helices of 
MNV VPg overlay well with those of FCV, and could explain why the M20FCV 
VPg chimera was still able to induce arrest whereas the M20EGFP construct was 
not. Mutations to Y40, Y45, R32 or D48 disrupt the structured core of MNV VPg 
(146) and could be investigated either individually or in combination to 
determine the contribution of the helices to a cell cycle arrest.  
 
One of the findings in this thesis is that MNV VPg is an RNA binding protein. In 
recent years it has become apparent that disordered RNA binding proteins can 
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have profound regulatory effects on the cell (285, 286, 313). Despite the 
abundance of these proteins, in many cases the biological consequences of 
disordered RNA binding proteins are poorly characterised. As a disordered 
RNA binding protein MNV VPg may play a significant role in regulation of RNA 
within the host cell with possible links to cell cycle progression. RNAseq analysis 
of MNV infected cells has shown a significant downregulation of ribosomal 
RNAs (unpublished data from Dr Zabeen Lateef). While this will affect multiple 
cellular pathways, one known outcome is to induce a cell cycle arrest in the G1 
phase though the stabilisation of p53 (314). Many viruses manipulate the cell 
cycle through p53 dependent pathways, suggesting that this is an attractive 
target and should be further investigated. 
 
Disordered RNA binding proteins bind RNA either non-specifically or 
specifically although in many cases it is not clear how this specificity is achieved. 
Specificity can be induced by various mechanisms including post translational 
modifications, interactions with other proteins or the tertiary structure of the 
RNA (286). This suggests that although MNV VPg RNA binding activity appears 
to be non-specific by EMSA, in cells the interaction could be specific for either 
host or viral RNA. Identification of direct RNA interactions in the cell could 
indicate additional functional roles of VPg during the viral lifecycle and may 
indicate a causative mechanism for the cell cycle arrest. RNA-VPg interactions 
could be studied using RNA immunoprecipitation techniques followed by 
sequencing. Expression of identified sequences could be confirmed by qRT-PCR 
to determine RNA levels and western blot to determine protein levels.  
 
The host factor, eIF4E, is commonly targeted by viruses to induce a beneficial 
replication environment (reviewed in (299)). Immunofluorescence experiments 
indicate that MNV infection dysregulates the nuclear localisation of eIF4E. It is 
important to establish if the dysregulation of eIF4E is driven by VPg or another 
viral protein. This could be performed using transfections of either DNA or RNA 
to produce MNV VPg in cells followed by immunofluorescence. Similar 
experiments using VPg constructs with mutated or truncated N-terminal motifs 
could be used to determine the role of the N-terminus for eIF4E dysregulation.  
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Downregulation or inhibition of the activity of eIF4E leads to a G0/G1 cell cycle 
arrest. It is possible that the increased nuclear localisation of eIF4E in 
combination with direct binding provides a mechanism for the VPg induced cell 
cycle arrest. Expression of survivin is driven in an eIF4E dependent manner and 
has been shown to be downregulated during MNV infection (315). The 
downregulation of survivin could be consistent with an inhibition of eIF4E 
translation activity. The expression of other proteins such as c-myc and p27 (306) 
which are expressed in an eIF4E dependent and eIF4E independent manner 
respectively should be determined.  
 
A consistent theme throughout this section suggests that a systematic analysis 
of key cell cycle regulators important for the G1/S transition should be 
undertaken. This approach would identify protein changes by western blot to 
either total or activated cell cycle regulators in the context of MNV infection or 
VPg transfection. The levels and activation of proteins such as p53, Rb and 
CDK4/6/2 should be analysed in addition to the regulators already mentioned. 
Identification of changes to cell cycle pathways will indicate mechanisms for the 





1. Vinje J, Estes MK, Esteves P, Green KY, Katayama K, Knowles NJ, et al. 
ICTV Virus Taxonomy Profile: Caliciviridae. J Gen Virol. 2019. 
2. Kaplan JE, Gary GW, Baron RC, Singh N, Schonberger LB, Feldman R, et 
al. Epidemiology of Norwalk gastroenteritis and the role of Norwalk virus 
in outbreaks of acute nonbacterial gastroenteritis. Ann Intern Med. 
1982;96(6 Pt 1):756-61. 
3. Hoover EA, Kahn DE. Experimentally induced feline calicivirus infection: 
clinical signs and lesions. J Am Vet Med Assoc. 1975;166(5):463-8. 
4. Abrantes J, van der Loo W, Le Pendu J, Esteves PJ. Rabbit haemorrhagic 
disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review. 
Vet Res. 2012;43:12. 
5. Turan T, Isidan H, Atasoy MO, Irehan B. Detection and Molecular Analysis 
of Bovine Enteric Norovirus and Nebovirus in Turkey. J Vet Res. 
2018;62(2):129-35. 
6. Bridger JC, Hall GA, Brown JF. Characterization of a calici-like virus 
(Newbury agent) found in association with astrovirus in bovine diarrhea. 
Infect Immun. 1984;43(1):133-8. 
7. Radford AD, Coyne KP, Dawson S, Porter CJ, Gaskell RM. Feline 
calicivirus. Vet Res. 2007;38(2):319-35. 
8. Caringella F, Elia G, Decaro N, Martella V, Lanave G, Varello K, et al. 
Feline calicivirus infection in cats with virulent systemic disease, Italy. Res 
Vet Sci. 2019;124:46-51. 
9. Oka T, Wang Q, Katayama K, Saif LJ. Comprehensive review of human 
sapoviruses. Clin Microbiol Rev. 2015;28(1):32-53. 
10. Sakai Y, Nakata S, Honma S, Tatsumi M, Numata-Kinoshita K, Chiba S. 
Clinical severity of Norwalk virus and Sapporo virus gastroenteritis in 
children in Hokkaido, Japan. Pediatr Infect Dis J. 2001;20(9):849-53. 
11. Wolf S, Reetz J, Otto P. Genetic characterization of a novel calicivirus from 
a chicken. Arch Virol. 2011;156(7):1143-50. 
12. Wolf S, Reetz J, Hoffmann K, Grundel A, Schwarz BA, Hanel I, et al. 
Discovery and genetic characterization of novel caliciviruses in German 
and Dutch poultry. Arch Virol. 2012;157(8):1499-507. 
 126 
13. Farkas T, Sestak K, Wei C, Jiang X. Characterization of a rhesus monkey 
calicivirus representing a new genus of Caliciviridae. J Virol. 
2008;82(11):5408-16. 
14. L'Homme Y, Sansregret R, Plante-Fortier E, Lamontagne AM, Ouardani M, 
Lacroix G, et al. Genomic characterization of swine caliciviruses 
representing a new genus of Caliciviridae. Virus Genes. 2009;39(1):66-75. 
15. Mor SK, Phelps NBD, Ng TFF, Subramaniam K, Primus A, Armien AG, et 
al. Genomic characterization of a novel calicivirus, FHMCV-2012, from 
baitfish in the USA. Arch Virol. 2017;162(12):3619-27. 
16. Mikalsen AB, Nilsen P, Froystad-Saugen M, Lindmo K, Eliassen TM, Rode 
M, et al. Characterization of a novel calicivirus causing systemic infection 
in atlantic salmon (Salmo salar L.): proposal for a new genus of 
caliciviridae. PLoS One. 2014;9(9):e107132. 
17. Kapikian AZ, Wyatt RG, Dolin R, Thornhill TS, Kalica AR, Chanock RM. 
Visualization by immune electron microscopy of a 27-nm particle 
associated with acute infectious nonbacterial gastroenteritis. J Virol. 
1972;10(5):1075-81. 
18. Chhabra P, de Graaf M, Parra GI, Chan MC, Green K, Martella V, et al. 
Updated classification of norovirus genogroups and genotypes. J Gen 
Virol. 2019. 
19. Bull RA, Hansman GS, Clancy LE, Tanaka MM, Rawlinson WD, White PA. 
Norovirus recombination in ORF1/ORF2 overlap. Emerg Infect Dis. 
2005;11(7):1079-85. 
20. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, Parashar UD, 
et al. Global prevalence of norovirus in cases of gastroenteritis: a systematic 
review and meta-analysis. Lancet Infect Dis. 2014;14(8):725-30. 
21. Bartsch SM, Lopman BA, Ozawa S, Hall AJ, Lee BY. Global Economic 
Burden of Norovirus Gastroenteritis. PLoS One. 2016;11(4):e0151219. 
22. Hoa Tran TN, Trainor E, Nakagomi T, Cunliffe NA, Nakagomi O. 
Molecular epidemiology of noroviruses associated with acute sporadic 
gastroenteritis in children: global distribution of genogroups, genotypes 
and GII.4 variants. J Clin Virol. 2013;56(3):185-93. 
23. Burke RM, Shah MP, Wikswo ME, Barclay L, Kambhampati A, Marsh Z, et 
al. The Norovirus Epidemiologic Triad: Predictors of Severe Outcomes in 
US Norovirus Outbreaks, 2009-2016. J Infect Dis. 2019;219(9):1364-72. 
 127 
24. Siebenga JJ, Vennema H, Zheng DP, Vinje J, Lee BE, Pang XL, et al. 
Norovirus illness is a global problem: emergence and spread of norovirus 
GII.4 variants, 2001-2007. J Infect Dis. 2009;200(5):802-12. 
25. Pan L, Xue C, Fu H, Liu D, Zhu L, Cui C, et al. The novel norovirus 
genotype GII.17 is the predominant strain in diarrheal patients in 
Shanghai, China. Gut Pathog. 2016;8:49. 
26. Iritani N, Yamamoto SP, Abe N, Kanbayashi D, Kubo H, Uema M, et al. 
GII.17 norovirus infections in outbreaks of acute nonbacterial 
gastroenteritis in Osaka City, Japan during two decades. J Med Virol. 2019. 
27. Lun JH, Hewitt J, Sitabkhan A, Eden JS, Enosi Tuipulotu D, Netzler NE, et 
al. Emerging recombinant noroviruses identified by clinical and waste 
water screening. Emerg Microbes Infect. 2018;7(1):50. 
28. Lun JH, Hewitt J, Yan GJH, Enosi Tuipulotu D, Rawlinson WD, White PA. 
Recombinant GII.P16/GII.4 Sydney 2012 Was the Dominant Norovirus 
Identified in Australia and New Zealand in 2017. Viruses. 2018;10(10). 
29. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. 
Determination of the 50% human infectious dose for Norwalk virus. J 
Infect Dis. 2014;209(7):1016-22. 
30. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, et al. 
Norwalk virus shedding after experimental human infection. Emerg Infect 
Dis. 2008;14(10):1553-7. 
31. Tung G, Macinga D, Arbogast J, Jaykus LA. Efficacy of commonly used 
disinfectants for inactivation of human noroviruses and their surrogates. J 
Food Prot. 2013;76(7):1210-7. 
32. Frange P, Touzot F, Debre M, Heritier S, Leruez-Ville M, Cros G, et al. 
Prevalence and clinical impact of norovirus fecal shedding in children with 
inherited immune deficiencies. J Infect Dis. 2012;206(8):1269-74. 
33. Marques Mendanha de Oliveira D, Souza M, Souza Fiaccadori F, Cesar 
Pereira Santos H, das Dores de Paula Cardoso D. Monitoring of Calicivirus 
among day-care children: evidence of asymptomatic viral excretion and 
first report of GI.7 Norovirus and GI.3 Sapovirus in Brazil. J Med Virol. 
2014;86(9):1569-75. 
34. Ye X, Van JN, Munoz FM, Revell PA, Kozinetz CA, Krance RA, et al. 
Noroviruses as a Cause of Diarrhea in Immunocompromised Pediatric 
 128 
Hematopoietic Stem Cell and Solid Organ Transplant Recipients. Am J 
Transplant. 2015;15(7):1874-81. 
35. Robilotti E, Deresinski S, Pinsky BA. Norovirus. Clin Microbiol Rev. 
2015;28(1):134-64. 
36. Netzler NE, Enosi Tuipulotu D, White PA. Norovirus antivirals: Where are 
we now? Med Res Rev. 2019;39(3):860-86. 
37. Wyatt RG, Greenberg HB, Dalgard DW, Allen WP, Sly DL, Thornhill TS, et 
al. Experimental infection of chimpanzees with the Norwalk agent of 
epidemic viral gastroenteritis. J Med Virol. 1978;2(2):89-96. 
38. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. 
Laboratory efforts to cultivate noroviruses. J Gen Virol. 2004;85(Pt 1):79-87. 
39. Ball JM, Estes MK, Hardy ME, Conner ME, Opekun AR, Graham DY. 
Recombinant Norwalk virus-like particles as an oral vaccine. Arch Virol 
Suppl. 1996;12:243-9. 
40. Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, et al. Chimpanzees 
as an animal model for human norovirus infection and vaccine 
development. Proc Natl Acad Sci U S A. 2011;108(1):325-30. 
41. Rockx BH, Bogers WM, Heeney JL, van Amerongen G, Koopmans MP. 
Experimental norovirus infections in non-human primates. J Med Virol. 
2005;75(2):313-20. 
42. Subekti DS, Tjaniadi P, Lesmana M, McArdle J, Iskandriati D, Budiarsa IN, 
et al. Experimental infection of Macaca nemestrina with a Toronto 
Norwalk-like virus of epidemic viral gastroenteritis. J Med Virol. 
2002;66(3):400-6. 
43. Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ. Pathogenesis 
of a genogroup II human norovirus in gnotobiotic pigs. J Virol. 
2006;80(21):10372-81. 
44. Souza M, Cheetham SM, Azevedo MS, Costantini V, Saif LJ. Cytokine and 
antibody responses in gnotobiotic pigs after infection with human 
norovirus genogroup II.4 (HS66 strain). J Virol. 2007;81(17):9183-92. 
45. Souza M, Azevedo MS, Jung K, Cheetham S, Saif LJ. Pathogenesis and 
immune responses in gnotobiotic calves after infection with the genogroup 
II.4-HS66 strain of human norovirus. J Virol. 2008;82(4):1777-86. 
46. Taube S, Kolawole AO, Hohne M, Wilkinson JE, Handley SA, Perry JW, et 
al. A mouse model for human norovirus. MBio. 2013;4(4). 
 129 
47. Kolawole AO, Rocha-Pereira J, Elftman MD, Neyts J, Wobus CE. Inhibition 
of human norovirus by a viral polymerase inhibitor in the B cell culture 
system and in the mouse model. Antiviral Res. 2016;132:46-9. 
48. Van Dycke J, Ny A, Conceicao-Neto N, Maes J, Hosmillo M, Cuvry A, et al. 
A robust human norovirus replication model in zebrafish larvae. PLoS 
Pathog. 2019;15(9):e1008009. 
49. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, et al. 
Enteric bacteria promote human and mouse norovirus infection of B cells. 
Science. 2014;346(6210):755-9. 
50. Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, 
Tenge VR, et al. Replication of human noroviruses in stem cell-derived 
human enteroids. Science. 2016;353(6306):1387-93. 
51. Costantini V, Morantz EK, Browne H, Ettayebi K, Zeng XL, Atmar RL, et 
al. Human Norovirus Replication in Human Intestinal Enteroids as Model 
to Evaluate Virus Inactivation. Emerg Infect Dis. 2018;24(8):1453-64. 
52. Guix S, Asanaka M, Katayama K, Crawford SE, Neill FH, Atmar RL, et al. 
Norwalk virus RNA is infectious in mammalian cells. J Virol. 
2007;81(22):12238-48. 
53. Asanaka M, Atmar RL, Ruvolo V, Crawford SE, Neill FH, Estes MK. 
Replication and packaging of Norwalk virus RNA in cultured mammalian 
cells. Proc Natl Acad Sci U S A. 2005;102(29):10327-32. 
54. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY. Stable 
expression of a Norwalk virus RNA replicon in a human hepatoma cell 
line. Virology. 2006;353(2):463-73. 
55. Katayama K, Murakami K, Sharp TM, Guix S, Oka T, Takai-Todaka R, et al. 
Plasmid-based human norovirus reverse genetics system produces 
reporter-tagged progeny virus containing infectious genomic RNA. Proc 
Natl Acad Sci U S A. 2014;111(38):E4043-52. 
56. Oliveira LM, Blawid R, Orilio AF, Andrade BYG, Souza ACA, Nagata T. 
Development of an infectious clone and replicon system of norovirus GII.4. 
J Virol Methods. 2018;258:49-53. 
57. Chang KO, George DW. Interferons and ribavirin effectively inhibit 
Norwalk virus replication in replicon-bearing cells. J Virol. 
2007;81(22):12111-8. 
 130 
58. Kitano M, Hosmillo M, Emmott E, Lu J, Goodfellow I. Selection and 
Characterization of Rupintrivir-Resistant Norwalk Virus Replicon Cells In 
Vitro. Antimicrob Agents Chemother. 2018;62(5). 
59. Enosi Tuipulotu D, Netzler NE, Lun JH, Mackenzie JM, White PA. TLR7 
Agonists Display Potent Antiviral Effects against Norovirus Infection via 
Innate Stimulation. Antimicrob Agents Chemother. 2018;62(5). 
60. Van Dycke J, Arnoldi F, Papa G, Vandepoele J, Burrone OR, Mastrangelo E, 
et al. A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, 
Rotavirus, and Sapovirus-Induced Diarrhea. J Infect Dis. 2018;218(11):1753-
8. 
61. Sosnovtsev S, Green KY. RNA transcripts derived from a cloned full-length 
copy of the feline calicivirus genome do not require VpG for infectivity. 
Virology. 1995;210(2):383-90. 
62. Oka T, Takagi H, Tohya Y. Development of a novel single step reverse 
genetics system for feline calicivirus. J Virol Methods. 2014;207:178-81. 
63. Urakami H, Ikarashi K, Okamoto K, Abe Y, Ikarashi T, Kono T, et al. 
Chlorine sensitivity of feline calicivirus, a norovirus surrogate. Appl 
Environ Microbiol. 2007;73(17):5679-82. 
64. Mormann S, Heissenberg C, Pfannebecker J, Becker B. Tenacity of human 
norovirus and the surrogates feline calicivirus and murine norovirus 
during long-term storage on common nonporous food contact surfaces. J 
Food Prot. 2015;78(1):224-9. 
65. Wu H, Zu S, Sun X, Liu Y, Tian J, Qu L. N-Terminal Domain of Feline 
Calicivirus (FCV) Proteinase-Polymerase Contributes to the Inhibition of 
Host Cell Transcription. Viruses. 2016;8(7). 
66. Chaudhry Y, Nayak A, Bordeleau ME, Tanaka J, Pelletier J, Belsham GJ, et 
al. Caliciviruses differ in their functional requirements for eIF4F 
components. J Biol Chem. 2006;281(35):25315-25. 
67. Cannon JL, Papafragkou E, Park GW, Osborne J, Jaykus LA, Vinje J. 
Surrogates for the study of norovirus stability and inactivation in the 
environment: aA comparison of murine norovirus and feline calicivirus. J 
Food Prot. 2006;69(11):2761-5. 
68. Farkas T, Cross RW, Hargitt E, 3rd, Lerche NW, Morrow AL, Sestak K. 
Genetic diversity and histo-blood group antigen interactions of rhesus 
enteric caliciviruses. J Virol. 2010;84(17):8617-25. 
 131 
69. Chang KO, Sosnovtsev SV, Belliot G, Kim Y, Saif LJ, Green KY. Bile acids 
are essential for porcine enteric calicivirus replication in association with 
down-regulation of signal transducer and activator of transcription 1. Proc 
Natl Acad Sci U S A. 2004;101(23):8733-8. 
70. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HWt. STAT1-dependent 
innate immunity to a Norwalk-like virus. Science. 2003;299(5612):1575-8. 
71. Wobus CE, Karst SM, Thackray LB, Chang KO, Sosnovtsev SV, Belliot G, et 
al. Replication of Norovirus in cell culture reveals a tropism for dendritic 
cells and macrophages. PLoS Biol. 2004;2(12):e432. 
72. Wobus CE, Thackray LB, Virgin HWt. Murine norovirus: a model system 
to study norovirus biology and pathogenesis. J Virol. 2006;80(11):5104-12. 
73. Rocha-Pereira J, Jacobs S, Noppen S, Verbeken E, Michiels T, Neyts J. 
Interferon lambda (IFN-lambda) efficiently blocks norovirus transmission 
in a mouse model. Antiviral Res. 2018;149:7-15. 
74. Grau KR, Roth AN, Zhu S, Hernandez A, Colliou N, DiVita BB, et al. The 
major targets of acute norovirus infection are immune cells in the gut-
associated lymphoid tissue. Nat Microbiol. 2017;2(12):1586-91. 
75. Hsu CC, Wobus CE, Steffen EK, Riley LK, Livingston RS. Development of a 
microsphere-based serologic multiplexed fluorescent immunoassay and a 
reverse transcriptase PCR assay to detect murine norovirus 1 infection in 
mice. Clin Diagn Lab Immunol. 2005;12(10):1145-51. 
76. Mumphrey SM, Changotra H, Moore TN, Heimann-Nichols ER, Wobus 
CE, Reilly MJ, et al. Murine norovirus 1 infection is associated with 
histopathological changes in immunocompetent hosts, but clinical disease 
is prevented by STAT1-dependent interferon responses. J Virol. 
2007;81(7):3251-63. 
77. Wilen CB, Lee S, Hsieh LL, Orchard RC, Desai C, Hykes BL Jr., et al. 
Tropism for tuft cells determines immune promotion of norovirus 
pathogenesis. Science. 2018;360(6385):204-8. 
78. Haga K, Fujimoto A, Takai-Todaka R, Miki M, Doan YH, Murakami K, et 
al. Functional receptor molecules CD300lf and CD300ld within the CD300 
family enable murine noroviruses to infect cells. Proc Natl Acad Sci U S A. 
2016;113(41):E6248-E55. 
 132 
79. Orchard RC, Wilen CB, Doench JG, Baldridge MT, McCune BT, Lee YC, et 
al. Discovery of a proteinaceous cellular receptor for a norovirus. Science. 
2016;353(6302):933-6. 
80. McFadden N, Bailey D, Carrara G, Benson A, Chaudhry Y, Shortland A, et 
al. Norovirus regulation of the innate immune response and apoptosis 
occurs via the product of the alternative open reading frame 4. PLoS 
Pathog. 2011;7(12):e1002413. 
81. Sosnovtsev SV, Belliot G, Chang KO, Prikhodko VG, Thackray LB, Wobus 
CE, et al. Cleavage map and proteolytic processing of the murine norovirus 
nonstructural polyprotein in infected cells. J Virol. 2006;80(16):7816-31. 
82. Simmonds P, Karakasiliotis I, Bailey D, Chaudhry Y, Evans DJ, Goodfellow 
IG. Bioinformatic and functional analysis of RNA secondary structure 
elements among different genera of human and animal caliciviruses. 
Nucleic Acids Res. 2008;36(8):2530-46. 
83. Vashist S, Urena L, Chaudhry Y, Goodfellow I. Identification of RNA-
protein interaction networks involved in the norovirus life cycle. J Virol. 
2012;86(22):11977-90. 
84. Baker ES, Luckner SR, Krause KL, Lambden PR, Clarke IN, Ward VK. 
Inherent structural disorder and dimerisation of murine norovirus NS1-2 
protein. PLoS One. 2012;7(2):e30534. 
85. Lateef Z, Gimenez G, Baker ES, Ward VK. Transcriptomic analysis of 
human norovirus NS1-2 protein highlights a multifunctional role in murine 
monocytes. BMC Genomics. 2017;18(1):39. 
86. Hyde JL, Mackenzie JM. Subcellular localization of the MNV-1 ORF1 
proteins and their potential roles in the formation of the MNV-1 replication 
complex. Virology. 2010;406(1):138-48. 
87. McCune BT, Tang W, Lu J, Eaglesham JB, Thorne L, Mayer AE, et al. 
Noroviruses Co-opt the Function of Host Proteins VAPA and VAPB for 
Replication via a Phenylalanine-Phenylalanine-Acidic-Tract-Motif Mimic 
in Nonstructural Viral Protein NS1/2. MBio. 2017;8(4). 
88. Nice TJ, Strong DW, McCune BT, Pohl CS, Virgin HW. A single-amino-acid 
change in murine norovirus NS1/2 is sufficient for colonic tropism and 
persistence. J Virol. 2013;87(1):327-34. 
 133 
89. Lee S, Liu H, Wilen CB, Sychev ZE, Desai C, Hykes BL Jr., et al. A Secreted 
Viral Nonstructural Protein Determines Intestinal Norovirus Pathogenesis. 
Cell Host Microbe. 2019;25(6):845-57 e5. 
90. Robinson BA, Van Winkle JA, McCune BT, Peters AM, Nice TJ. Caspase-
mediated cleavage of murine norovirus NS1/2 potentiates apoptosis and is 
required for persistent infection of intestinal epithelial cells. PLoS Pathog. 
2019;15(7):e1007940. 
91. Li TF, Hosmillo M, Schwanke H, Shu T, Wang Z, Yin L, et al. Human 
Norovirus NS3 Has RNA Helicase and Chaperoning Activities. J Virol. 
2018;92(5). 
92. Han KR, Lee JH, Kotiguda GG, Jung KH, Chung MS, Kang S, et al. 
Nucleotide triphosphatase and RNA chaperone activities of murine 
norovirus NS3. J Gen Virol. 2018;99(11):1482-93. 
93. Hyde JL, Sosnovtsev SV, Green KY, Wobus C, Virgin HW, Mackenzie JM. 
Mouse norovirus replication is associated with virus-induced vesicle 
clusters originating from membranes derived from the secretory pathway. 
J Virol. 2009;83(19):9709-19. 
94. Cotton BT, Hyde JL, Sarvestani ST, Sosnovtsev SV, Green KY, White PA, et 
al. The Norovirus NS3 Protein Is a Dynamic Lipid- and Microtubule-
Associated Protein Involved in Viral RNA Replication. J Virol. 2017;91(3). 
95. Fritzlar S, Aktepe TE, Chao YW, Kenney ND, McAllaster MR, Wilen CB, et 
al. Mouse Norovirus Infection Arrests Host Cell Translation Uncoupled 
from the Stress Granule-PKR-eIF2alpha Axis. MBio. 2019;10(3). 
96. Doerflinger SY, Cortese M, Romero-Brey I, Menne Z, Tubiana T, Schenk C, 
et al. Membrane alterations induced by nonstructural proteins of human 
norovirus. PLoS Pathog. 2017;13(10):e1006705. 
97. Sharp TM, Guix S, Katayama K, Crawford SE, Estes MK. Inhibition of 
cellular protein secretion by norwalk virus nonstructural protein p22 
requires a mimic of an endoplasmic reticulum export signal. PLoS One. 
2010;5(10):e13130. 
98. Leen EN, Sorgeloos F, Correia S, Chaudhry Y, Cannac F, Pastore C, et al. A 
Conserved Interaction between a C-Terminal Motif in Norovirus VPg and 
the HEAT-1 Domain of eIF4G Is Essential for Translation Initiation. PLoS 
Pathog. 2016;12(1):e1005379. 
 134 
99. Belliot G, Sosnovtsev SV, Chang KO, McPhie P, Green KY. 
Nucleotidylylation of the VPg protein of a human norovirus by its 
proteinase-polymerase precursor protein. Virology. 2008;374(1):33-49. 
100. May J, Korba B, Medvedev A, Viswanathan P. Enzyme kinetics of the 
human norovirus protease control virus polyprotein processing order. 
Virology. 2013;444(1-2):218-24. 
101. Nakamura K, Someya Y, Kumasaka T, Ueno G, Yamamoto M, Sato T, et al. 
A norovirus protease structure provides insights into active and substrate 
binding site integrity. J Virol. 2005;79(21):13685-93. 
102. Someya Y, Takeda N, Miyamura T. Identification of active-site amino acid 
residues in the Chiba virus 3C-like protease. J Virol. 2002;76(12):5949-58. 
103. Kuyumcu-Martinez M, Belliot G, Sosnovtsev SV, Chang KO, Green KY, 
Lloyd RE. Calicivirus 3C-like proteinase inhibits cellular translation by 
cleavage of poly(A)-binding protein. J Virol. 2004;78(15):8172-82. 
104. Fritzlar S, Aktepe TE, Chao YW, Kenney ND, McAllaster MR, Wilen CB, et 
al. Mouse Norovirus Infection Arrests Host Cell Translation Uncoupled 
from the Stress Granule-PKR-eIF2alpha Axis. MBio. 2019;10(3). 
105. Ng KK, Pendas-Franco N, Rojo J, Boga JA, Machin A, Alonso JM, et al. 
Crystal structure of norwalk virus polymerase reveals the carboxyl 
terminus in the active site cleft. J Biol Chem. 2004;279(16):16638-45. 
106. Lee JH, Alam I, Han KR, Cho S, Shin S, Kang S, et al. Crystal structures of 
murine norovirus-1 RNA-dependent RNA polymerase. J Gen Virol. 
2011;92(Pt 7):1607-16. 
107. Rohayem J, Robel I, Jager K, Scheffler U, Rudolph W. Protein-primed and 
de novo initiation of RNA synthesis by norovirus 3Dpol. J Virol. 
2006;80(14):7060-9. 
108. Lee JH, Park BS, Han KR, Biering SB, Kim SJ, Choi J, et al. Insight Into the 
Interaction Between RNA Polymerase and VPg for Murine Norovirus 
Replication. Front Microbiol. 2018;9:1466. 
109. Rohayem J, Jager K, Robel I, Scheffler U, Temme A, Rudolph W. 
Characterization of norovirus 3Dpol RNA-dependent RNA polymerase 
activity and initiation of RNA synthesis. J Gen Virol. 2006;87(Pt 9):2621-30. 
110. Bull RA, Eden JS, Rawlinson WD, White PA. Rapid evolution of pandemic 
noroviruses of the GII.4 lineage. PLoS Pathog. 2010;6(3):e1000831. 
 135 
111. Belliot G, Sosnovtsev SV, Mitra T, Hammer C, Garfield M, Green KY. In 
vitro proteolytic processing of the MD145 norovirus ORF1 nonstructural 
polyprotein yields stable precursors and products similar to those detected 
in calicivirus-infected cells. J Virol. 2003;77(20):10957-74. 
112. Emmott E, de Rougemont A, Hosmillo M, Lu J, Fitzmaurice T, Haas J, et al. 
Polyprotein processing and intermolecular interactions within the viral 
replication complex spatially and temporally control norovirus protease 
activity. J Biol Chem. 2019;294(11):4259-71. 
113. Medvedev A, Viswanathan P, May J, Korba B. Regulation of human 
norovirus VPg nucleotidylylation by ProPol and nucleoside triphosphate 
binding by its amino terminal sequence in vitro. Virology. 2017;503:37-45. 
114. Belliot G, Sosnovtsev SV, Chang KO, Babu V, Uche U, Arnold JJ, et al. 
Norovirus proteinase-polymerase and polymerase are both active forms of 
RNA-dependent RNA polymerase. J Virol. 2005;79(4):2393-403. 
115. Thackray LB, Wobus CE, Chachu KA, Liu B, Alegre ER, Henderson KS, et 
al. Murine noroviruses comprising a single genogroup exhibit biological 
diversity despite limited sequence divergence. J Virol. 2007;81(19):10460-73. 
116. Borg I, Jahun AS, Thorne L, Sorgeloos F, Bailey D, Goodfellow I. Murine 
norovirus virulence factor 1 (VF1) protein contributes to viral fitness 
during persistent infection. bioRxiv. 2019. 
117. Laurent S, Vautherot JF, Madelaine MF, Le Gall G, Rasschaert D. 
Recombinant rabbit hemorrhagic disease virus capsid protein expressed in 
baculovirus self-assembles into viruslike particles and induces protection. J 
Virol. 1994;68(10):6794-8. 
118. Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and 
antigenicity of the Norwalk virus capsid protein. J Virol. 1992;66(11):6527-
32. 
119. Venkataram Prasad BV, Hardy ME, Estes MK. Structural studies of 
recombinant Norwalk capsids. J Infect Dis. 2000;181 Suppl 2:S317-21. 
120. Leroux-Roels G, Cramer JP, Mendelman PM, Sherwood J, Clemens R, 
Aerssens A, et al. Safety and Immunogenicity of Different Formulations of 
Norovirus Vaccine Candidate in Healthy Adults: A Randomized, 
Controlled, Double-Blind Clinical Trial. J Infect Dis. 2018;217(4):597-607. 
 136 
121. Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, et al. Safety 
and immunogenicity of an oral tablet norovirus vaccine, a phase I 
randomized, placebo-controlled trial. JCI Insight. 2018;3(13). 
122. Treanor JJ, Atmar RL, Frey SE, Gormley R, Chen WH, Ferreira J, et al. A 
novel intramuscular bivalent norovirus virus-like particle vaccine 
candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in 
healthy adults. J Infect Dis. 2014;210(11):1763-71. 
123. Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray 
crystallographic structure of the Norwalk virus capsid. Science. 
1999;286(5438):287-90. 
124. Tan M, Huang P, Meller J, Zhong W, Farkas T, Jiang X. Mutations within 
the P2 domain of norovirus capsid affect binding to human histo-blood 
group antigens: evidence for a binding pocket. J Virol. 2003;77(23):12562-
71. 
125. Napthine S, Lever RA, Powell ML, Jackson RJ, Brown TD, Brierley I. 
Expression of the VP2 protein of murine norovirus by a translation 
termination-reinitiation strategy. PLoS One. 2009;4(12):e8390. 
126. Glass PJ, White LJ, Ball JM, Leparc-Goffart I, Hardy ME, Estes MK. 
Norwalk virus open reading frame 3 encodes a minor structural protein. J 
Virol. 2000;74(14):6581-91. 
127. Conley MJ, McElwee M, Azmi L, Gabrielsen M, Byron O, Goodfellow IG, et 
al. Calicivirus VP2 forms a portal-like assembly following receptor 
engagement. Nature. 2019;565(7739):377-81. 
128. Sosnovtsev SV, Belliot G, Chang KO, Onwudiwe O, Green KY. Feline 
calicivirus VP2 is essential for the production of infectious virions. J Virol. 
2005;79(7):4012-24. 
129. Vongpunsawad S, Venkataram Prasad BV, Estes MK. Norwalk Virus 
Minor Capsid Protein VP2 Associates within the VP1 Shell Domain. J Virol. 
2013;87(9):4818-25. 
130. Lin Y, Fengling L, Lianzhu W, Yuxiu Z, Yanhua J. Function of VP2 protein 
in the stability of the secondary structure of virus-like particles of 
genogroup II norovirus at different pH levels: function of VP2 protein in 
the stability of NoV VLPs. J Microbiol. 2014;52(11):970-5. 
 137 
131. Rockx BH, Vennema H, Hoebe CJ, Duizer E, Koopmans MP. Association of 
histo-blood group antigens and susceptibility to norovirus infections. J 
Infect Dis. 2005;191(5):749-54. 
132. de Graaf M, van Beek J, Koopmans MP. Human norovirus transmission 
and evolution in a changing world. Nat Rev Microbiol. 2016;14(7):421-33. 
133. Perry JW, Wobus CE. Endocytosis of murine norovirus 1 into murine 
macrophages is dependent on dynamin II and cholesterol. J Virol. 
2010;84(12):6163-76. 
134. Chung L, Bailey D, Leen EN, Emmott EP, Chaudhry Y, Roberts LO, et al. 
Norovirus translation requires an interaction between the C Terminus of 
the genome-linked viral protein VPg and eukaryotic translation initiation 
factor 4G. J Biol Chem. 2014;289(31):21738-50. 
135. Daughenbaugh KF, Wobus CE, Hardy ME. VPg of murine norovirus binds 
translation initiation factors in infected cells. Virol J. 2006;3:33. 
136. Hosmillo M, Chaudhry Y, Kim DS, Goodfellow I, Cho KO. Sapovirus 
translation requires an interaction between VPg and the cap binding 
protein eIF4E. J Virol. 2014;88(21):12213-21. 
137. Yunus MA, Lin X, Bailey D, Karakasiliotis I, Chaudhry Y, Vashist S, et al. 
The murine norovirus core subgenomic RNA promoter consists of a stable 
stem-loop that can direct accurate initiation of RNA synthesis. J Virol. 
2015;89(2):1218-29. 
138. Gutierrez-Escolano AL, Vazquez-Ochoa M, Escobar-Herrera J, Hernandez-
Acosta J. La, PTB, and PAB proteins bind to the 3(') untranslated region of 
Norwalk virus genomic RNA. Biochem Biophys Res Commun. 
2003;311(3):759-66. 
139. Hyde JL, Gillespie LK, Mackenzie JM. Mouse norovirus 1 utilizes the 
cytoskeleton network to establish localization of the replication complex 
proximal to the microtubule organizing center. J Virol. 2012;86(8):4110-22. 
140. Santiana M, Ghosh S, Ho BA, Rajasekaran V, Du WL, Mutsafi Y, et al. 
Vesicle-Cloaked Virus Clusters Are Optimal Units for Inter-organismal 
Viral Transmission. Cell Host Microbe. 2018;24(2):208-20 e8. 
141. Goodfellow I. The genome-linked protein VPg of vertebrate viruses - a 
multifaceted protein. Curr Opin Virol. 2011;1(5):355-62. 
 138 
142. Fuentes C, Bosch A, Pinto RM, Guix S. Identification of human astrovirus 
genome-linked protein (VPg) essential for virus infectivity. J Virol. 
2012;86(18):10070-8. 
143. Revill PA, Davidson AD, Wright PJ. Mushroom bacilliform virus RNA: the 
initiation of translation at the 5' end of the genome and identification of the 
VPg. Virology. 1998;249(2):231-7. 
144. Jiang J, Laliberte JF. The genome-linked protein VPg of plant viruses-a 
protein with many partners. Curr Opin Virol. 2011;1(5):347-54. 
145. Dunham DM, Jiang X, Berke T, Smith AW, Matson DO. Genomic mapping 
of a calicivirus VPg. Arch Virol. 1998;143(12):2421-30. 
146. Leen EN, Kwok KY, Birtley JR, Simpson PJ, Subba-Reddy CV, Chaudhry Y, 
et al. Structures of the compact helical core domains of feline calicivirus 
and murine norovirus VPg proteins. J Virol. 2013;87(10):5318-30. 
147. Hwang HJ, Min HJ, Yun H, Pelton JG, Wemmer DE, Cho KO, et al. 
Solution structure of the porcine sapovirus VPg core reveals a stable three-
helical bundle with a conserved surface patch. Biochem Biophys Res 
Commun. 2015;459(4):610-6. 
148. Muhaxhiri Z, Deng L, Shanker S, Sankaran B, Estes MK, Palzkill T, et al. 
Structural basis of substrate specificity and protease inhibition in Norwalk 
virus. J Virol. 2013;87(8):4281-92. 
149. Schein CH, Oezguen N, Volk DE, Garimella R, Paul A, Braun W. NMR 
structure of the viral peptide linked to the genome (VPg) of poliovirus. 
Peptides. 2006;27(7):1676-84. 
150. Rantalainen KI, Eskelin K, Tompa P, Makinen K. Structural flexibility 
allows the functional diversity of potyvirus genome-linked protein VPg. J 
Virol. 2011;85(5):2449-57. 
151. Rantalainen KI, Uversky VN, Permi P, Kalkkinen N, Dunker AK, Makinen 
K. Potato virus A genome-linked protein VPg is an intrinsically disordered 
molten globule-like protein with a hydrophobic core. Virology. 
2008;377(2):280-8. 
152. Hebrard E, Bessin Y, Michon T, Longhi S, Uversky VN, Delalande F, et al. 
Intrinsic disorder in Viral Proteins Genome-Linked: experimental and 
predictive analyses. Virol J. 2009;6:23. 
 139 
153. Hansen JC, Lu X, Ross ED, Woody RW. Intrinsic protein disorder, amino 
acid composition, and histone terminal domains. J Biol Chem. 
2006;281(4):1853-6. 
154. Darling AL, Uversky VN. Intrinsic Disorder and Posttranslational 
Modifications: The Darker Side of the Biological Dark Matter. Front Genet. 
2018;9:158. 
155. Atkinson SC, Audsley MD, Lieu KG, Marsh GA, Thomas DR, Heaton SM, 
et al. Recognition by host nuclear transport proteins drives disorder-to-
order transition in Hendra virus V. Sci Rep. 2018;8(1):358. 
156. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the 
protein structure-function paradigm. J Mol Biol. 1999;293(2):321-31. 
157. Olspert A, Hosmillo M, Chaudhry Y, Peil L, Truve E, Goodfellow I.  ... -RNA 
linkage and posttranslational modifications of feline calicivirus and murine 
norovirus VPg proteins. PeerJ. 2016;4:e2134. 
158. Hafren A, Makinen K. Purification of viral genome-linked protein VPg 
from potato virus A-infected plants reveals several post-translationally 
modified forms of the protein. J Gen Virol. 2008;89(Pt 6):1509-18. 
159. Olspert A, Peil L, Hebrard E, Fargette D, Truve E. Protein-RNA linkage 
and post-translational modifications of two sobemovirus VPgs. J Gen Virol. 
2011;92(Pt 2):445-52. 
160. Herod MR, Salim O, Skilton RJ, Prince CA, Ward VK, Lambden PR, et al. 
Expression of the murine norovirus (MNV) ORF1 polyprotein is sufficient 
to induce apoptosis in a virus-free cell model. PLoS One. 2014;9(3):e90679. 
161. Yen JB, Wei LH, Chen LW, Chen LY, Hung CH, Wang SS, et al. Subcellular 
Localization and Functional Characterization of GII.4 Norovirus-Encoded 
NTPase. J Virol. 2018;92(5). 
162. Urakova N, Frese M, Hall RN, Liu J, Matthaei M, Strive T. Expression and 
partial characterisation of rabbit haemorrhagic disease virus non-structural 
proteins. Virology. 2015;484:69-79. 
163. Beauchemin C, Boutet N, Laliberte JF. Visualization of the interaction 
between the precursors of VPg, the viral protein linked to the genome of 
turnip mosaic virus, and the translation eukaryotic initiation factor iso 4E 
in Planta. J Virol. 2007;81(2):775-82. 
 140 
164. Sun L, Jing B, Andika IB, Hu Y, Sun B, Xiang R, et al. Nucleo-cytoplasmic 
shuttling of VPg encoded by Wheat yellow mosaic virus requires 
association with the coat protein. J Gen Virol. 2013;94(Pt 12):2790-802. 
165. Puustinen P, Makinen K. Uridylylation of the potyvirus VPg by viral 
replicase NIb correlates with the nucleotide binding capacity of VPg. J Biol 
Chem. 2004;279(37):38103-10. 
166. Mitra T, Sosnovtsev SV, Green KY. Mutagenesis of tyrosine 24 in the VPg 
protein is lethal for feline calicivirus. J Virol. 2004;78(9):4931-5. 
167. Machin A, Martin Alonso JM, Parra F. Identification of the amino acid 
residue involved in rabbit hemorrhagic disease virus VPg uridylylation. J 
Biol Chem. 2001;276(30):27787-92. 
168. McKnight KL, Lemon SM. The rhinovirus type 14 genome contains an 
internally located RNA structure that is required for viral replication. RNA. 
1998;4(12):1569-84. 
169. Paul AV, Rieder E, Kim DW, van Boom JH, Wimmer E. Identification of an 
RNA hairpin in poliovirus RNA that serves as the primary template in the 
in vitro uridylylation of VPg. J Virol. 2000;74(22):10359-70. 
170. Paul AV, Peters J, Mugavero J, Yin J, van Boom JH, Wimmer E. 
Biochemical and genetic studies of the VPg uridylylation reaction catalyzed 
by the RNA polymerase of poliovirus. J Virol. 2003;77(2):891-904. 
171. Paul AV, Yin J, Mugavero J, Rieder E, Liu Y, Wimmer E. A "slide-back" 
mechanism for the initiation of protein-primed RNA synthesis by the RNA 
polymerase of poliovirus. J Biol Chem. 2003;278(45):43951-60. 
172. Bailey D, Karakasiliotis I, Vashist S, Chung LM, Rees J, McFadden N, et al. 
Functional analysis of RNA structures present at the 3' extremity of the 
murine norovirus genome: the variable polypyrimidine tract plays a role in 
viral virulence. J Virol. 2010;84(6):2859-70. 
173. Pettersson RF, Ambros V, Baltimore D. Identification of a protein linked to 
nascent poliovirus RNA and to the polyuridylic acid of negative-strand 
RNA. J Virol. 1978;27(2):357-65. 
174. Fukushi S, Kojima S, Takai R, Hoshino FB, Oka T, Takeda N, et al. Poly(A)- 
and primer-independent RNA polymerase of Norovirus. J Virol. 
2004;78(8):3889-96. 
 141 
175. Herbert TP, Brierley I, Brown TD. Identification of a protein linked to the 
genomic and subgenomic mRNAs of feline calicivirus and its role in 
translation. J Gen Virol. 1997;78 ( Pt 5):1033-40. 
176. Burroughs JN, Brown F. Presence of a covalently linked protein on 
calicivirus RNA. J Gen Virol. 1978;41(2):443-6. 
177. Hinnebusch AG, Lorsch JR. The mechanism of eukaryotic translation 
initiation: new insights and challenges. Cold Spring Harb Perspect Biol. 
2012;4(10). 
178. Zhu J, Wang B, Miao Q, Tan Y, Li C, Chen Z, et al. Viral Genome-Linked 
Protein (VPg) Is Essential for Translation Initiation of Rabbit Hemorrhagic 
Disease Virus (RHDV). PLoS One. 2015;10(11):e0143467. 
179. Nomoto A, Kitamura N, Golini F, Wimmer E. The 5'-terminal structures of 
poliovirion RNA and poliovirus mRNA differ only in the genome-linked 
protein VPg. Proc Natl Acad Sci U S A. 1977;74(12):5345-9. 
180. Eskelin K, Hafren A, Rantalainen KI, Makinen K. Potyviral VPg enhances 
viral RNA Translation and inhibits reporter mRNA translation in planta. J 
Virol. 2011;85(17):9210-21. 
181. Royall E, Doyle N, Abdul-Wahab A, Emmott E, Morley SJ, Goodfellow I, et 
al. Murine norovirus 1 (MNV1) replication induces translational control of 
the host by regulating eIF4E activity during infection. J Biol Chem. 
2015;290(8):4748-58. 
182. Chaudhry Y, Skinner MA, Goodfellow IG. Recovery of genetically defined 
murine norovirus in tissue culture by using a fowlpox virus expressing T7 
RNA polymerase. J Gen Virol. 2007;88(Pt 8):2091-100. 
183. Kaiser WJ, Chaudhry Y, Sosnovtsev SV, Goodfellow IG. Analysis of 
protein-protein interactions in the feline calicivirus replication complex. J 
Gen Virol. 2006;87(Pt 2):363-8. 
184. Subba-Reddy CV, Yunus MA, Goodfellow IG, Kao CC. Norovirus RNA 
synthesis is modulated by an interaction between the viral RNA-dependent 
RNA polymerase and the major capsid protein, VP1. J Virol. 
2012;86(18):10138-49. 
185. Davies C, Brown CM, Westphal D, Ward JM, Ward VK. Murine norovirus 
replication induces G0/G1 cell cycle arrest in asynchronously growing 
cells. J Virol. 2015;89(11):6057-66. 
 142 
186. Davies C, Ward VK. Expression of the NS5 (VPg) Protein of Murine 
Norovirus Induces a G1/S Phase Arrest. PLoS One. 2016;11(8):e0161582. 
187. Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription 
during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14(8):518-28. 
188. Bloom J, Cross FR. Multiple levels of cyclin specificity in cell-cycle control. 
Nat Rev Mol Cell Biol. 2007;8(2):149-60. 
189. Henley SA, Dick FA. The retinoblastoma family of proteins and their  
 regulatory functions in the mammalian cell division cycle. Cell Div.  
 2012;7(1):10. 
190. Morgan DO. Principles of CDK regulation. Nature. 1995;374(6518):131-4. 
191.  Pardee AB. A restriction point for control of normal animal cell 
proliferation. Proc Natl Acad Sci U S A. 1974;71(4):1286-90. 
192. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by  
 transcription factor E2F1. Proc Natl Acad Sci U S A. 1995;92(26):12146-50. 
193.  Schulze A, Zerfass K, Spitkovsky D, Middendorp S, Berges J, Helin K, et 
al. Cell cycle regulation of the cyclin A gene promoter is mediated by a 
variant E2F site. Proc Natl Acad Sci U S A. 1995;92(24):11264-8. 
194.  Lundberg AS, Weinberg RA. Functional inactivation of the retinoblastoma 
protein requires sequential modification by at least two distinct cyclin-cdk 
complexes. Mol Cell Biol. 1998;18(2):753-61. 
195.  Morris L, Allen KE, La Thangue NB. Regulation of E2F transcription by 
cyclin E-Cdk2 kinase mediated through p300/CBP co-activators. Nat Cell 
Biol. 2000;2(4):232-9. 
196.  Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-
CDK2 is a regulator of p27Kip1. Genes Dev. 1997;11(11):1464-78. 
197.  Coverley D, Laman H, Laskey RA. Distinct roles for cyclins E and A 
during DNA replication complex assembly and activation. Nat Cell Biol. 
2002;4(7):523-8. 
198. Ekholm-Reed S, Mendez J, Tedesco D, Zetterberg A, Stillman B, Reed SI.  
 Deregulation of cyclin E in human cells interferes with prereplication  
 complex assembly. J Cell Biol. 2004;165(6):789-800. 
199.  Hara E, Hall M, Peters G. Cdk2-dependent phosphorylation of Id2 
modulates activity of E2A-related transcription factors. EMBO J. 
1997;16(2):332-42. 
 143 
200.  Deed RW, Hara E, Atherton GT, Peters G, Norton JD. Regulation of Id3 
cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell Biol. 
1997;17(12):6815-21. 
201. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA  
 binding function underlies suppression of an S phase checkpoint. Cell.  
 1995;83(7):1149-58. 
202.  Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H. Cyclin 
A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of 
E2F-1/DP-1 by phosphorylation. Mol Cell Biol. 1994;14(12):8420-31. 
203.  Fung TK, Poon RY. A roller coaster ride with the mitotic cyclins. Semin 
Cell Dev Biol. 2005;16(3):335-42. 
204.  Fung TK, Ma HT, Poon RY. Specialized roles of the two mitotic cyclins in 
somatic cells: cyclin A as an activator of M phase-promoting factor. Mol 
Biol Cell. 2007;18(5):1861-73. 
205.  Chae HD, Yun J, Bang YJ, Shin DY. Cdk2-dependent phosphorylation of 
the NF-Y transcription factor is essential for the expression of the cell 
cycle-regulatory genes and cell cycle G1/S and G2/M transitions. 
Oncogene. 2004;23(23):4084-8. 
206.  Laoukili J, Alvarez M, Meijer LA, Stahl M, Mohammed S, Kleij L, et al. 
Activation of FoxM1 during G2 requires cyclin A/Cdk-dependent relief of 
autorepression by the FoxM1 N-terminal domain. Mol Cell Biol. 
2008;28(9):3076-87. 
207.  Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, et al. Chk1 is 
an essential kinase that is regulated by Atr and required for the G(2)/M 
DNA damage checkpoint. Genes Dev. 2000;14(12):1448-59. 
208.  Matsuoka S, Huang M, Elledge SJ. Linkage of ATM to cell cycle regulation 
by the Chk2 protein kinase. Science. 1998;282(5395):1893-7. 
209.  Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, 
Luo J, et al. ATM and ATR substrate analysis reveals extensive protein 
networks responsive to DNA damage. Science. 2007;316(5828):1160-6. 
210.  Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et 
al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of 
DNA damage to Cdk regulation through Cdc25. Science. 
1997;277(5331):1497-501. 
 144 
211.  O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in 
the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. 
EMBO J. 1997;16(3):545-54. 
212.  Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, et 
al. 14-3-3sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 
1997;1(1):3-11. 
213.  Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, et al. GADD45-induced 
cell cycle G2-M arrest associates with altered subcellular distribution of 
cyclin B1 and is independent of p38 kinase activity. Oncogene. 
2002;21(57):8696-704. 
214.  el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et 
al. WAF1, a potential mediator of p53 tumor suppression. Cell. 
1993;75(4):817-25. 
215.  Li J, Meyer AN, Donoghue DJ. Nuclear localization of cyclin B1 mediates 
its biological activity and is regulated by phosphorylation. Proc Natl Acad 
Sci U S A. 1997;94(2):502-7. 
216.  . Guo L, Mohd KS, Ren H, Xin G, Jiang Q, Clarke PR, et al. Phosphorylation 
of importin-alpha1 by CDK1-cyclin B1 controls mitotic spindle assembly. J 
Cell Sci. 2019;132(18). 
217.  Draviam VM, Orrechia S, Lowe M, Pardi R, Pines J. The localization of 
human cyclins B1 and B2 determines CDK1 substrate specificity and 
neither enzyme requires MEK to disassemble the Golgi apparatus. J Cell 
Biol. 2001;152(5):945-58. 
218.  Peter M, Nakagawa J, Doree M, Labbe JC, Nigg EA. In vitro disassembly 
of the nuclear lamina and M phase-specific phosphorylation of lamins by 
cdc2 kinase. Cell. 1990;61(4):591-602. 
219.  Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity 
of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the 
G1/S transition. EMBO J. 1994;13(18):4302-10. 
220.  Perdiguero E, Nebreda AR. Regulation of Cdc25C activity during the 
meiotic G2/M transition. Cell Cycle. 2004;3(6):733-7. 
221.  Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear 
translocation of human Cdc25C during prophase. EMBO Rep. 
2002;3(4):341-8. 
 145 
222.  Li Z, Liu J, Li J, Kong Y, Sandusky G, Rao X, et al. Polo-like kinase 1 (Plk1) 
overexpression enhances ionizing radiation-induced cancer formation in 
mice. J Biol Chem. 2017;292(42):17461-72. 
223.  Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-
16 E7 oncoprotein is able to bind to the retinoblastoma gene product. 
Science. 1989;243(4893):934-7. 
224.  Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates 
association of p53 with the E6 oncoprotein of human papillomavirus types 
16 or 18. EMBO J. 1991;10(13):4129-35. 
225.  Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 
oncoprotein encoded by human papillomavirus types 16 and 18 promotes 
the degradation of p53. Cell. 1990;63(6):1129-36. 
226.  Davy CE, Jackson DJ, Raj K, Peh WL, Southern SA, Das P, et al. Human 
papillomavirus type 16 E1 E4-induced G2 arrest is associated with 
cytoplasmic retention of active Cdk1/cyclin B1 complexes. J Virol. 
2005;79(7):3998-4011. 
227.  Song B, Yeh KC, Liu J, Knipe DM. Herpes simplex virus gene products 
required for viral inhibition of expression of G1-phase functions. Virology. 
2001;290(2):320-8. 
228.  Paladino P, Marcon E, Greenblatt J, Frappier L. Identification of 
herpesvirus proteins that contribute to G1/S arrest. J Virol. 
2014;88(8):4480-92. 
229.  Hobbs WE, 2nd, DeLuca NA. Perturbation of cell cycle progression and 
cellular gene expression as a function of herpes simplex virus ICP0. J Virol. 
1999;73(10):8245-55. 
230.  .. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt 
P, et al. Human immunodeficiency virus type 1 Vpr induces DNA 
replication stress in vitro and in vivo. J Virol. 2006;80(21):10407-18. 
231.  Lewis PF, Emerman M. Passage through mitosis is required for 
oncoretroviruses but not for the human immunodeficiency virus. J Virol. 
1994;68(1):510-6. 
232.  Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia 
virus DNA depends on mitosis. EMBO J. 1993;12(5):2099-108. 
 146 
233.  Yuan X, Yao Z, Wu J, Zhou Y, Shan Y, Dong B, et al. G1 phase cell cycle 
arrest induced by SARS-CoV 3a protein via the cyclin D3/pRb pathway. 
Am J Respir Cell Mol Biol. 2007;37(1):9-19. 
234. Jiang W, Wang Q, Chen S, Gao S, Song L, Liu P, et al. Influenza A Virus  
 NS1 Induces G0/G1 Cell Cycle Arrest by Inhibiting the Expression and  
 Activity of RhoA Protein. Journal of Virology. 2013;87(6):3039-52. 
235.  Turpin E, Luke K, Jones J, Tumpey T, Konan K, Schultz-Cherry S. 
Influenza virus infection increases p53 activity: role of p53 in cell death 
and viral replication. J Virol. 2005;79(14):8802-11. 
236.  Wang X, Deng X, Yan W, Zhu Z, Shen Y, Qiu Y, et al. Stabilization of p53 
in influenza A virus-infected cells is associated with compromised MDM2-
mediated ubiquitination of p53. J Biol Chem. 2012;287(22):18366-75. 
237.  Zhirnov OP, Klenk HD. Control of apoptosis in influenza virus-infected 
cells by up-regulation of Akt and p53 signaling. Apoptosis. 
2007;12(8):1419-32. 
238.  Nailwal H, Sharma S, Mayank AK, Lal SK. The nucleoprotein of influenza 
A virus induces p53 signaling and apoptosis via attenuation of host 
ubiquitin ligase RNF43. Cell Death Dis. 2015;6:e1768. 
239.  Zhu L, Zhao W, Lu J, Li S, Zhou K, Jiang W, et al. Influenza virus matrix 
protein M1 interacts with SLD5 to block host cell cycle. Cell Microbiol. 
2019;21(8):e13038. 
240.  Wang Y, Wang R, Li Y, Sun Y, Song C, Zhan Y, et al. Newcastle disease 
virus induces G0/G1 cell cycle arrest in asynchronously growing cells. 
Virology. 2018;520:67-74. 
241.  Liao Y, Gu F, Mao X, Niu Q, Wang H, Sun Y, et al. Regulation of de novo 
translation of host cells by manipulation of PERK/PKR and GADD34-PP1 
activity during Newcastle disease virus infection. J Gen Virol. 
2016;97(4):867-79. 
242.  Wurm T, Chen H, Hodgson T, Britton P, Brooks G, Hiscox JA. 
Localization to the nucleolus is a common feature of coronavirus 
nucleoproteins, and the protein may disrupt host cell division. J Virol. 
2001;75(19):9345-56. 
243.  Dove B, Brooks G, Bicknell K, Wurm T, Hiscox JA. Cell cycle 
perturbations induced by infection with the coronavirus infectious 
 147 
bronchitis virus and their effect on virus replication. J Virol. 
2006;80(8):4147-56. 
244.  Li FQ, Xiao H, Tam JP, Liu DX. Sumoylation of the nucleocapsid protein 
of severe acute respiratory syndrome coronavirus. FEBS Lett. 
2005;579(11):2387-96. 
245. Chau TN, Lee KC, Yao H, Tsang TY, Chow TC, Yeung YC, et al. SARS- 
 associated viral hepatitis caused by a novel coronavirus: report of three  
 cases. Hepatology. 2004;39(2):302-10. 
246.  Ding L, Huang Y, Dai M, Zhao X, Du Q, Dong F, et al. Transmissible 
gastroenteritis virus infection induces cell cycle arrest at S and G2/M 
phases via p53-dependent pathway. Virus Res. 2013;178(2):241-51. 
247.  Ding L, Huang Y, Du Q, Dong F, Zhao X, Zhang W, et al. TGEV 
nucleocapsid protein induces cell cycle arrest and apoptosis through 
activation of p53 signaling. Biochem Biophys Res Commun. 
2014;445(2):497-503. 
248.  Chen CJ, Sugiyama K, Kubo H, Huang C, Makino S. Murine coronavirus 
nonstructural protein p28 arrests cell cycle in G0/G1 phase. J Virol. 
2004;78(19):10410-9. 
249.  Chen CJ, Makino S. Murine coronavirus replication induces cell cycle 
arrest in G0/G1 phase. J Virol. 2004;78(11):5658-69. 
250.  Sun P, Wu H, Huang J, Xu Y, Yang F, Zhang Q, et al. Porcine epidemic 
diarrhea virus through p53-dependent pathway causes cell cycle arrest in 
the G0/G1 phase. Virus Res. 2018;253:1-11. 
251.  Su YC, Reshi L, Chen LJ, Li WH, Chiu HW, Hong JR. Nuclear targeting of 
the betanodavirus B1 protein via two arginine-rich domains induces G1/S 
cell cycle arrest mediated by upregulation of p53/p21. Sci Rep. 
2018;8(1):3079. 
252.  Mai W, Liu H, Chen H, Zhou Y, Chen Y. RGNNV-induced cell cycle arrest 
at G1/S phase enhanced viral replication via p53-dependent pathway in 
GS cells. Virus Research. 2018;256:142-52. 
253.  Chen LJ, Su YC, Hong JR. Betanodavirus non-structural protein B1: A 
novel anti-necrotic death factor that modulates cell death in early 
replication cycle in fish cells. Virology. 2009;385(2):444-54. 
254. Souza BS, Sampaio GL, Pereira CS, Campos GS, Sardi SI, Freitas LA, et al.  
 Zika virus infection induces mitosis abnormalities and apoptotic cell death  
 148 
 of human neural progenitor cells. Sci Rep. 2016;6:39775. 
255. Das S, Basu A. Japanese encephalitis virus infects neural progenitor cells  
 and decreases their proliferation. J Neurochem. 2008;106(4):1624-36. 
256.  Chiu HC, Huang WR, Liao TL, Chi PI, Nielsen BL, Liu JH, et al. 
Mechanistic insights into avian reovirus p17-modulated suppression of 
cell cycle CDK-cyclin complexes and enhancement of p53 and cyclin H 
interaction. J Biol Chem. 2018;293(32):12542-62. 
257.  Yu J, Zhang L, Ren P, Zhong T, Li Z, Wang Z, et al. Enterovirus 71 
mediates cell cycle arrest in S phase through non-structural protein 3D. 
Cell Cycle. 2015;14(3):425-36. 
258.  Li S, Lu LF, Liu SB, Zhang C, Li ZC, Zhou XY, et al. Spring viraemia of 
carp virus modulates p53 expression using two distinct mechanisms. PLoS 
Pathog. 2019;15(3):e1007695. 
259.  Quan R, Wei L, Zhu S, Wang J, Cao Y, Xue C, et al. Involvement of miR-
15a in G0/G1 Phase Cell Cycle Arrest Induced by Porcine Circovirus Type 
2 Replication. Sci Rep. 2016;6:27917. 
260.  Davies C. Murine Norovirus Manipulation of the Cell Cycle. Dunedin, 
New Zealand: University of Otago; 2015. 
261.  Baker E. Characterisation of the NS1-2 and NS4 proteins of murine 
norovirus. Dunedin, New Zealand: University of Otago; 2012. 
262.  Waugh E. Murine Norovirus Manipulation of the Immune Response. 
Dunedin, New Zealand: University of Otago; 2014. 
263.  Kronqvist N, Sarr M, Lindqvist A, Nordling K, Otikovs M, Venturi L, et al. 
Efficient protein production inspired by how spiders make silk. Nat 
Commun. 2017;8:15504. 
264.  Bendak K, Loughlin FE, Cheung V, O'Connell MR, Crossley M, Mackay JP. 
A rapid method for assessing the RNA-binding potential of a protein. 
Nucleic Acids Res. 2012;40(14):e105. 
265.  Ward VK, McCormick CJ, Clarke IN, Salim O, Wobus CE, Thackray LB, et 
al. Recovery of infectious murine norovirus using pol II-driven expression 
of full-length cDNA. Proc Natl Acad Sci U S A. 2007;104(26):11050-5. 
266.  Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch 
T, et al. Fiji: an open-source platform for biological-image analysis. Nat 
Methods. 2012;9(7):676-82. 
 149 
267.  Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, 
scalable generation of high-quality protein multiple sequence alignments 
using Clustal Omega. Mol Syst Biol. 2011;7:539. 
268.  Yan J, Kurgan L. DRNApred, fast sequence-based method that accurately 
predicts and discriminates DNA- and RNA-binding residues. Nucleic 
Acids Res. 2017;45(10):e84. 
269.  Arpino JA, Rizkallah PJ, Jones DD. Crystal structure of enhanced green 
fluorescent protein to 1.35 A resolution reveals alternative conformations 
for Glu222. PLoS One. 2012;7(10):e47132. 
270.  Wei X, Henke VG, Strubing C, Brown EB, Clapham DE. Real-time 
imaging of nuclear permeation by EGFP in single intact cells. Biophys J. 
2003;84(2 Pt1):1317-27. 
271.  Rajamaki ML, Valkonen JP. Control of nuclear and nucleolar localization 
of nuclear inclusion protein a of picorna-like Potato virus A in Nicotiana 
species. Plant Cell. 2009;21(8):2485-502. 
272.  Wojtal I, Podsiadla-Bialoskorska M, Grzela R, Bujak M, Szolajska E, 
Chroboczek J. Peptides derived from plant virus VPg protein inhibit eIF4E 
oncogene. bioRxiv. 2018. Available from: https://doi.org/10.1101/298455. 
273.  Kohn M, Lederer M, Wachter K, Huttelmaier S. Near-infrared (NIR) dye-
labeled RNAs identify binding of ZBP1 to the noncoding Y3-RNA. RNA. 
2010;16(7):1420-8. 
274. Auweter SD, Fasan R, Reymond L, Underwood JG, Black DL, Pitsch S, et  
 al. Molecular basis of RNA recognition by the human alternative splicing  
 factor Fox-1. EMBO J. 2006;25(1):163-73. 
275.  Kuroyanagi H. Fox-1 family of RNA-binding proteins. Cell Mol Life Sci. 
2009;66(24):3895-907. 
276.  Cooper K. Rb, whi it's not just for metazoans anymore. Oncogene. 
2006;25(38):5228-32. 
277.  Cross FR, Buchler NE, Skotheim JM. Evolution of networks and sequences 
in eukaryotic cell cycle control. Philos Trans R Soc Lond B Biol Sci. 
2011;366(1584):3532-44. 
278.  Giotti B, Joshi A, Freeman TC. Meta-analysis reveals conserved cell cycle 
transcriptional network across multiple human cell types. BMC Genomics. 
2017;18(1):30. 
 150 
279.  Hakansson P, Hofer A, Thelander L. Regulation of mammalian 
ribonucleotide reduction and dNTP pools after DNA damage and in 
resting cells. J Biol Chem. 2006;281(12):7834-41. 
280.  Koc A, Wheeler LJ, Mathews CK, Merrill GF. Replication-independent 
MCB gene induction and deoxyribonucleotide accumulation at G1/S in 
Saccharomyces cerevisiae. J Biol Chem. 2003;278(11):9345-52. 
281.  Pyronnet S, Dostie J, Sonenberg N. Suppression of cap-dependent 
translation in mitosis. Genes Dev. 2001;15(16):2083-93. 
282. Oliver SL, Asobayire E, Dastjerdi AM, Bridger JC. Genomic 
characterization of the unclassified bovine enteric virus Newbury agent-1 
(Newbury1) endorses a new genus in the family Caliciviridae. Virology. 
2006;350(1):240-50. 
283.  Sosnovtsev SV, Green KY. Identification and genomic mapping of the 
ORF3 and VPg proteins in feline calicivirus virions. Virology. 
2000;277(1):193-203. 
284. Messina E, Gazzaniga P, Micheli V, Guaglianone MR, Barbato S, Morrone 
S, et al. Guanine nucleotide depletion triggers cell cycle arrest and 
apoptosis in human neuroblastoma cell lines. Int J Cancer. 2004;108(6):812-
7. 
285.  Hentze MW, Castello A, Schwarzl T, Preiss T. A brave new world of 
RNA-binding proteins. Nat Rev Mol Cell Biol. 2018;19(5):327-41. 
286. Jarvelin AI, Noerenberg M, Davis I, Castello A. The new (dis)order in RNA 
regulation. Cell Commun Signal. 2016;14:9. 
287.  Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, et 
al. Insights into RNA biology from an atlas of mammalian mRNA-binding 
proteins. Cell. 2012;149(6):1393-406. 
288.  Smith CA, Calabro V, Frankel AD. An RNA-binding chameleon. Mol Cell. 
2000;6(5):1067-76. 
289.  Bayer TS, Booth LN, Knudsen SM, Ellington AD. Arginine-rich motifs  
present multiple interfaces for specific binding by RNA. RNA. 
2005;11(12):1848-57. 
290.  Blackinton JG, Keene JD. Post-transcriptional RNA regulons affecting cell 
cycle and proliferation. Semin Cell Dev Biol. 2014;34:44-54. 
291.  Lafarga V, Cuadrado A, Lopez de Silanes I, Bengoechea R, Fernandez-
Capetillo O, Nebreda AR. p38 Mitogen-activated protein kinase- and HuR-
 151 
dependent stabilization of p21(Cip1) mRNA mediates the G(1)/S 
checkpoint. Mol Cell Biol. 2009;29(16):4341-51. 
292.  Kanakkanthara A, Jeganathan KB, Limzerwala JF, Baker DJ, Hamada M, 
Nam HJ, et al. Cyclin A2 is an RNA binding protein that controls Mre11 
mRNA translation. Science. 2016;353(6307):1549-52. 
293.  Lama J, Sanz MA, Rodriguez PL. A role for 3AB protein in poliovirus 
genome replication. J Biol Chem. 1995;270(24):14430-8. 
294.  Xiang W, Harris KS, Alexander L, Wimmer E. Interaction between the 5'-
terminal cloverleaf and 3AB/3CDpro of poliovirus is essential for RNA 
replication. J Virol. 1995;69(6):3658-67. 
295.  Harris KS, Xiang W, Alexander L, Lane WS, Paul AV, Wimmer E. 
Interaction of poliovirus polypeptide 3CDpro with the 5' and 3' termini of 
the poliovirus genome. Identification of viral and cellular cofactors needed 
for efficient binding. J Biol Chem. 1994;269(43):27004-14. 
296.  Xiang W, Cuconati A, Paul AV, Cao X, Wimmer E. Molecular dissection of 
the multifunctional poliovirus RNA-binding protein 3AB. RNA. 
1995;1(9):892-904. 
297.  Barton DJ, O'Donnell BJ, Flanegan JB. 5' cloverleaf in poliovirus RNA is a 
cis-acting replication element required for negative-strand synthesis. 
EMBO J. 2001;20(6):1439-48. 
298. Lyons T, Murray KE, Roberts AW, Barton DJ. Poliovirus 5'-terminal  
 cloverleaf RNA is required in cis for VPg uridylylation and the initiation of  
 negative-strand RNA synthesis. J Virol. 2001;75(22):10696-708. 
299.  Montero H, Garcia-Roman R, Mora SI. eIF4E as a control target for 
viruses. Viruses. 2015;7(2):739-50. 
300.  Lynch M, Fitzgerald C, Johnston KA, Wang S, Schmidt EV. Activated 
eIF4E-binding protein slows G1 progression and blocks transformation by 
c-myc without inhibiting cell growth. J Biol Chem. 2004;279(5):3327-39. 
301.  Chen B, Zhang B, Xia L, Zhang J, Chen Y, Hu Q, et al. Knockdown of 
eukaryotic translation initiation factor 4E suppresses cell growth and 
invasion, and induces apoptosis and cell cycle arrest in a human lung 
adenocarcinoma cell line. Mol Med Rep. 2016;13(4):3384. 
302.  Brenner C, Nakayama N, Goebl M, Tanaka K, Toh-e A, Matsumoto K. 
CDC33 encodes mRNA cap-binding protein eIF-4E of Saccharomyces 
cerevisiae. Mol Cell Biol. 1988;8(8):3556-9. 
 152 
303.  Altmann M, Trachsel H. Altered mRNA cap recognition activity of 
initiation factor 4E in the yeast cell cycle division mutant cdc33. Nucleic 
Acids Res. 1989;17(15):5923-31. 
304.  Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. 
eIF4E is a central node of an RNA regulon that governs cellular 
proliferation. J Cell Biol. 2006;175(3):415-26. 
305.  Sukarieh R, Sonenberg N, Pelletier J. Nuclear assortment of eIF4E 
coincides with shut-off of host protein synthesis upon poliovirus infection. 
J Gen Virol. 2010;91(Pt 5):1224-8. 
306. Jiang H, Coleman J, Miskimins R, Miskimins WK. Expression of 
constitutively active 4EBP-1 enhances p27Kip1 expression and inhibits 
proliferation of MCF7 breast cancer cells. Cancer Cell Int. 2003;3(1):2. 
307.  Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin D1 and c-myc 
internal ribosome entry site (IRES)-dependent translation is regulated by 
AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-
dependent pathway. J Biol Chem. 2005;280(12):10964-73. 
308.  Martinez A, Sese M, Losa JH, Robichaud N, Sonenberg N, Aasen T, et al. 
Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-
Damaging Agents through an Interaction with 4E-T: A Rationale for Novel 
Therapeutic Approaches. PLoS One. 2015;10(4):e0123352. 
309.  Grzela R, Strokovska L, Andrieu JP, Dublet B, Zagorski W, Chroboczek J. 
Potyvirus terminal protein VPg, effector of host eukaryotic initiation factor 
eIF4E. Biochimie. 2006;88(7):887-96. 
310.  Hosmillo M, Lu J, McAllaster MR, Eaglesham JB, Wang X, Emmott E, et 
al. Noroviruses subvert the core stress granule component G3BP1 to 
promote viral VPg-dependent translation. Elife. 2019;8. 
311.  Sheth U, Parker R. Decapping and decay of messenger RNA occur in 
cytoplasmic processing bodies. Science. 2003;300(5620):805-8. 
312.  Levenson EA, Martens C, Kanakabandi K, Turner CV, Virtaneva K, 
Paneru M, et al. Comparative Transcriptomic Response of Primary and 
Immortalized Macrophages to Murine Norovirus Infection. J Immunol. 
2018;200(12):4157-69. 
313.  Ozdilek BA, Thompson VF, Ahmed NS, White CI, Batey RT, Schwartz JC. 
Intrinsically disordered RGG/RG domains mediate degenerate specificity 
in RNA binding. Nucleic Acids Res. 2017;45(13):7984-96. 
 153 
314. Deisenroth C, Zhang Y. Ribosome biogenesis surveillance: probing the  
 ribosomal protein-Mdm2-p53 pathway. Oncogene. 2010;29(30):4253-60. 
315. Bok K, Prikhodko VG, Green KY, Sosnovtsev SV. Apoptosis in murine 
norovirus-infected RAW264.7 cells is associated with downregulation of 




7 Appendix I: Recipes
All buffers were stored at room temperature unless otherwise stated
Competent cell preparation 
LB broth 
10 g/l bacto Tryptone 
5 g/l bacto Yeast Extract 
5 g/l sodium chloride 
15 g/l bacteriological Agar 
Autoclave, cool to 50 °C, add 
required antibiotics, pour plates 
and once set store at 4 °C 
For making LB broth omit the agar 
 
Transformation buffer I 
30 mM potassium acetate 
10 mM calcium chloride  
50 mM manganese chloride 
100 mM rubidium chloride 
15% glycerol 
Adjust to pH 5.6 with acetic acid 
and filter sterilise 
 
Transformation buffer II 
10 mM MOPS 
75 mM calcium chloride 
5% glycerol 
Adjust to pH 6.5 with potassium 




DNA agarose gel electrophoresis 
50 x TAE buffer 
242 g Tris 
57 ml acetic acid 
100 ml 0.5 M EDTA, pH 8 
Make up to 1000 ml with dH2O 
 
1% Agarose gel 
800 "l 50 x TAE buffer 
40 ml dH2O 
0.4 g DNA grade agarose 
Heat until dissolved 




1 x dPBS 
250 mM sucrose 
1 mM magnesium chloride 
 
Flow cytometry 
RNase A stock 
10 mg/ml RNaseA 
10 mM sodium acetate 
Boil for 15 minutes and pH to 7.4 







25 mM Tris pH 7.6 
150 mM sodium chloride 
1% NP-40 
1 % sodium deoxycholate 
0.1% SDS 
Store at 4 °C 
 
2 x SDS-PAGE sample buffer 
5 ml 10% SDS 
2 ml glycerol 
1.2 ml 1M Tris-HCl pH 6.8 
100 "l 1% Bromophenol Blue 
Make up to 9 ml with MilliQ water 
Before use, add 10% b-
mercaptoethanol 
 
6 x SDS-PAGE sample buffer 
4.2 ml 1M Tris pH 6.8 
3 ml glycerol 
1 g SDS 
0.93 g DTT 
100 "l 1% Bromophenol Blue 
Made up to 10 ml with MilliQ water 
 
Resolving buffer 








Resolving gel (15% acrylamide) 
2.8 ml 40% acrylamide/bis (29:1) 
1.875 ml resolving buffer 
2.825 ml MilliQ water 
37.5 "l 10% ammonium persulfate 
7.5 "l TEMED 
 
Resolving gel (12.5% acrylamide) 
2.34 ml 40% acrylamide/bis (29:1) 
1.875 ml resolving buffer 
3.28 MilliQ water 
37.5 "l 10% ammonium persulfate 
7.5 "l TEMED 
 
Stacking gel (4% acrylamide)  
0.25 ml 40% acrylamide /bis (29:1) 
1.25 ml stacking buffer 
1ml MilliQ water 
17.5 "l 10% ammonium persulfate 
3.5 "l TEMED 
 
10 x SDS-PAGE running buffer 
144 g glycine 
30 g Tris 
10 g SDS 
Make up to 1000 ml with distilled 
H2O  
 
Coomassie Stain Solution 
0.25% Coomassie Brilliant Blue 
G250 
45% methanol 
9% acetic acid 





10% acetic acid 
 
Western blot 
Anode Buffer I 
0.3 M Tris 
10% methanol 
Adjust to pH 10.4 and stored at 4 °C 
 
Anode buffer II 
25 mM Tris 
10% methanol 
Store at 4 °C 
 
Cathode buffer 
25 mM Tris 
40 mM glycine 
10% methanol 
Adjust to pH 9.4 and stored at 4 °C 
 
10 x PBS 
8 g sodium chloride 
0.2 g potassium chloride 
1.44 g sodium phosphate dibasic 
 
Blocking solution 
0.1% casein  
50 ml 1x PBS 
 
Antibody diluent 




Protein purification buffers 
Lysis buffer 
50 mM Tris, pH 8.0 
150 mM sodium chloride 
10% glycerol 
1% Triton X-100 
 
Wash buffer 
50 mM Tris, pH 8.0 
150 mM sodium chloride 
10% glycerol  
0.05% Triton X-100 
Store at 4 °C 
 
Elution buffer 
50 mM Tris, pH 8.0 
150 mM sodium chloride 
10% glycerol  
50 mM D-Biotin 
For EK treatment add 2 mM CaCl2 
 
RNA binding assays 
RNA binding buffer 
10 mM MOPS 
50 mM potassium chloride 
5 mM magnesium chloride 
1 mM DTT 
10% glycerol 
Store at 4 °C 
 
10 x RNA loading buffer 
200 mM potassium chloride 
100 mM Tris pH 7.4 
50% glycerol 
0.1% bromophenol blue 
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RNA native gels 
5 x TBE buffer 
450 mM Tris 
450 mM boric acid 
Autoclave and add 1 mM of filter 
sterilised EDTA 
 
5% TBE gel 
1 ml 5x TBE buffer 
1.25 ml 40% acrylamide/bis (29:1) 
7.75 ml MilliQ water 
50 "l 10% ammonium persulfate 
10 "l TEMED 
 
Crystal violet plaque assay 
Crystal violet stain solution 
0.2 g crystal violet 
100 ml MilliQ water 
Filter sterilise 
 
3.7% formaldehyde solution 
5 ml 37% formaldehyde 































8 Appendix II: Pentaprobe sequences 




5’ CGGAATTCTA CGAATTTTTC TTTTGTTTAT TTCCTTTCGC 
TTTGCTTCTC TTCCCTTCGT TCTGTTCCGT TTTACCTTGT CTTGCCTTAT 
CTTACTTTA 3’  
 
PP2 
5’ TATCTTACTT TAGTTTCATT TAATTGTGTT GTACTCTCCT 
CTGCGTTCAC TTAGCTTAAC TTGGTTTGGC TTGATTTGAC 
TTCAGTTGCG CTCTATTCTA 3’ 
 
PP3 
5’ CGCTCTATTC TACTGTCCTG TGCATTCAAT CGTTGAGTTC 
GATCTAGTCT CGTCTAACCC TCCCCTGCTC CGCTGGTCTG 
GCCTCGCCTA TCCTACCCAT 3’ 
 
PP4 
5’ TATCCTACCC ATTGGGCTCA TCTGATCCAT CCGGTCCCGT 
CCACTCGGCT ATGTTATGCT GTATTGCAGT CGTGTCGCGT 
CGAGCTGCCC TAATCCCACC 3’ 
 
PP5 
5’ CTAATCCCA CCTAGCGTAT CGGGTCATGT AGTGCTACGT 
TACGGCCCCCG CCCGGCATCA TATTATATCA CCCCAGTGTA 
ATGTGGTGTG AGGTTGGAG 3’ 
         
PP6 
5’ GTGAGGTTGG AGTCCGACCT GGAATCTCAG CCTGACGTGC 
CATGCGGTGC GATGTCACGC CGCGCCACGG TATAGTATGG 
TACGGGATCC CG 3’ 
 159 
PP7 
5’ TAAAGTAAGA TAAGGCAAGA CAAGGTAAAA CGGAACAGAA 
CCGAAGGGAA GAGAAGCAAA GCGAAAGGAA ATAAACAAAA 
GAAAAATTCG TAGAATTCCG 3’ 
         
PP8 
5’ TAGAATAGAG CGCAACTGAA GTCAAATCAA GCCAAACCAA 
GTTAAGCTAA GTGAACGCAG AGGAGAGTAC AACACAATTA 
AATGAAACTA AAGTAAGATA 3’ 
 
PP9 
5’ ATGGGTAGGA TAGGCGAGGC CAGACCAGCG GAGCAGGGGAG 
GGTTAGACGA GACTAGATCG AACTCAACGA TTGAATGCAC 
AGGACAGTAG AATAGAGCG 3’  
 
PP10 
5’ GGTGGGATTA GGGCAGCTCG ACGCGACACG ACTGCAATAC 
AGCATAACAT AGCCGAGTGG ACGGGACCGG ATGGATCAGA 
TGAGCCCAAT GGGTAGGATA 3’  
 
PP11 
5’ CTCCAACCTC ACACCACATT ACACTGGGGT GATATAATAT 
GATGCCGGGC GGGGGCCGTA ACGTAGCACT ACATGACCCG 
ATACGCTAGG TGGGATTAGG 3’ 
 
PP12 
5’ CGGGATCCCG TACCATACTA TACCGTGGCG CGGCGTGACA 
TCGCACCGCA TGGCACGTCA GGCTGAGATT CCAGGTCGGA 
CTCCAACCTCAC 3’  
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9 Appendix III: Expression of FCV VPg in 
CRFK cells 
CRFK cells are a feline cell line that supports the replication of FCV. To confirm 
the expression of FCV VPg, an RNA construct encoding VPg with a C-terminal 
Strep-tag II was transfected into CRFK cells.  
9.1 Methods 
CRFK cells were maintained in Advanced DMEM (Gibco) supplemented with 
10% FBS and incubations were performed at 37 °C + 5% CO2. Cells were 
passaged when they reached a confluency of approximately 70-80%. The 
medium was removed from cells and 2 ml trypsin/EDTA was added to the cell 
monolayer for approximately 10 minutes or until the monolayer had dispersed. 
Medium (8 ml) was added to the cells to inactivate trypsin and the cells were 
gently pipetted to break up clumps. The cells were counted and a 75 cm2 flask 
was seeded with 2x106 cells in 20 ml of medium.  
 
CRFK cells at 1x107 cells/ml were transfected with FCV VPg RNA using the 
Neon Transfection System (Thermo Fisher Scientific) with 1 pulse at 1500 V and 
30 mA. Cells were seeded in CRFK medium in 6-well plates and incubated for 
12 hours. CRFK cells were harvested and MagStrep XT beads to concentrate the 
protein, as described for RAW-Blue cells.  
9.2 Results 
Expression of a Strep-tag II labelled MNV VPg could be detected in CRFK cells 
at 12 hpt however FCV VPg could not be detected (Figure 9.1). The lack of FCV 





Figure 9.1 Expression of MNV VPg and FCV VPg in CRFK cells 
CRFK cells were transfected with VPg constructs corresponding to MNV VPg and FCV 
VPg, both labelled with a C-terminal Strep-tag II. Cells (~3x106 cells) were harvested at 
12 hpt, lysed and the protein concentrated on MagStrep “type 3” XT beads. The purified 

















10 Appendix IV: Expression and purification of 
NT* tagged VPg proteins 
 
Figure 10.1 Expression and purification of NT*MNV VPg TM, NT*MNV VPg K2-12 
and NT*HuNV VPg proteins 
Each protein was expressed in T. ni cells and purified using StrepTactin resin. The 
purification process was analysed by Coomassie blue staining of an SDS-PAGE gel and 
western blot against the Strep-tag II. 1; Total culture sample, 2; Soluble lysate, 3; Flow 
thorough that did not bind to resin, 4; wash and 5; ~5 µg of eluted protein. (A) 
Purification of NT*MNV VPg triple mutant. (B) Purification of NT*MNV VPg K2-12 
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11 Appendix IV: Presentations and Publications 
Publications 
McSweeney A, Davies C, Ward VK. Cell Cycle Arrest is a Conserved Function 
of Norovirus VPg Proteins. Viruses. 2019;11(3). 
 
Presentations 
10th Australasian Virology Society Meeting, Queenstown, NZ, 2019.  
Oral Presentation: The N-terminal region of MNV VPg contributes to cell cycle 
arrest and RNA binding 
 
7th International Calicivirus Conference, Sydney, Australia, 2019. 
Poster Presentation: The N-terminal region of MNV VPg contributes to cell cycle 
arrest and RNA binding 
 
Microbiology Department Research Retreat, Dunedin NZ, 2019. 
Poster presentation: The N-terminal region of MNV VPg contributes to cell cycle 
arrest and RNA binding 
Runner-up poster virology section 
 
American Society for Virology Conference, 37th Annual Meeting. University of 
Maryland, USA, 2018.  
Oral presentation: Interaction of MNV VPg and the host cell cycle 
 
School of Biomedical Sciences Postgraduate Symposium, Dunedin, NZ, 2018. 
Oral Presentation: Interaction of MNV VPg and the host cell cycle 
3rd place 10-minute talk category 
 
Microbiology Department Research Retreat, Dunedin NZ, 2018. 
Oral presentation: VPg and the host cell cycle 
 
9th Australasian Virology Society Meeting, Adelaide, Australia, 2017.  
Poster Presentation: Interaction of VPg and the host cell cycle 
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Microbiology Department Research Retreat, Dunedin NZ, 2017. 
Poster presentation: Interaction of VPg and the host cell cycle 
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Abstract: Murine norovirus (MNV) viral protein genome-linked (VPg) manipulates the cell cycle to
induce a G0/G1 arrest and gain a beneficial replication environment. All viruses of the norovirus
genus encode a VPg protein; however, it is unknown if the G0/G1 arrest induced by MNV VPg is
conserved in other members of the genus. RNA transcripts encoding a representative viral VPg from
five norovirus genogroups were transfected into RAW-Blue murine macrophages, and the percentage
of cells in each phase of the cell cycle was determined. A G0/G1 cell cycle arrest was observed for all
norovirus VPg proteins tested, and in the wider Caliciviridae family the arrest was also conserved
in rabbit hemorrhagic disease virus (RHDV) VPg and human sapovirus (HuSV) VPg. Truncation
of MNV VPg shows that the first 62 amino acids are sufficient for a cell cycle arrest, and alignment
of VPg sequences revealed a conserved motif in the N-terminal region of VPg. Analysis of VPg
constructs with single N-terminal region point mutations, or exchange of N-terminal regions between
VPg proteins, confirmed the importance of the N-terminal region for cell cycle arrest. These results
provide evidence that G0/G1 cell cycle arrest is a conserved function of norovirus VPg proteins that
involves the N-terminal region of these proteins.
Keywords: cell cycle; norovirus; Caliciviridae; VPg; G0/G1; MNV
1. Introduction
Noroviruses are a genus of the Caliciviridae family, which also includes the Nebovirus, Lagovirus,
Vesivirus and Sapovirus genera [1]. The norovirus genus is further divided into at least five genogroups
(GI–V), infecting a diverse range of host organisms [1,2]. Globally, human noroviruses (HuNV) are
a major cause of viral gastroenteritis, affecting people of all age groups [3]. Of these, viruses from GII
genotype 4 (GII.4) are responsible for the majority of infections [4–6].
Despite advances in the development of in vitro cell culture systems for HuNV, including B
cells and stem cell-derived human enteroids, direct study of the virus remains challenging [7–10].
Consequently, murine norovirus (MNV) is often used as a model virus, as it retains a similar genetic
layout to HuNV and exhibits robust replication in cell culture systems [11–13]. The norovirus genome
is organized into three open reading frames (ORF). ORF1 encodes a large polyprotein, which is
subsequently cleaved by the viral protease into the non-structural proteins NS1-2, NS3, NS4, NS5
(VPg), NS6, and NS7 [13]. ORF2 and ORF3 encode the major and minor capsid proteins, respectively.
MNV also has an additional fourth ORF encoding a virulence factor (VF1) thought to be important in
evading the host immune response [14,15].
Recently, it was shown that infection of a macrophage cell line with MNV results in a G0/G1 cell
cycle arrest, and that expression of MNV viral protein genome-linked (VPg) alone is sufficient to induce
Viruses 2019, 11, 217; doi:10.3390/v11030217 www.mdpi.com/journal/viruses
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the arrest [16,17]. MNV VPg is a multi-functional protein required for several important functions
within the cell, including genome replication and viral protein translation. A conserved tyrosine
residue at position 26 (Y26) of MNV VPg is thought to allow attachment of VPg to the 50 viral RNA,
and facilitate the function of VPg as a protein primer for viral RNA replication [18,19]. Substitution of
Y26 with an alanine (Y26A) prevents the interaction of MNV VPg with viral RNA [18,20]. In the context
of the cell cycle, a Y26A mutation has no effect on G0/G1 accumulation, suggesting that the cell cycle
arrest does not require attachment of MNV VPg to the viral RNA [16]. A second, well-characterized
function of MNV VPg is to recruit host eukaryotic initiation factors (eIFs) for preferential translation of
the viral genome during infection [21,22]. The C-terminus of MNV VPg contains an ~20 amino acid
motif, which directly interacts with the HEAT-1 domain of eIF4G [23]. Mutation of phenylalanine
123 (F123)within this motif substantially reduces binding to eIF4G; however, the same mutation has no
effect on the cell cycle arrest induced by MNV VPg [16,24]. Taken together, this suggests that the cell
cycle arrest is independent of two of the well-characterized functions of MNV VPg.
Although all caliciviruses encode a VPg protein, it is unknown if the ability to manipulate the
cell cycle is conserved. In this study, we expressed VPg proteins representing each of the norovirus
genogroups and other calicivirus genera, and screened for the ability of each to cause a G0/G1 cell cycle
arrest. We show that cell cycle manipulation by VPg is conserved within the norovirus genogroups,
and selected VPg proteins of other genera of the calicivirus family. The ability of MNV VPg to
manipulate the cell cycle was found to be associated with the N-terminal region of the protein—in
particular, the first 10 amino acids.
2. Materials and Methods
2.1. Cell Culture
RAW-Blue murine macrophages (InvivoGen, San Diego, CA, United States), a derivative of RAW
264.7 cells, were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
(v/v) fetal bovine serum. Cells were passaged when they reached 70–80% confluency, and were
maintained at 37  C with 5% CO2.
2.2. Plasmid Constructs
Synthetic VPg plasmid constructs were designed with all of the requirements for in vitro RNA
generation and synthesis (Table 1). A T7 promoter and a methionine were included at the 50 end,
and at the 30 a stop codon followed by a restriction enzyme site for template linearization was
included. Constructs were produced by Genscript (Genscript, Piscataway, NJ, USA) and cloned into
a pUC57-simple vector. The plasmids were then transformed into XL1 Blue MRF’ Escherichia coli cells,
and the plasmid DNA amplified by midi-prep (Invitrogen, Carlsbad, CA, United States).
Table 1. Synthetic viral protein genome-linked (VPg) constructs to investigate the conservation of
VPg-induced cell cycle arrest.
Virus a Genus and Genogroup Accession Number 30 Restriction Enzyme ConstructModification b
MNV Norovirus GV DQ285629 AvaI Strep-tag II
Norwalk virus Norovirus GI AAC64602 BamHI Strep-tag II
HuNV Norovirus GII JX459908 HindIII Strep-tag II
Jena virus Norovirus GIII CAA90480 BamHI No
Lake Macquarie virus Norovirus GIV AFJ21375 BamHI No
HuSV Sapovirus X86560 HindIII No
RHDV Lagovirus U54983 HindIII No
FCV Vesivirus M86379 HindIII Strep-tag II
Newbury 1 virus Nebovirus DQ013304 HindIII Strep-tag II
a MNV: murine norovirus; HuNV: human norovirus; HuSV: human sapovirus; RHDV: rabbit hemorrhagic disease
virus; FCV: feline calicivirus. b Where indicated a second construct was designed to incorporate a C-terminal
Strep-tag II for VPg detection. The Strep-tag II amino acid sequence was AWSHPQFEK.
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Synthetic MNV VPg point mutation constructs were designed as above, but with single amino
acid substitutions to alanine at lysine 5 or 7 (K5A or K7A), glycine 9 (G9A), and arginine 10 (R10A).
Synthetic truncated MNV VPg constructs were designed to remove the indicated amino acids (Figure 3).
Chimeric VPg constructs of MNV VPg with feline calicivirus (FCV) VPg or Newbury 1 VPg were
designed around a conserved leucine residue (L21 of MNV VPg) (Figure 4). A C-terminal Strep-tag II
epitope tag was incorporated for detection. All DNA constructs were sequenced to confirm correct
identity prior to the preparation of RNA transcripts.
2.3. Preparation of RNA Transcripts
Plasmids were linearized at the 30 end of the viral VPg gene using the appropriate restriction
enzyme (Table 1). Messenger RNA transcripts were generated using the mMessage mMachine T7
ultra transcription kit (Ambion; ThermoFisher Scientific, Waltham, MA, USA) and purified using the
MEGAclear transcription clean-up kit (Ambion), according to manufacturer’s instructions.
2.4. Transfection of RAW-Blue Cells
RAW-Blue cells were electroporated using the Neon transfection system, according to manufacturer’s
instructions (ThermoFisher Scientific). Briefly, 1 ⇥ 106 cells were mixed with 4–5 µg of in vitro transcript
RNA, and electroporated with 1 pulse at 1730 V and 20 mA. Following transfection, cells were seeded
into 2 mL of pre-warmed medium in a six-well plate, and incubated for the indicated time.
2.5. Confirmation of VPg Protein Expression
To confirm expression of VPg proteins, transfected cells were harvested and washed in
Dulbecco’s phosphate buffered saline (dPBS), lysed, and then separated by SDS-PAGE electrophoresis.
A broad-spectrum VPg antibody was not available to confirm expression of norovirus genogroup
and calicivirus VPg proteins, and therefore SDS-PAGE gel samples were sent for mass spectrometry
analysis (Centre for Protein Research, University of Otago, New Zealand). VPg constructs that could
not be detected by mass spectrometry were redesigned to incorporate a 30 Strep-tag II for western blot
analysis (Table 1). MNV VPg was also available with a 30 Strep-tag II. Cells transfected with tagged
constructs were lysed, and the cell lysate clarified using MagStrep “type 3” XT beads (2-4090-002,
IBA Lifesciences) and protein bound to those beads was analysed by western blot. Expression of
Strep-tag constructs, MNV VPg, and derivates of MNV VPg were detected using the appropriate
primary and secondary antibodies; Strep-tag II (34850; Qiagen, Hilden, Germany), MNV-1 VPg [25],
actin (I-19) (sc1616; Santa Cruz; Santa Cruz, CA, United States), DyLight 800 donkey anti-rabbit
IgG (SA5-10040; Thermo Scientific), and DyLight 680 donkey anti-mouse IgG (SA5-10090; Thermo
Scientific). Images were viewed on the Odyssey Fc imaging system (LI-COR).
2.6. Cell Cycle Analysis
Following transfection, the percentage of cells in each phase of the cell cycle was measured by flow
cytometry. Cells were harvested, washed in dPBS, and fixed overnight in 3 mL of cold 70% ethanol.
Subsequently, the cells were washed and resuspended in dPBS. The DNA was stained with 50 µg/mL
propidium iodide (P4170; Sigma) and the RNA degraded with 0.1 mg/mL RNase A (R4875; Sigma) for
45 min at 37  C. Stained cells were analysed using fluorescence-activated cell sorting (FACS), and the
cell cycle phases were assigned using MODfit LT 3.0 software (Verity Software House; Topsham,
ME, United States).
2.7. Statistical Analysis
Data is presented as means and standard deviations. Results were analysed by a one-way ANOVA
with Dunnett’s post-test, and p values of 0.05 were considered statistically significant.
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2.8. Alignments
Alignments of VPg amino acid sequences were performed using Clustal omega software on the
default settings and manually adjusted [26].
3. Results
All viruses of the Caliciviridae family encode a VPg protein, but it is unknown if the cell cycle
manipulation shown for MNV VPg is conserved. To determine if VPg proteins from other noroviruses
are able to induce a G0/G1 cell cycle arrest, a single VPg was selected from each of the five norovirus
genogroups (GI–V) and analysed for its effect on the cell cycle (Figure 1). VPg RNA was transfected into
asynchronous RAW-Blue murine macrophages. Transfection of RNA transcripts encoding enhanced
green fluorescent protein (EGFP) show a transfection efficiency of over 90%, as determined by FACS
analysis [25]. As a broad-spectrum VPg antibody was not available, expression of VPg from genogroups
GIII, GIV, and GV was confirmed by mass spectrometry analysis (Table S1). GI VPg and GII VPg
could not be detected by mass spectrometry, and were subsequently epitope labelled with a Strep-tag
II and purified on MagStrep beads to confirm expression by western blot (Figure S1). Two protein
bands of similar molecular weights were observed for GI VPg (Figure S1). Analysis of the cell cycle
by flow cytometry showed that at 12 hours post-transfection (hpt), all norovirus VPg proteins caused
an increase in G0/G1 phase cells and a decrease in S phase cells (Figure 1B). In particular, VPg from
GI and GII human noroviruses strongly increased the percentage of cells in G0/G1 to 85% and 81%,
respectively, compared to mock transfected cells at 60%. GIII VPg from the Jena virus induced a modest
though significant G0/G1 population increase, and a corresponding decrease in the S phase population
was observed, although this was not significant (Figure 1B).
Previous work has demonstrated that VPg has conserved functions within the Caliciviridae
family [27]. We were interested to investigate if the cell cycle arrest observed for members of the
norovirus genus is conserved within other caliciviruses. A representative viral VPg from each of the
five genera was tested, and the effect on the cell cycle analysed (Figure 2). Expression of human
sapovirus (HuSV) VPg and rabbit hemorrhagic disease virus (RHDV) VPg was detected by mass
spectrometry, and these proteins increased the G0/G1 population to 80% and 82%, respectively
(Table S1; Figure 2B). Expression of Newbury 1 VPg and FCV VPg could not be confirmed by mass
spectrometry, and Strep-tagged versions were not detected by western blot analysis (Figure S1).
The G0/G1 phase cell cycle arrest is independent of MNV VPg amino acids Y26 and F123,
key residues for genome replication and viral protein translation [16]. We therefore sought to determine
if a specific region of MNV VPg was responsible for a G0/G1 phase cell cycle arrest. The structure of
MNV VPg has been solved by NMR, and contains a helical core comprised of two alpha helices with
unstructured N- and C-termini [20] (Figure 3). Three constructs were designed to span the regions of
MNV VPg (Figure 3A). The construct VPg 1–62 includes the N-terminal region and the alpha helices,
VPg 11–124 includes all regions except the first 10 amino acids, and VPg 11–107 includes the alpha
helices, but excludes the N-terminal region and the eIF4G binding site (Figure 3A). Expression of VPg
1–62, VPg 11–124, and VPg 11–107 was confirmed by western blot (Figure 3B). The antibody used
was generated against full-length MNV VPg; while the antibody binds to each construct, the affinity
where regions of the protein were truncated is unknown, and therefore comparative expression was
not attempted (Figure 3B). The N-terminal half of MNV VPg (1–62) caused a significant G0/G1 cell
cycle arrest (73%) when compared to mock transfected cells (53%) (Figure 3C). Interestingly, both VPg
11–124 and VPg 11–107 had no significant effect on the cell cycle in either the G0/G1 phase or the
S phase (Figure 3C). Overall, this indicates that a region within VPg 1–62 is sufficient to induce a cell
cycle arrest that is contributed to, at least in part, by the first 10 amino acids.
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Figure 1. Conservation of a G0/G1 phase cell cycle arrest among norovirus genogroups. RAW-Blue cells
were transfected with 4–5 µg of in vitro transcript RNA corresponding to enhanced green fluorescent
protein (EGFP), murine norovirus (MNV) VPg, as well as genogroup (G) GI VPg, GII VPg, GIII VPg,
or GIV VPg. Mock transfected (MT) cells were seeded at the time of transfection as a negative
control. At 12 hours post-transfection (hpt), cells were harvested for fluorescence-activated cell sorting
(FACS) analysis of the cell cycle. (A) Representative FACS histograms from one of three experiments.
(B) The histograms were analysed using MODfit LT 3.0, and the percentage of cells in each phase of
the cell cycle are shown. The results present the mean and SD from three independent experiments.
Statistical significance was determined for comparisons between transfected cells and mock transfected
cells, using a one-way ANOVA with Dunnett’s post-test. * p  0.05, ** p  0.01 and **** p  0.0001.
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Figure 2. Human sapovirus (HuSV) VPg and rabbit hemorrhagic disease virus (RHDV) VPg induce
a G0/G1 phase cell cycle arrest. RAW-Blue cells were transfected with 4–5 µg of in vitro transcript RNA
corresponding to EGFP, MNV VPg, HuSV VPg, RHDV VPg, feline calicivirus (FCV) VPg, or Newbury1
VPg. Mock transfected (MT) cells were seeded at the time of transfection as a negative control. At 12 hpt,
cells were harvested for FACS analysis of the cell cycle. (A) Representative FACS histograms from
one of three experiments. (B) The histograms were analysed using MODfit LT 3.0, and the percentage
of cells in each phase of the cell cycle are shown. The results present the mean and SD from three
independent experiments. Statistical significance was determined for comparisons between transfected
cells and mock transfected cells using a one-way ANOVA with Dunnett’s post-test. **** p  0.0001.
We next looked to identify conserved motifs within the first 62 amino acids of the VPg proteins
tested (Figure 4). Alignment of the proteins identified a conserved N-terminal motif, KGKxKxGRG
(K3 to G11 for MNV VPg), that was present in all VPg proteins confirmed to arrest the cell cycle,
except for GIII (Jena virus) VPg (Figure 4), which is missing the GRG component of this motif.
To investigate the role of the KGKxKxGRG motif in a G0/G1 cell cycle arrest, MNV VPg constructs
were designed with single point mutations to alanine at positions K5, K7, G9, and R10. Expression of
each MNV VPg mutant was confirmed by western blot (Figure 5A). Analysis of the cell cycle indicated
an ~10% reduction in the G0/G1 population for K5A, K7A and R10A when compared to full-length
MNV VPg, but mutation of G9 did not significantly affect the cell cycle (Figure 5C). These results
indicate that lysine and arginine residues within the N-terminal region of MNV VPg are important for
a cell cycle arrest.
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Figure 3. Expression of VPg 1–62 induces a G0/G1 phase cell cycle arrest. RAW-Blue cells were
transfected with 4–5 µg of in vitro transcript RNA corresponding to MNV VPg, VPg 1–62, VPg 11–124,
or VPg 11–107. Mock transfected (MT) cells were seeded at the time of transfection as a negative control.
At 12 hpt, cells were harvested for western blot and FACS analysis of the cell cycle. (A) Schematic of
full-length MNV VPg and synthetic constructs. Numbers indicate the amino acid position within key
structural elements. (B) Representative western blot of full length MNV VPg and VPg truncations.
Histograms (C) from FACS analysis were analysed on MODfit LT 3.0, and the percentage of cells in
each phase of the cell cycle graphed (D). The results present the mean and SD from three independent
experiments. Statistical significance was determined for comparisons between transfected cells and
mock transfected cells using a one-way ANOVA with Dunnett’s post-test. *** p  0.001.
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Figure 4. Alignment of the first 62 amino acids of VPg from different norovirus genogroups and
representative members of the Caliciviridae family. An asterisk (*) indicates identical residues. A colon
(:) indicates residues that are identical in >50% of sequences. Conserved amino acids of the N-terminal
region are shown in red, and in bold red are MNV VPg residues used for point mutations. The tyrosine
residue (Y) corresponding to Y26 of MNV VPg is shown in bold. A conserved leucine residue used
as the junction point for the construction of chimeric VPg proteins is shown in blue. The represented
genogroups are GI Norwalk virus VPg, GII Sydney 2012 VPg, GIII Jena virus VPg, and GIV Lake
Macquarie VPg.
Figure 5. Mutation of positively charged amino acids within the N-terminal region of MNV VPg
reduces the G0/G1 cell cycle arrest. RAW-Blue cells were transfected with 4–5 µg of in vitro transcript
RNA, corresponding to MNV VPg or single-point mutant versions K5A, K7A, G9A, or R10A. Mock
transfected (MT) cells were seeded at the time of transfection as a negative control. At 12 hpt, cells
were harvested for western blot and FACS analysis of the cell cycle. (A) Expression of MNV VPg and
point mutants was determined by western blot with actin as a loading control. (B) Representative
FACS histograms from one of three experiments. (C) The histograms were analysed using MODfit LT
3.0, and the percentage of cells in each phase of the cell cycle are shown. The results present the mean
and SD from three independent experiments. Statistical significance was determined for comparisons
between mutanted VPg transfections and MNV VPg transfected cells using a one-way ANOVA with
Dunnett’s post-test. * p  0.05 and ** p  0.01.
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This study has demonstrated that the N-terminal region of MNV VPg is important for a G0/G1
arrest and that alignment of VPg proteins shows a conserved KGKxKxGRG motif among the VPg
proteins of the norovirus genogroups (HuSV and RHDV) (Figure 4). However, in Newbury 1 VPg the
motif is almost completely absent, and in FCV VPg it is separated in two by a stretch of eight amino
acids (Figure 4). Both of these proteins failed to express from in vitro RNA transcripts in RAW-Blue
cells, and the cell cycle response could not be determined. We designed chimeric VPg to test the
functionality of the N-terminal regions of Newbury 1 VPg and FCV VPg in the context of MNV VPg,
and to address if the N-terminal region of MNV VPg is sufficient to drive a cell cycle arrest when
combined with Newbury 1 virus or FCV VPg.
Newbury 1 virus is predicted to express a VPg product of ~65 amino acids, compared to the
124 amino acid MNV VPg [28]. Alignment of the first 62 amino acids identified a conserved leucine
residue across all VPg proteins, located five amino acids immediately prior to the absolutely conserved
tyrosine essential for nucleotidylation, and hence replication of caliciviruses. This leucine residue is at
position 10 and 21 of Newbury 1 VPg and MNV VPg, respectively (Figure 4). Synthetic chimeric VPg
constructs were designed by exchanging the N-terminal regions of Newbury 1 VPg and MNV VPg
prior to the leucine residue, and a C-terminal Strep-tag II was added for protein detection (Figure 6).
The resulting chimeric proteins were designated Nb19/MNV VPg (representing the first nine amino
acids of Newbury 1 virus fused to the MNV VPg from leucine 21) and M20/Nb1 VPg (representing the
first 20 amino acids of MNV VPg fused to Newbury 1 virus VPg from leucine 10). Expression of each
chimeric construct was confirmed by purification of Strep-tag II protein on MagStrep beads followed
by western blot (Figure 6). Transfection of Nb19/MNV VPg into RAW-Blue cells showed no change in
the cell cycle when compared to mock transfected cells, and suggests that the N-terminal region of
Newbury 1 VPg does not affect the cell cycle (Figure 6). Transfection of M20/Nb1 VPg also had no
effect on the cell cycle, and indicates that there are region(s) of MNV VPg beyond the first 20 amino
acids required to achieve a G0/G1 arrest in RAW-Blue cells, which are absent in Newbury 1 VPg.
A second set of chimeric VPg constructs were designed for FCV VPg and MNV VPg, using the
conserved leucine residue at position 19 of FCV VPg as the fusion point. The resulting chimeric
VPg proteins were designated F18/MNV VPg and M20/FCV VPg (Figure 7). Expression of each
chimera was confirmed by purification of Strep-tag II protein on beads followed by western blot
(Figure 7), including expression of the predominantly FCV VPg (M20/FCV VPg) that could not be
expressed in its unmodified form. Transfection of F18/MNV VPg induced a modest change in the
S phase population, but this was not supported by a significant change in the G0/G1 population
(Figure 7). This suggests that the N-terminal region of FCV is not functional for a G0/G1 cell cycle
arrest in the system tested here. In contrast, M20/FCV VPg containing the N-terminus of MNV VPg
fused to FCV VPg induced a cell cycle arrest comparable to MNV VPg alone (Figure 7) despite low
overall protein expression (Figure 7). This implies that FCV VPg may be able to induce a cell cycle
arrest in the appropriate context.
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Figure 6. Chimeric MNV VPg and Newbury 1 VPg proteins do not induce a cell cycle arrest. RAW-Blue
cells were transfected with 4–5 µg of in vitro transcript RNA corresponding to EGFP, MNV VPg,
or chimeric VPg constructs. Mock transfected (MT) cells were seeded at the time of transfection as
a negative control. At 12 hpt, cells were harvested for western blot and FACS analysis of the cell
cycle. (A) Schematic for the design of chimeric VPg constructs. Chimeric constructs were designed
around a conserved leucine reside of MNV VPg and Newbury 1 VPg to exchange the N-terminal region.
(B) Expression of MNV VPg and chimeric VPg proteins was determined by purification of Strep-tag
II protein on beads followed by western blot. (C) Representative FACS histograms from one of three
experiments. (D) The histograms were analysed using MODfit LT 3.0 and the percentage of cells in
each phase of the cell cycle are shown. The results present the mean and SD from three independent
experiments. Statistical significance was determined for comparisons between transfected cells and
mock transfected cells using a one-way ANOVA with Dunnett’s post-test. * p  0.05.
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Figure 7. A chimeric protein M20/FCV VPg induces a G0/G1 arrest. RAW-Blue cells were transfected
with 4–5 µg of in vitro transcript RNA corresponding to EGFP, MNV VPg, or chimeric VPg constructs.
Mock transfected (MT) cells were seeded at the time of transfection as a negative control. At 12 hpt,
cells were harvested for western blot and FACS analysis of the cell cycle. (A) Schematic for the design
of chimeric VPg constructs. Chimeric constructs were designed around a conserved leucine reside of
MNV VPg and FCV VPg to exchange the N-terminal region. (B) Expression of MNV VPg and chimeric
VPg proteins was determined by purification of Strep-tag II protein on beads followed by western blot.
(C) Representative FACS histograms from one of three experiments. (D) The histograms were analysed
using MODfit LT 3.0, and the percentage of cells in each phase of the cell cycle are shown. The results
present the mean and SD from three independent experiments. Statistical significance was determined
for comparisons between transfected cells and mock transfected cells using a one-way ANOVA with
Dunnett’s post-test. * p  0.05 and **** p  0.0001.
4. Discussion
4.1. Induction of a G0/G1 Arrest is a General Function of VPg Proteins from a Diverse Range of
Norovirus Isolates
MNV VPg was previously reported to induce a G0/G1 phase cell cycle arrest in RAW-Blue
macrophages [16]. We have established that a cell cycle arrest is a conserved function of representative
VPg proteins from the other norovirus genogroups, including human noroviruses, as well as VPg
proteins from the Sapovirus (HuSV) and Lagovirus (RHDV) genera. We also provide evidence that
Vesivirus (FCV) VPg may also induce a cell cycle arrest, although that could not be confirmed.
Expression of each VPg construct was confirmed by either mass spectrometry or western blot of
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a Strep-tag II construct. To achieve detectable levels of Strep-tag II VPg, protein lysates were purified
and concentrated on MagStrep beads, and we were therefore not able to correlate the relative protein
expression with the magnitude of a G0/G1 cell cycle arrest. The result for Strep-tag II GI VPg indicates
that low levels of VPg expression are sufficient to induce a cell cycle arrest (Figure S1). We have
interpreted a statistically significant change in the G0/G1 population as being indicative of a cell cycle
arrest, regardless of protein expression level.
Despite originating from viruses with a range of different hosts, including humans, cows and
rabbits, the cell cycle arrest induced in murine macrophages by these VPg proteins is essentially
indistinguishable from that of MNV VPg in the assays used in this study. The cell cycle consists of
a series of sequential steps, many of which are highly conserved. Given that each of these VPg proteins
induce an arrest in a single murine cell line, it seems likely that there is also a conserved mechanism.
The G1 phase of the cell cycle serves as a growth phase, during which there are high levels of
ribonucleotides and high translation efficiency for genome replication and protein translation [29,30].
MNV capsid protein production and viral titre have been shown to be highest in cells that are actively
progressing through the G1 phase [17]. We propose that similar to MNV, each of these respective
viruses is able to induce a favorable environment, and thus gain a replication advantage within the
host cell through the induction of a G0/G1 arrest.
4.2. A Conserved N-Terminal Motif is Required for Cell Cycle Arrest
The mechanism employed by MNV VPg to induce a G0/G1 cell cycle arrest is currently unknown.
We therefore sought to identify structural elements of MNV VPg required for an arrest, which may
provide insights into the mechanism. Three constructs—VPg 1–62, VPg 11–124, and VPg 11–107—were
designed to span the structural and functional regions of MNV VPg, and were tested for a cell cycle
arrest. The N-terminal region of MNV VPg spanning amino acids 1–62 was sufficient for a G0/G1
cell cycle arrest, while the other two constructs tested had no effect on the cell cycle. This suggests
that an element(s) within the first 62 amino acids of MNV VPg is required for an arrest, and provides
further evidence that the arrest is independent to the C-terminal eIF4G binding domain [16]. Further,
the addition of a C-terminal tag to the VPg of GI, GII, and GV noroviruses did not affect the ability of
these VPg proteins to induce a cell cycle arrest.
We performed an alignment of VPg protein sequences spanning amino acids 1–62, and identified
a conserved N-terminal motif: KGKxKxGRG. The motif is conserved within all norovirus genogroups,
HuSV VPg, and RHDV VPg, all of which can induce a G0/G1 cell cycle arrest. There was some
variation in the degree of cell cycle arrest for different genogroup VPg proteins that contain this motif,
indicating that this motif alone is not the only factor involved in cell cycle arrest (Figure 1). The ability
to induce a G0/G1 arrest was associated, in part, with the positively charged amino acids K5, K7,
and R10 within the N-terminal motif of MNV VPg (Figure 5).
MNV VPg mutations at K5 and K7 have previously been investigated in the context of MNV
infections. Viruses expressing either of these mutations show a 10-fold reduction in virus titre compared
to non-mutated viruses, suggesting that these amino acids are important for the viral lifecycle [20].
During infection, mutation of either K5 or K7 of MNV VPg does not significantly affect translation
initiation factor binding or the ability of VPg to act as a primer for genome replication [20,24].
Altogether, this suggests that the reduced G0/G1 arrest observed with our K5A and K7A MNV VPg
constructs is not due to the impairment of functions related to viral translation or genome replication.
Additionally, in HuNV VPg, the N-terminal region has been shown to be involved in nucleoside
triphosphate (NTP) binding [31]. While native HuNV VPg binds all four NTPs at similar levels,
this activity is noticeably reduced when lysine to alanine mutations at positions 2–13 are introduced [31].
NTPs, particularly purines, have been shown to regulate control of the G1 to S phase transition and
progression through the S phase [32]. Depletion of the purine and guanine triggers a G1 cell cycle arrest
in human neuroblastoma cell lines [33]. We would hypothesize that, for K5A at least, the cell cycle
arrest is independent of NTP binding activity, as a mutation of HuNV VPg at K2–5, which includes the
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amino acid corresponding to K5 of MNV VPg, does not inhibit NTP binding. The role of the K7A and
R10A point mutations used in this study on NTP binding has not been examined. Future experiments
should focus on whether there is a direct link between NTP binding and the MNV VPg G0/G1 cell
cycle arrest, focusing specifically on the role of amino acids within the N-terminal region.
It is unclear why both Newbury 1 VPg and FCV VPg failed to express as full-length proteins in
this study. Newbury 1 VPg was designed from predicted cleavage sites within the ORF1 polyprotein,
and has not been extensively studied [28]. The Newbury 1 VPg produced is only 65 amino acids in
length compared to other VPg proteins, which range from 111–138 amino acids, and it is possible
that a functional protein is not produced. In contrast FCV VPg has been detected during infection
and expressed in E. coli; however, it could not be detected using our system [34–36]. Based on the
amino acid alignment, we wanted to test the N-terminal regions of Newbury 1 VPg and FCV VPg
to determine if they are functional in an arrest. Chimeric VPg proteins were designed to express the
N-terminal regions of Newbury 1 VPg or FCV VPg in the context of MNV VPg. A cell cycle arrest was
not observed for Nb19/MNV VPg or F18/MNV VPg, suggesting that these N-terminal regions are
not functional for a cell cycle arrest as chimeric proteins, although the native proteins may function
differently. The N-terminal regions of Newbury 1 VPg and FCV VPg share less similarity with the
consensus KGKxKxGRG motif, and further highlight the importance of this region for a G0/G1 cell
cycle arrest. In contrast chimeras, expressing the N-terminal region of MNV VPg with the C-terminus
of either Newbury 1 VPg or FCV VPg, were designed to investigate if the MNV VPg N-terminal region
was important and could confer cell cycle arrest capability to these proteins. While M20/FCV VPg
induced a G0/G1 arrest, M20/Nb1 VPg was not able to arrest cells, suggesting that an unidentified
C-terminal element, absent in Newbury 1 VPg, is important. FCV VPg is more similar to MNV VPg
than Newbury 1 VPg in structure, function, and protein size [20,21,27] and this finding suggests that
in the correct context, FCV VPg may be able to induce a cell cycle arrest.
This work has shown that induction of a G0/G1 cell cycle arrest is a conserved function of
norovirus VPg proteins that extends to VPg proteins from other members of the Caliciviridae family,
including HuSV VPg and RHDV VPg. Within these protein sequences, we have identified a conserved
motif: KGKxKxGRG. The importance of the N-terminal motif to cell cycle arrest was shown through
the use of truncation, point mutations, and chimeric MNV VPg constructs. Overall, this shows that the
N-terminal region of VPg is required for a G0/G1 cell cycle arrest by noroviruses.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/11/3/217/s1;
Table S1: Detection of norovirus genogroup VPg and calicivirus VPg by mass spectrometry; Figure S1: Detection
of norovirus genogroup and calicivirus VPg proteins. VPg proteins that were not detected by mass spectrometry
were tagged with a C-terminal Strep-tag II and RAW-Blue cells transfected with 4–5 µg of the respective RNA.
At 12 hpt cells were harvested, lysed and the protein concentrated on MagStrep “type 3” XT beads. Purified
lysates were then probed for the presence of a Strep-tag by western blotting.
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